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ABSTRACT 
 
 
Latin America is a region of diversity, inequality, poverty and an outstanding capacity to 
remain stable despite these challenges. The HIV epidemic in the region resembles these same 
characteristics, with a wide range of risk behaviours, a disproportionate burden in vulnerable 
groups and yet perhaps a highly effective response. 
Brazil and Colombia have extensively deployed prevention strategies and delivered 
antiretroviral treatment and there are still further expansions in sight. However, the likely 
impact of these HIV programmes on the epidemic has never been evaluated. This thesis 
addresses these gaps by retrospectively evaluating the impact of antiretroviral treatment and 
prevention campaigns on new HIV infections. This is done by means of mathematical models 
that represent HIV transmission in these settings and which creates a counterfactual 
projection for the trajectory the epidemic might otherwise have taken. These estimations are 
interpreted in the context of ambitious plans to scale treatment further, along with a growing 
realisation of the long-term costs that these programmes imply. 
Tracking the epidemic is essential for the evaluation of programmes in the next phase of the 
response. To support this, a new method for incidence estimation is proposed. This method 
relies exclusively on case-report data, which is robust in these settings, and a flexible model 
specification that should be suitable for a wide range of epidemic scenarios. The parameters 
for the model are estimated in Bayesian framework and applied to the case study of 
Colombia. These resulting estimates of the historic course of the epidemic in Colombia are 
strikingly different to that which has previously been estimated and casts new light on the 
nature of epidemics in this region and the response to it that is now required.  
Overall, these results stand as the first analysis of this kind in the region and present useful 
results and methods that should support a continued effective response to HIV epidemic in 
this region. 
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1 BACKGROUND 
Since the first documented case in 1981, the number of people estimated to be living with 
HIV/AIDS in 2012 was 32 to 38 million. Of those, at least 2.3 million were incident 
infections happening in the same year [1]. According to the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) 2010 report, the global trend of HIV prevalence now seems to be 
declining after having peaked in 1999. This is most likely due to the extended provision of 
antiretroviral treatment (ART) and other  preventive strategies which have resulted in a 19% 
reduction in AIDS mortality between 2004 and 2009 [2].  
In the absence of a feasible form of intervention that could completely eradicate HIV in the 
population, it is imminent to draw upon the available primary prevention tools in order to 
explore new ways of containing the spread of infection. Those tools have existed for many 
years in the form of condoms, antiretroviral therapy (ART) and needle exchange 
programmes, shaping the epidemic as we know it.   
This study intends to shed light on the interaction between some of these preventive 
interventions when applied to the specific context of concentrated epidemics. It will do so by 
retrospectively evaluating the impact of combined HIV prevention in South America. It also 
explores a method to estimate incidence of HIV, capitalising on the strength of local 
surveillance systems in the region.   
This chapter is an introduction to the epidemic, reviewing concepts of infection transmission, 
HIV prevention, the epidemiology of HIV, and a historical background of the pandemic, with 
a focus in South America – the theoretical framework of this thesis.   
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2 HIV: A SUCCESS OF BIOLOGY, A CATASTROPHE OF PUBLIC HEALTH 
2.1 The origins 
Several decades have passed since HIV made its initial jump from African primates to its first 
human host. It then went on to become the most widespread and deadly epidemics of the late 
20
th
 and 21
st
 centuries.  
The zoonotic origin of the HIV epidemic is widely accepted and has been largely reported 
and investigated [3]. An exhaustive and unprecedented hunt for the origins of HIV has taken 
place all over the world since HIV’s first public appearance in 1981. 
After the isolation of HIV-1 virus and its –mostly- undisputed role as the causing agent of the 
acquired immunodeficiency syndrome [4], much research has been carried out to explain the 
origin of the pandemic not only from an evolutionary point of view but as an epidemiological 
phenomenon.  
HIV-1 and HIV-2, both from similar origin, are the only two members of the Lentivirus 
family of retroviruses known to infect humans and cause the clinical syndrome commonly 
known as AIDS. Though they are part of the same family, the origin of these two viruses is 
different. Both however can be traced back to simian ancestors in different geographical 
locations in Africa. The Simian Immunodeficiency Virus (SIV) is the simian counterpart of 
HIV in humans and it is its ancestral source. The SIV virus circulates naturally in primates in 
different African locations and contrary to its name, it does not cause immunodeficiency 
among its natural hosts. However, it is known to cause an aggressive form of illness when 
transmitted inter-species. It acquired its scientific name, SIV, when different species of 
primates like the rhesus macaques and other Asian species fell-ill after being infected with 
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SIV in laboratories all over the United States of America (USA). It turned out that these 
animals had been kept in long-term captivity together with other species now recognized as 
being the natural African hosts of SIV [5].  
SIV has infected several species of non-human primates, and each infecting virus 
corresponds to a specific phylogenetic lineage. SIVsm was named after its natural host, the 
sooty mangabey (Cercocebus atys) monkey of western Africa. SIVsm is the closest related 
virus to HIV-2. Its prevalence finds its highest levels among the sooty mangabey monkeys in 
Guinea-Bissau, Senegal and Côte d’Ivoire, which also holds the highest prevalence of HIV-2 
in adults [6].  
In West African countries HIV-2 has been the cause of a more silent epidemic than HIV-1 
has been in the rest of the continent. Causing milder symptoms and having a 
characteristically longer incubation period, HIV-2 can remain unnoticed during the life-span 
of infected individuals [5]. Cases of HIV-2 infection outside West Africa are rare, with some 
clusters of transmission occurring in Mediterranean countries and Portugal among others, 
most likely due to intense migration during the years of the independence conflict (mid 
1970s) in the former Portuguese-Guinea, now Guinea-Bissau [5].   
SIVcpz is the simian origin of HIV-1, and was named after its host Pan troglodytes or 
chimpanzee. This lineage of SIV is the common ancestor for all the known groups in HIV-1, 
namely M, N, O and P, and each one of these groups is thought to correspond to a specific 
simian-to-human transmission event [3]. M stands for “major”, N for “non-M”, and O for 
“outlier”. P is the newest one, only discovered in 2009, and its letter is meant to be after 
“pending further identification” since only one human case has been reported [7] . Group M 
is the one encompassing the greatest majority of HIV-1 strains found among infected 
individuals today. Groups N, O and P are outliers contrasted to the epidemic spread of group 
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M, and are almost restricted to the western part of central Africa, namely Cameroon, Gabon 
and Congo [3]. For the purpose of this thesis HIV-1 group M, will be referred to as HIV.    
On the other hand, group M comprises several subtypes or “clades”, designated with capital 
letters from A to K. It is interesting to notice the geographical relation of these subtypes: A 
and C are the most common mainly because they caused the epidemics in South Africa, 
central Europe and Southeast Asia. Subtype B was the one spreading through the Americas, 
Australia and Europe, and is the main subtype in the epidemic among MSM around the 
world. However, it is more common now to see different subtypes and recombinants (CRF) 
in places not originally related to that clade [8] (Figure 1).  
 
 
Figure 1 World distribution of HIV-1 subtypes distribution. Source: Hemelaar 2012[9]. 
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The means by which SIV jumped from primates to become HIV is disputed, but the most 
feasible sequence of events involves the very ancient tradition of hunting and consuming 
bush-meat in Central Africa. A close and repeated contact with simian blood and fluids might 
have offered a good-enough chance for SIV to pass into humans. However, more intricate 
explanations have been proposed, like one involving the trials of the attenuated Polio virus 
vaccine in the former Belgian Congo in the 1950s [3]. This hypothesis suggests that 
chimpanzee-kidney cells carrying SIVcpz were used to cultivate the virus which posteriorly 
gave birth to the world expansion of HIV-1 group M epidemic. However the fact is that the 
animals used in such experiments were actually bonobos rather than chimpanzees,  
contradicting all the evidence currently known about the virus origins [3].   
When exactly did those first transmission events happen is uncertain, but with help of 
phylogenetic techniques and molecular clock procedures it has been estimated that it could 
have been around 1930 with an uncertainty range of 20 years [10].     
 
2.2 The epidemic expansion 
After that colossal sequence of events that ended up with HIV successfully transmitting from 
human-to-human, a confluence of factors were necessary for HIV to achieve its epidemic 
expansion. Cultural and behavioural factors might have contributed to the initial burst of 
transmission. It is difficult to pin-point a single factor behind the epidemic spread in Africa, 
and today it is more accepted that behaviour heterogeneities, together with other biological 
conditions, had a synergistic effect on the initial epidemic growth. The non-uniformity 
observed in HIV prevalence across different parts of central, eastern and southern Africa has 
revealed the reason of these uneven patterns. Sexual behaviour, mainly the number of sexual 
partners and concomitant partnerships, has been reported as an explanation, but this alone 
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does not sufficiently explain the fast rate at which HIV has spread in African countries [11]. 
Biological factors affecting HIV transmission have inevitably been involved, such as co-
infections with other sexually transmitted disease (STD) (herpes simplex virus-2 , 
syphilis)[11, 12], and different levels of circumcision in the male population in some 
areas[13]. Other causal factors include the socio-economic background of the most affected 
communities as well as the role of women in the community and patterns of transactional sex 
[14]. The widespread use of non-sterile syringes during mass vaccination campaigns carried 
out by European and American missions in Africa has also been hypothesised  as a possible 
cause behind the initial epidemic expansion [5], but the evidence is mostly anecdotic.  
The transatlantic journey of HIV is likely to have happened several decades after the 
approximated initial inter-species transmission events. HIV-1 has been found with 
polymerase chain reaction (PCR) analysis in pathological specimens and blood samples 
collected from patients suffering from syndromes similar to AIDS, dating as far back as  the 
1960s in the USA and 1959 in Europe [5]. As it was mentioned before, HIV-1 subtype B was 
the one that spread all over the Americas and parts of Western Europe. But its first port of 
arrival is now known to have been Haiti. Haiti has the oldest HIV-1 epidemic outside of 
Africa, and is almost exclusively caused by HIV-1 subtype B. All strains that sparked 
subsequent epidemics in North, Central and South America (known as the subtype B 
epidemic clade) have a common ancestor in Haiti’s subtype B. This first strain was estimated 
to have been introduced in Haiti around 1969 [15], possibly by Haitian migrant workers in 
the Democratic Republic of Congo who then returned to their country [5]. This may partly 
explain the early observations of AIDS cases being more frequently reported among Haitian 
immigrants living in the USA.  
 The first syndromic report of AIDS dates back to 1981. However, retrospective analyses of 
blood samples carried out in the 1980s in New York and San Francisco, showed a 5% 
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seroprevalence of HIV-1among MSM in 1978 [16, 17], suggesting that the virus had already 
spread silently for a while.   
Some important epidemiological insights can be drawn from the previous description of HIV 
and its origins. The first one is that HIV was circulating in the general population in Central 
Africa for several decades before making its way to America. Even outside Africa, as 
reported above, silent transmission was occurring maybe as early as the late 1950s. The 
introduction of HIV from Haiti to the USA might have influenced the trends that were 
observed in the following years. Haiti, despite having a heterosexual epidemic was known for 
being a hub for homosexual and bisexual tourism, particularly among North American men 
[18]. Other factors related to the changing perceptions of sexuality, particularly among MSM, 
the “sexual liberation” era, the appearance of places for gay socialisation and sexual 
exchange (like saunas, bars and clubs) could have been of central importance in the spread of 
the virus in the USA and Europe[19, 20]. 
This suggests that behavioural, cultural and historical factors were shaping -since the early 
1960s- different types of epidemics around the world. These differences in the pattern and 
extent of transmission across contexts motivated the classification of epidemics.  
Aimed at standardizing the categorization and further response to HIV, UNAIDS developed a 
classification based on the prevalence levels among different groups. This numerical 
surrogate of the dynamics of infection divided epidemics as low-level, concentrated and 
generalized. Low-level epidemics were those where HIV prevalence had not exceeded 5% in 
any sub-group or key population. Concentrated epidemics were those with prevalence greater 
than 5% in at least one sub-population but less than 1% in the general population (pregnant 
women). Finally, generalized epidemics were those where HIV prevalence was consistently 
greater than 1% in the general population [21]. This categorization appeared to be very broad 
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to understand and encompass other types of epidemics described all over the world, like 
mixed epidemics, falling in between concentrated and generalized, where sub-populations 
sustain higher than usual levels of HIV prevalence but are consistently lower than 5%. For 
this reason, more recent attempts to assess epidemic types have focused on describing and 
disentangling the drivers of transmission and focusing on the prevention effect of 
interventions for controlling HIV transmission at the population level [22-24].         
  
3 HIV IN LATIN AMERICA  
 
3.1 Background  
The great diversity of cultures, ethnic groups and traditions encompassing Latin America, 
makes it impossible to talk about one “Latin American culture”. Similarly, it is equally hard 
to attribute the same epidemic patterns to HIV transmission to the whole region.  
HIV and AIDS have had a different impact in Latin American countries however similar 
structural factors have helped to the propagation of the epidemic in this region: health 
inequalities, sexual discrimination, stigma and homophobia.  
In 2012 an estimated 1.4 million (1.1 to 1.7) people living with HIV and AIDS (PLHA) lived  
in Latin America, which is approximately 200,000 more people than in 2001 [25, 26](Figure 
2).  
Between 2011 and 2012, around 83,000 people acquired the HIV infection in the region.  For 
the same period 53,000 deaths resulted in relation to HIV and AIDS [25, 26].   
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Figure 2 Number of people living with HIV and AIDS and population size in Latin America: Nine countries 
with the greatest number of PLHA according to UNAIDS estimation, contrasted to population size. Source: [25, 
26].   
 
As can be seen in Figure 2, the size of the major epidemics in Latin America, according to 
estimations from the latest UNAIDS Global Report [25, 27] is a reflection of the overall size 
of the total population.  
 
3.2  Men who have sex with men (MSM) 
Since the epidemic in the region has been characteristically concentrated among a key 
population, MSM, it is necessary to look into this population group to understand the 
epidemiological nuances within the region.  
The MSM population has high HIV prevalence in the entire Latin American & Caribbean 
region but is particularly high in Central and South America. Jamaica stands above these 
countries with the highest prevalence in the whole region. Figure 3 shows the highest 
estimations of HIV prevalence for selected countries in the region [25, 27]. 
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Figure 3 HIV Prevalence in MSM in selected countries of Latin America in 2009-2010. Source: 
UNAIDS Global Report 2013 [25, 27]. 
 
 
MSM contribute with over 50% of the new HIV infections in Latin America [2, 28-31]. This 
disproportionate concentration of risk is perpetuated by high levels of stigma, marginalization 
and even penalization, which strengthens segregation and hampers MSM population’s access 
to prevention campaigns and health services [2, 28, 32-34]. Ultimately, it forces gay and 
bisexual men to surreptitious unprotected activity.  
Nine countries in Latin America and the Caribbean still consider male-to-male intercourse as 
a criminal act with penalties ranging from hard labour to life imprisonment (Table 1).  
Legal frameworks that embody homophobic legislation can thus greatly disadvantage efforts 
to eradicate HIV and AIDS. In the words of the  UNAIDS Executive Director Michel Sidibé 
“In most of the countries in the Caribbean that don't have repressive laws, HIV prevalence is 
between 1% and 8% among men who have sex with men. This contrasts sharply with a range 
of between 20% and 32% in countries which outlaw sex between men” [35] .  
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Penalization might also discourage the disclosure of sexual preferences between partners, 
leading to a frequent phenomenon of concealed bisexuality [2, 36]. Although the use of this 
term is not straight-forward, it could be used in this context since most of the men engaging 
in bisexual activity seek to maintain their role in society as heterosexuals and therefore do not 
identify themselves as bisexual or homosexual. In a survey on sexual behaviour carried out in 
Bogota, Colombia, 20% out of 533 men reported sexual contact with other men during their 
lives, and only 11% considered themselves as homosexual or bisexual [37].  
 
Table 1 Penalization of homosexuality and any male to male intercourse in the Caribbean 
and Latin America. 
Country Legal 
Condition  
Penalization 
Antigua Illegal Imprisonment from 15 years to life  under the charge of 
“Buggery” 
Barbados Illegal Imprisonment from 15 years to life  under the charge of 
“Buggery” 
Costa Rica Illegal Imprisonment from 10 year under the charge of 
“Unnatural Crime” 
Dominica Illegal Imprisonment from 10 year under the charge of 
“Buggery” 
Grenada Illegal Imprisonment from 10 year under the charge of 
“Unnatural Connection” 
Guyana Illegal Imprisonment for life  under the charge of “Buggery” 
Jamaica Illegal Imprisonment for 10 years and hard labour  under the 
charge of “Unnatural Crime” 
Saint Kitts/Nevis Illegal Imprisonment for 10 years and hard labour  under the 
charge of “Buggery” 
Saint Vicent and 
Grenadines 
Illegal Imprisonment for 10 years and hard labour  under the 
charge of “Buggery” 
Source : ILGA, International lesbian, gay, bisexual, trans and intersex association [38]. 
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In MSM concentrated epidemics, bisexual activity becomes an epidemiological bridge 
between high transmissibility networks and a lower risk heterosexual groups, where women 
are the most affected, as is especially the case in the Caribbean epidemic. For that region, 
women outnumber the cases reported in males but the epidemic shows high levels of 
concentration among MSM [2]. This reflects not only the disjointment between prevalence 
estimations and current transmission but also, and more importantly, the limited access to 
health services and the systematic discouragement of HIV testing among the MSM 
population group.    
 
3.3 Female Sex Workers (FSW) 
FSW workers are the second group most affected in the region with countries like Guyana 
and Haiti displaying prevalence greater than 5%. This epidemic has been of particular 
importance in most Caribbean countries. The Population Attributable fraction (PAF) of HIV 
infections to FSW has been estimated to be 7% (3.9% to 9.9%) in Latin America and 9% 
(7.6% to 11.6%) in the Caribbean [39].   
Figure 4 shows a selection of countries in the region with the highest estimates of prevalence 
[25]. In these countries, low levels of condom use has been reported, signalling the important 
role of transmission in this group [26].  
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Figure 4 HIV Prevalence in FSW from selected countries of the Caribbean and Latin America. 
Source: UNAIDS Global report 2013 [25]  
 
 
 
Concentration of risk in this group is a complex issue, since there are great geographical 
variations even within countries, where some port cities, touristic places and work camp sites 
(for oil exploration, mining) can mobilize a great number of sex workers, making the regional 
assessment more difficult [40-42]. 
3.4 People who Injects Drugs (PWID) 
PWID in Latin America have been associated with the biggest cities and mostly in the 
southern cone of South America, with Brazil and Argentina reporting the highest incidences. 
Around 50% of PWID in Argentina live with HIV and 48% in Brazil for the same population. 
In Brazil only 25% of these receive ART [43].   
As will be described below, the epidemic among PWID was of major relevance in the 
southern and southeastern parts of Brazil, reaching HIV prevalence as high as 60% in Rio de 
Janeiro in 1992 [44]. This trend seemed to have changed in Brazil, with the trends in drug use 
leading to a reduction in the total number of people using injected drugs [45]. In Colombia, 
during all the 1990s and most of the 2000s, injecting behaviour was not regarded as a main 
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contributor to the epidemic. However, the use of heroin has increased in more recent years 
[45].  
The presence of HIV-1 subtype C in the southern cone of the continent, contrary to the large 
dominance of subtype B in the northern countries is thought to be related to HIV transmission 
networks of PWID. At least in Argentina, Paraguay, Uruguay and Brazil, subtype C has been 
reported, as well as many recombination variants from the co-existence with subtype B [46, 
47]. Subtype B though is the dominant HIV-1 subtype in these countries. The presence of 
subtype C in the same areas where drug injecting behaviour is more important suggests that 
this clade could be attached to a network of transmission. However, different studies have 
failed to demonstrate this consistently [8, 48].         
 
3.5 The HIV epidemic in Colombia  
3.5.1 Social and cultural context  
Transmission seems to be occurring more intensely in the MSM population group in 
Colombia. Conversely, the role of other vulnerable groups like FSW and their clients, and 
PWID have been less explored and the cross sectional studies carried out do not suggest a 
significant concentration in these groups.  
Colombia is the host of heterogeneous patterns of transmission with characteristics of the 
Caribbean epidemic in the northern coast and an influence of the Andean countries in the 
southern half (Figure 5).  
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Figure 5 Map of Colombia in the north of South America. Source [49].  
 
A growing number of female cases of HIV in the recent years suggest that the influence of 
this Caribbean pattern of transmission is becoming stronger in the country.  
Caribbean countries have the largest epidemic among women and female sex workers in the 
region in Latin America [39]. This condition is fuelled by the bisexual activity of MSM as 
well as male sex work. It is not a coincidence that cities like Cartagena, Santa Marta and 
Medellín in the Caribbean coast and north of Colombia have been recognized as the main 
centres of sex tourism in the country [50]. Homophobia and gender inequalities, so 
commonly seen all over Latin America, complete the picture for transmission of HIV [51, 
52].   
Caribbean and Andean cultures are at the centre of the country’s behavioural diversity 
grounded in the historical and geographical conditions of these regions. Historically, the 
Caribbean coast have had strongly defined gender roles with women traditionally acting as 
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family keepers, confined to their homes to a great extent. Men, as economic providers might 
become itinerant supporters, frequently engaging in simultaneous polygyny (i.e. concurrency) 
as part of their role. This role is not only accepted but encouraged by society, feeding the 
stereotype of “manhood” and hyper-sexuality with which Caribbean men are frequently 
identified [51, 53].        
Widespread gender inequalities are also found in the centre and south of the country, but 
attitudes towards sex are a very different story. In these areas sexual behaviour is experienced 
in a less explicit way. Sex is a less commented subject, possibly due to a deeply rooted 
Roman Catholic tradition influencing morality in these communities [50]. 
Social and political factors have also played their part in providing a backdrop of 
displacement and vulnerability which have facilitated HIV transmission in Colombia.  An 
armed conflict has taken place for over 60 years in Colombia and the ongoing struggle 
between the army, the guerrillas and the paramilitaries to exert control in rural areas, has 
forced a large part of the rural population to move from the countryside to the cities. 
According to the Internal Displacement Monitoring Centre (IDMC), Colombia has the largest 
internally-displaced population in the world, with a total of between 4.9 and 5.5 million [54].  
Forced to leave their homes, the only solution for this population is moving to slums around 
the cities putting themselves in critical situations of vulnerability: out of reach from the health 
system, at the mercy of transactional sex for survival, drug use and sexual violence [55].         
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3.5.2 Epidemiology of HIV in Colombia 
The first case of AIDS was reported in 1983 and since then around 80,000 cases have been 
reported. The male ratio in reported cases was 12:1 in 1983, and over the years the impact 
among women has taken more importance, with an estimated ratio by 2010 of 2:1 [27].  
The age pattern of all reported cases shows a greater impact in the youngest groups, with 1 
out of three new cases occurring within the age range of 25 to 34 years [56].   
HIV prevalence has been estimated in the overall population of Colombia through seven 
cross-sectional studies, mostly among pregnant women, and generally remaining below 0.5%, 
finding a peak at around 0.6% in 2003 and declining from there to the more recent estimation 
of 0.2% in 2009 [27](Figure 6). 
 
 
Figure 7 HIV Prevalence in Colombia: from seven national surveys carried out among pregnant women (1988, 
1991, 2000, 2003, and 2009) and adults (1994, 1997).    
    
MSM have been the most affected group as demonstrated by several surveys. Two cross 
sectional studies in 2000 and 2004 found an HIV prevalence of 19% and 25% respectively 
[50, 57]. In 2010 a behavioural and seroprevalence survey among MSM was carried out in 
seven cities in the country, finding HIV prevalence between 5% and 24%. When stratified by 
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age, the prevalence among those older than 25 doubled and even tripled in some cases the 
values for the group < 25 years, showing an important ageing pattern of HIV epidemic in 
MSM in Colombia [58].     
On the other hand, female sex workers in Colombia have been estimated to have HIV 
prevalence between 0.8% and 1.4%, according to different studies [27, 42].  PWID have been 
largely overlooked over the years in part because it was thought that injecting behaviour did 
not have a major role in the drug consumption spectrum of the country. A survey in 2003 
showed a prevalence of 1% in current PWID and 1.6% among ex-PWID [50]. The most 
recent survey from 2011 in the cities of Medellin and Pereira showed a HIV prevalence of 
3.8% (CI 95%: 0.8%-7.1%) and 2%(CI95% 0.5% - 3.7%) respectively [59] . 
 
3.5.3 Response to HIV epidemic  
The beginning of the Highly Active Antiretroviral Therapy (HAART) era in 1996 caught 
Colombia in the middle of a complete makeover of its health system. For many decades 
Colombians accessed health services through the social insurance scheme for civil servants or 
private insurers. The great majority, with neither the money nor the civil servant’s 
employment, had no option but to queue for the meagre welfare attention provided by 
hospitals and health centres. The health reform came to life in 1996 with the intention of 
bringing access to health services to every Colombian regardless of their financial position. In 
a couple of years the results were stunning, increasing the coverage of health services from 
25% in 1986 to 75% in 2005, and around 90%  in 2010[60]. The new social system now 
consists of two schemes: the Contribution Regime (CS) and the Subsidised Regime (SR). The 
CS encompasses all the population in the formal labour force and their families. The SR, 
financed by the CS, covers the rest of the population and is designed to reach those in the 
poorest conditions [61].  
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HIV patients that previously had to pay for their own treatment -in the era of monotherapy 
and at the beginning of HAART- from 1997 had complete access to free treatment and 
attention. HIV testing and treatment was included in the system but the number of available 
drugs was limited.    
ART has been offered in Colombia since 2012 to HIV+ individuals with symptomatic disease 
or a CD4+ count < 500 cell/mm
3
. This recommendation changed from the previous 
guidelines in which treatment was delayed among the HIV+ until CD4+ < 250 cell/mm
3
 or 
between 250 and 350 cell/mm
3
 with a viral load greater than 100.000 copies of RNA HIV-
1/mL.   
The preferred first line ART scheme is based on two nucleoside reverse transcriptase 
inhibitor (NRTI) (abacavir/lamivudine, tenofovir/emtricitabine) plus one nucleoside reverse 
transcriptase inhibitor (NNRTI) (efavirenz) or a boosted protease inhibitor (atazanir/ritonavir, 
darunavir/ritonavir) or an integrase inhibitor like raltegravir [62].          
 
3.6 AIDS and treatment in Brazil 
Brazil reported its first case of AIDS in 1982.  From there, the country experienced the 
biggest epidemic expansion seen in Latin America reaching 10,000 cases detected by 1990 
[63], in what is now referred to as the first epidemic expansion in Brazil. This initial growth 
was largely due to transmission among MSM, most of them living in the big cities of the 
South East (i.e. Sao Paulo and Rio de Janerio). By 1985 the male-to-female ratio was 24:1 in 
the reported cases, reflecting the burden of homosexual transmission at the time.   
A second wave took place from 1990 to 1992, affecting mostly PWID in the South, and 
raising the count of cases to 76,000 by 1993 [44, 64]. The third expansion started in 1993 
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after a consistent spread among gay and bisexual men in urban areas which gave way to a 
new trend of heterosexualization of the epidemic in the early 1990s. By 1994 the rate of 
infection (by cases reported) was higher among heterosexuals than in MSM [65] and  the 
outlook of HIV in Brazil by 1995 was that of an epidemic at the brink of generalization. With 
at least two risk groups displaying HIV prevalence greater than 25% in different parts of the 
country (63% in PWID from Rio [44] and 35% in MSM from Santos [66]) and the death toll 
reaching its peak (Figure 7), the Brazilian government made an unprecedented move by 
introducing universal free access to ART for every person with AIDS in Brazil. The process 
was not as straight forward, and more details about the Brazilian struggle are provided in 
Chapter 3, but the consequence was remarkable: By 2006 12% of all the patients receiving 
treatment in middle and low income countries lived in Brazil [64].      
      
 
Figure 7 Reported AIDS cases and AIDS deaths in Brazil 1981-2010.Source: Departamento de DST, Aids e 
Hepatites Virais 
 
Although ART played a major role in controlling Brazil’s epidemic, other preventive 
strategies were also set in place for tackling HIV transmission, like the expanded distribution 
of condoms with subsidised prices, and needle exchange programmes [67].   
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The current picture has changed considerably. The epidemic among PWID has slowly faded 
out partly because of a change in urban consumption patterns, with most of the PWID now 
consuming crack cocaine, and also due to a very high mortality rate among this group [44, 
68]. The latest UNAIDS estimation of HIV prevalence in the general population was 0.55% 
in 2013 [69], and a large survey in MSM from 10 cities in 2010 found a prevalence of 10.5% 
[70].  
The current coverage of ART (as the number of people treated over the estimated PLHA) 
estimated by UNAIDS is 46% [69], and the total number of people in ART up to 2013 was 
313,175 with an average annual increase of 30,000 new people starting ART since 2002 [71].  
The story of Brazil’s treatment campaign does not stop there. The government of Brazil 
announced in 2013 its intention to further expand its already colossal HIV programme, so as 
to implement Treatment as Prevention (TasP) at national scale, and offering ART to every 
person who is HIV+ irrespective of the infection’s clinical stage. The programme is planned 
to provide treatment to 100,000 new patients by the end of 2014, at a cost of approximately 
US$ 100 million [72]. The World’s eyes are on Brazil, eager to see how this new venture 
develops and what solutions it will offer to all the challenges and concerns raised by the 
scientific community about implementing TasP as the main treatment strategy.      
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4  HIV PREVENTION: FOCUS ON TREATMENT 
 
4.1 Treatment as Prevention 
An observation that became a fact and is believed to be at the core of what we now know as 
TasP is as follows: when HIV+ people taking ART reach undetectable levels of viral load 
the risk of transmission to their serodiscordant couples is drastically reduced. If we 
bring this to a population scale, the result is consistent reduction of HIV incidence.  
This is not a new idea, and the concept has been around for over 20 years. Garnett and 
Anderson [73] explored the idea of the population effect of treatment relying on the fact that 
antiretrovirals reduced viral load. However, it was too early in the HAART era to predict the 
real potential of combined therapy for steadily suppressing viral load. In 1996, combined 
therapy was just starting to take over as the mandatory prescription for patients with AIDS. 
The evidence at the moment was mainly coming from individuals on dual and monotherapy, 
showing consistently that after initiation of treatment it was a matter of weeks to months 
before observing a rapid re-emergence of viral loads to pre-treatment levels [74]. Biological 
mechanisms, like a high rate of viral replication and mutation made viral load very difficult to 
control with the early antiretroviral schemes.  
More arguments to this debate came from the impressive effect of antiretrovirals (ARVs) for 
preventing mother to child transmission (PMTCT) with almost 50% risk reduction against 
placebo [75].    
A few years later, evidence about the relationship of viral load and transmission was made 
available from HIV trials in Rakai, Uganda [76]. This triggered others to envision the use of 
treatment as a form of prevention in real life settings [77-80]. Further observational studies in 
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serodiscordant couples confirmed the initial observations [81, 82], and the HPTN 052 trial 
gave the final blow to any doubts still standing [83].        
 
4.2 Challenges of TasP   
With all this said the big question needs to be answered: how to implement TasP in real life 
conditions and reach the desirable benefits?  
This type of question is a “modelling question” and has indeed been addressed with 
mathematical simulations, specifically Universal Test and Treat (UTT) (i.e. active and 
universal HIV testing) which also poses a challenge since HIV tests could be as scarce as 
ART in many contexts (49). Mathematical models have explored UTT with different levels of 
impact, even suggesting by Granich et al. reductions in HIV incidence below 1% by the year 
2016, and that HIV eradication was a feasible goal [84]. Strong assumptions about the 
dynamics of the epidemic and the feasibility of the strategy were made in order to reach these 
conclusions. The first and most important assumption is that all the HIV+ could be reached 
by universal voluntary testing. This overlooks the many factors that influence individuals to 
take HIV tests and accept the treatment with full compliance [85, 86]. Furthermore the lack 
of understanding about the role of the epidemiological setting in the overall effectiveness of 
ART might be an another barrier to the effectiveness of TasP or at least to the extrapolation 
of trial and modelling results [87].  
Will the effectiveness of ART be diminished by a lack of coverage of hard-to-reach 
populations?  How can we enrol, and keep track of patients on ART whose risk comes from 
illegal activities? How much will their HIV testing cost? Some of these questions have been 
partially answered. Modelling exercises in high risk groups have already remarked the 
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exceptional role of ART for reducing HIV incidence in concentrated epidemics. Such are the 
cases of Australia and San Francisco where HIV transmission is still highly concentrated 
among MSM [88, 89]. However, these models dealt with the distribution and uptake of ART 
rather than the challenges of targeted screening.  
How much it costs and how it is going to be funded are questions that remain unanswered by 
the proponents of TasP. Implementation of UTT has proven to be costly and to be far beyond 
the available budget for the most affected countries.  In the previously mentioned work by 
Granich et al., they projected that the short-run cost could be between USD$ 2.3 and 5.3 
billion per year, which is nearly three times the cost of the standard strategy for screening and 
treatment in South Africa, and is almost 50% of the Global Fund’s total budget to fight AIDS, 
TB and malaria for the next three years.
1
 That model also showed that after 2015 the cost of 
the theoretical strategy began to fall while the cost of the usual delayed-treatment strategy 
climbed due to the increasing number of people needing therapy [84]. However, more recent 
evidence remarks the cost-effectiveness of expanded criteria for ART initiation, finding it 
highly cost-effective in South Africa among other contexts [90].  
Here lies one of the obstacles that need to be hurdled and that some are already boldly 
addressing, like the mentioned case of Brazil: what will be the returns of that immense initial 
investment to a country’s economy in the mid and long-term when HIV incidence actually 
starts to fall? The answer to this question will emerge over time through our close 
observation of Brazil 
A different concern around ART as prevention is related to the frequently unrecognized 
coexistence of ART with other behavioural and biomedical interventions, resulting in an 
overestimation of treatment effects, which could eventually lead to both decreased rates of 
                                                          
1
  Global Fund to fight AIDS, malaria and tuberculosis announced a three year budget of US$ 11.7 Billion.  See 
http://www.theglobalfund.org/en/  [accessed 27/10/2010].  
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utilization of preventive measures and to increased risky behaviour [91]. Besides, viral 
resistance, adverse reactions as well as social acceptability, fuel the debate about prioritizing 
the public health benefits of TasP over the individual costs [92]. 
If treatment is prevention, it will be subject to the same difficulties as other preventive 
measures, such as “prevention fatigue”, meaning that the long term exposure to TasP might 
lead to a loss of impact (lost adherence, treatment drop-out) and the consequential re-
emergence of infectiousness [34, 93, 94]. This has been demonstrated in contexts of highly 
concentrated HIV epidemics like San Francisco, showing an increase in unprotected anal sex 
despite the abundance of preventive efforts on safe sex; similar findings come from France 
[34, 93].  
It could be said that we are living a historical moment in the fight against HIV and that TasP 
is meant to be a central part of the future response to AIDS.  
 
5 EVALUATION OF HIV PREVENTION PROGRAMMES  
As challenging as is implementation of preventive interventions is the evaluation of impact. 
Prevention programs are carried out in the hope of tangible benefits (e.g. Cost-Savings, life-
years saved, infections averted), and its assessment is of central importance in the design of 
interventions.  
Programmes can be evaluated through different methods that will be described in this section, 
namely Randomised Control Trials, observational cohort studies, ecological studies, and 
finally mathematical modelling.  
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Before describing these forms of evaluation, it is important to mention a few concepts of 
epidemiological studies that may guide our understanding about health programme 
assessments.    
To start with, a measure of the effect of an intervention is commonly defined as an estimator 
to measure disease occurrence and make comparisons between population groups.  It also 
often seen as an attribute of a specific epidemiological design [95]. This is how, for example, 
incidence is the best way of measuring the occurrence of events in prospective studies (RCTs, 
observational cohorts). Other measures as prevalence are more useful for different designs 
like surveys and cross-sectional studies, and not too informative about the rate of appearance 
of specific events.  
Furthermore, not only the measure of the event requires a thoughtful selection, but the event 
itself. Some diseases, and also interventions, have specific characteristics that drive the 
researcher to choose one or other endpoint/outcome (i.e. the event to be observed). Infections 
with a very long incubation period might require too long follow-up time until symptomatic 
disease is observable, thus choosing a symptom to measure incidence in this case might be 
costly in every sense. Also, our growing knowledge about a specific disease might evolve 
with the time and affects our choice of both outcome and measure of effect. 
For the specific case of HIV/AIDS, different endpoints in the natural history of disease can be 
identified and measured. The job of the HIV researcher is to define which one of these 
outcomes is the most pertinent to assess the impact of an intervention. HIV offers an 
interesting example of how knowledge has influenced the way we measure and choose 
outcomes.   
Antiretroviral drugs where introduced in 1984 and the complexity of its combinations 
changed with the years, from AZT (zidovudine) monotherapy [96], dual therapy [97], and 
Chapter 1: Introduction 
 
39 
 
HAART [98].  Monotherapy and dual therapy were first assessed in terms of its immediate 
impact in the clinical condition of AIDS patients: mortality, CD4+ cell count, weight-loss and 
the appearance opportunistic infections [96] [97]. A triple combination of drugs proved to be 
highly potent for reducing morbidity and mortality, and combined therapy started to be 
offered to patients in earlier stages of their disease. At this point progression to AIDS was the 
primary endpoint of interest together with changes in CD4+ count [98, 99]. Evidence was 
reported about the relationship between viral-replication control and immunological 
restoration [100], and also the importance of suppressing viral load  for containing viral re-
emergence from latent reservoirs [101, 102]. This shifted the scope of primary endpoint from 
the clinical syndrome to viral load. Currently, viral load suppression is the endpoint of 
election in almost every trial for ART [103-105]. More recent findings, discussed above in 
this chapter, gave a whole new dimension to the study of ART in HIV+ positive patients, by 
turning treatment into prevention. Then the endpoint had to be re-assessed in order to put 
ART in the preventive toolbox together with other prevention strategies (i.e. condoms, 
circumcision, microbicides) that measure HIV incidence as their primary outcome of interest 
[106, 107].  
A summary of the evolution of primary outcomes in ART trials can be seen in Table 1.  
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Table 2 Summary of Primary outcome evolution in ART trials 
Timeline Form of Delivery Primary outcome HIV Research Milestone Reference 
1987-1988 Monotherapy Death 
ARVs reduce mortality 
and incidence of 
opportunistic infections in 
AIDS patients 
[96] 
1988-1996 Dual therapy Death [97] 
1996-2000 
HAART (triple 
combination 
therapy) 
CD4+ count 
Progression to 
AIDS 
Combination of three 
drugs restores immune 
system and extends 
survival 
[98] 
2000- HAART 
Viral load 
suppression  
(HIV-1 RNA < 
50 copies /mL) 
Viral suppression prevents 
viral re-emergence and is 
related to immune 
restoration 
[101-103] 
2011- 
ART* 
(combination 
therapy) 
 
HIV Incidence 
ART reduces the risk of 
acquiring HIV in HIV- 
partners in serodiscordant 
couples 
[83] 
*ART is the current name given to all forms of combined therapy (at least three drugs).   
 
Primary prevention programmes, as opposed to other forms of therapeutic interventions 
(secondary prevention), are intended to have an effect before the event of infection actually 
occurs, thus the most direct assessment of HIV prevention would be the rate of appearance of 
new HIV infections (i.e. incidence).  
As explained above, outcomes might change as we move upstream in the causal pathway of 
prevention, as an example, measuring uptake of a vaccination programme might be 
informative of its preventive capacity if we already know that the vaccine is effective. This is 
how most of preventive interventions are measured through intermediate outcomes, like 
increase in condom use or reduction of STI incidence [108]. This could be useful either 
because HIV+ positive individuals are part of the study population, thus a change in risk 
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behaviour is desirable [109], or because the intermediate outcome is a known step in the 
causal pathway of events to acquire HIV.  The choice between one and the other has been 
discussed before  [109], but briefly, intermediate outcomes are more likely to be used in 
contexts of low HIV incidence like industrialized countries where estimating HIV incidence 
would require too large sample sizes  [109, 110]. Choosing between primary and intermediate 
outcomes is particularly complex in concentrated epidemics among hard to reach populations 
like MSM. Also, measuring HIV incidence in any context, irrespective of the level of HIV 
incidence, is costly and requires following individuals for longer periods of time [109].      
Two chapters of this thesis address the problem of evaluating the impact of ART for reducing 
HIV incidence in different contexts. Accordingly, a better understanding of how the 
preventive impact of ART has been evaluated is presented in the following section, 
describing the main findings and the possible limitations and gaps, building like this a 
framework to understand the possible contribution of this thesis.  
 
5.1 Randomised Controlled Trials (RCTs) in ART prevention 
RCTs are the gold standard for measuring the effect of interventions as they provide a highly 
controlled environment to observe differences in the outcomes across trial arms[95]. In this 
regard, HPTN 052 [83] provided definitive evidence of the effect of ART for preventing 
transmission of HIV at the individual level.   
In August 2011 the HIV Prevention Trial Network (HPTN) officially announced that HPTN 
052 was being halted three years before its intended date of termination due to an interim 
analysis showing a 96% risk reduction in HIV transmission among the intervention arm. 
HPTN 052 was a randomized controlled trial which enrolled 1763 serodiscordant couples 
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across 13 countries (Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, USA 
and Zimbabwe). Serodiscordant couples were recruited if the HIV+ partner had a CD4 cell 
count between 350 and 500cell/mm3. HIV infected partners were randomized to receive 
either immediate antiretroviral treatment or delayed care according to the World Health 
Organization (WHO) recommendation (treat if CD4 < 250 cell/mm3). Both arms of the study 
received permanent counselling on safe sex, free condoms and treatment for other sexually 
transmitted diseases. The uninfected couples were frequently tested for HIV and when 
infection was detected they were redirected for clinical management. An early assessment of 
the trial outcomes revealed that 39 new infections were reported during the time of study, of 
which 28 could be genetically traced to the infected serodiscordant partner. Out of these 28 
incident cases, 27 were part of the delayed treatment arm, which translates in a 96% 
reduction in the risk of transmission. 
HPTN 052 was a controlled RCT which recruited serodiscordant couples and the evidence it 
produced is a landmark for the individual HIV transmission literature. But, what is the effect 
of ART at the population level? What would be the “real life” effect of this intervention? 
These were not answered by HPTN 052.  
The context of a serodiscordant couple is as ideal a context as it could possibly be for 
observing and virologically linking HIV transmission events, but is not representative of the 
sexual behaviours that have previously explain –up to a point- the wide spread of HIV in 
Africa. Stable couples might not be the norm in contexts with a high frequency of multiplicity 
of sexual partners, in the short and the long-term (concurrency) and high rates of migration. 
Also, the uptake of testing and compliance to treatment not to mention the health system 
capacity to provide ART and retain individuals on treatment [111].      
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These are some of reasons why a new series of studies that explored the effect of treatment at 
the population level were urgently needed.  
Cluster-Randomized Controlled Trials (C-RCTs) have been planned or are currently on-going 
to test the principle of TasP hypothesis at the community level. Three studies have been 
proposed, and a summary of their main characteristics can be seen in table 3.  
Two of the studies (PopART and ANRS 12249) test effect of universal test and immediate 
ART regardless of CD4+ count on HIV incidence compared against standard of care 
according to WHO guidelines as of 2011 (i.e. treat only when CD4+ <350 cell/mm3) [112, 
113]. The third study (CDC/HSPH in Botswana) took a different approach of test and treat, 
and was originally designed to compare the standard of care in the control arm against an 
intervention of HIV testing and provision of ART for all HIV-infected persons with CD4+ 
<350 cells/ml or with HIV-1 RNA >10,000 copies/ml [114]
2
. This novel approach relies on 
the fact that individuals with higher viral load have a greater contribution to HIV 
transmission [115, 116]. 
  
5.2 Observational studies of serodiscordant couples 
Several observational studies have produced estimates on the effect of ART for preventing 
HIV transmission in serodiscordant-couples and at the community level. 
Studies of the effect of ART in serodiscordant couples have been systematically reviewed 
and pooled by Anglemyer et al. (Figure 8) [117]. This systematic review collected the 
evidence on the effect of ART for reducing the risk of HIV transmission within 
                                                          
2
 This information is as of 2012. No further information about this trial was made available. However, was 
recently referred by Wang et al. 114. Wang, R., et al., Sample size considerations in the design of cluster 
randomized trials of combination HIV prevention. Clin Trials, 2014. 11(3): p. 309-318. 
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serodiscordant couples. Prospective and retrospective cohorts were included as well as one 
RCT (HPTN 052). The pooled estimate (Rate Ratio) when only observational studies that 
considered combined therapy (no mono or dual therapy) was 0.36 (95%CI 0.17 to 0.75). This 
is a mean reduction of 64% in HIV transmission.       
 
 
Figure 8 Forest plot of observational cohorts of ART in serodiscordant couples: pooled estimates when studies 
with mono and dual therapy were removed. Source: Anglemyer et al. [117] 
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Table 3 Summary of main characteristics of on-going C-RCTs of combined prevention 
Study PopART (HPTN 071) CDC/HSPH
a
 ANRS 12249 
Site Zambia+South Africa 
(Western Cape) 
Botswana Hlabisa, KwaZulu-Natal, 
South Africa 
Number of arms 3 2 2 
Intervention arms A: Universal community 
home-based testing,; 
active linkage of HIV+-
positive individuals to 
care and immediate ART 
according to national 
guidelines and/or male 
circumcision (MC);. 
 
 B: Same as A but ART 
at CD4 < 350 cells/mµl 
A: Enhanced HIV testing 
(including mobile and 
home-based testing), 
active linkage to care and 
treatment; enhanced MC; 
ART for all HIV-infected 
persons with CD4 < 350 
cells/µl or with HIV-1 
RNA > 10,000 copies/ml; 
and point-of-care CD4 
testing in antenatal clinics 
with universal HAART in 
pregnancy started by 28 
wk gestation, as well as 
HIV retesting at delivery 
among women HIV-
negative in second 
trimester or earlier 
A: home-based HIV 
testing, active linkage to 
care and immediate ART 
initiation regardless of 
CD4 count and clinical 
stage. 
 
Control arm C: Enhanced standard of 
care
d 
B: Standard of care
b
 B: Standard of care
b
 
Design Triplet matched Pair matched Pair matched 
Number of randomized 
clusters 
   
Total 24 (South Africa: 9, 
Zambia: 15) 
30 34 
Per arm 8 15 17 
Average size of 
randomized cluster 
50,000 (25,000 >18 y) 5,800 34,000 
Overall cohort follow up 
Age eligibility 18–44 y 16–64 y 16 y or older 
Size per cluster ~2,500 adults per cluster  ~500 adults per cluster ~1000 
Total size 60,000 15,000 27,000 
Primary outcome HIV incidence
e 
HIV incidence
e
 HIV incidence
e
 
Follow up duration 2 y 3–4 y 2 y 
HIV Incidence 
assumption 
1.0–1.5 per 100 person-
years 
~1.5 per 100 person-years ~2.9 per 100 person-years 
Anticipated HIV 
prevalence at baseline 
15% 25% ~20% 
Target reduction in 
incidence 
In arm A versus C: –50% 
to 60%; in arm B versus 
C: –25% to 30% 
In arm A versus B: ~50%  In arm A versus B: ~30% 
Stages when modelling 
is currently planned  
Start, final Start Start 
Status Running  Planning Running 
a Data as of March 2012. 
bStandard of care is ART for HIV-positive individuals with CD4 < 350 cells/µl or AIDS. 
cStandard of care is standard referral to MC and ART according to Tanzania guidelines (this will soon change from CD4 < 200 cells/µl to 
CD4 < 350 cells/µl, initially focusing on HIV-positive people with tuberculosis and pregnant women). 
dStandard of care is no home-based testing or home-based visit to facilitate linkage to ART. ART given according to country guidelines; 
standard referral to MC. 
eCumulative HIV incidence measured over the trial duration. 
CDC/HSPH, US Centers for Disease Control and Prevention/Harvard School of Public Health; HAART, highly active ART; JHU/USAID, 
Johns Hopkins University/United States Agency of International Development; PopART (HPTN 071), HIV Prevention Trials Network. 
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As can be seen in the Figure 8, only three studies had a significant effect. The observational 
cohorts by Donnell et al. [81], and Sullivan et al. were both prospective, as opposed to the 
study by Jia et al. [118] in which an observational cohort was reconstructed retrospectively 
and analysed.  
Donnell et al. recruited 3480 couples in seven countries (Botswana, Kenya, Rwanda, South 
Africa, Tanzania, Uganda, and Zambia) where one partner was both positive for HIV+ and 
HSV-2. Couples were followed for 2 years and were part of an on-going RCT in that region. 
Sullivan et al. followed 2,993 serodiscordant couples in Rwanda and Zambia from 2002 to 
2008.   
On the other hand, Jia et al. reconstructed the largest serodiscordant couples cohort known to 
date, using records from China’s HIV national programme from 2003 to 2011 about 38,862 
serodiscordant couples [118]. 
It is interesting to note that the largest effects were observed with the prospective analysis of 
cohorts made by Donnell et al. and Sullivan et al. Prospective observational cohorts could 
provide a better and more direct assessment of the initial conditions of participants as well as 
a precise discrimination of events and the precise time of observation.  On the other hand, the 
retrospective cohort Jia et al. offers a substantially bigger sample, and the retrospective nature 
of the analyses removes any observer effect as cited before. However, one major subject 
concern about these results is the lack of evidence to confirm that the infections observed 
correspond to the discordant partner and not a third party. This was not caused by the design 
of the study but by the fact that virological linkage was not feasible. This might severely 
underestimate the effect of ART. Only Donnell et al. performed tests to virologically link the 
events of transmission tests [81].   
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5.3 Ecological studies and observational cohorts for the population effect of ART   
Other studies have performed ecological observations in an attempt to establish a relation 
between the presence of ART in the community and reductions in HIV incidence. The 
ecological nature of this analysis implies that different populations were assessed to establish 
the exposure and the effect of the intervention of interest. Three of these studies were carried 
out in San Francisco [119-121], other three in British Columbia, Canada [78, 122, 123] and 
one in Taiwan [124]. In the latter, Fang et al. analysed a retrospective cohort in Taiwan, 
finding that a policy of free ART delivery to every HIV+ citizen reduced HIV transmission 
by 53% [124]. 
Montaner et al. and Lima et al. [78, 122, 123], examined this case for the population of 
British Columbia in Canada concluding that an association between ART expansion, 
decreased community viral load and the reduction of new infections have been present in that 
community. They used unlinked datasets (one for new cases and other for viral load and 
CD4+ count data) from two different provincial centres.  
Similarly, the studies in San Francisco assessed established a relation between coverage of 
ART in the community for a period of time and changes in HIV prevalence.  
Several limitations can be pointed out about this analysis. First, their conclusions are 
vulnerable to ecological fallacy, since there is no causal relation between the exposure (ART 
in the community) and the event (reductions in HIV incidence). This allows for a myriad of 
factors not taken into account to be influencing the observed reductions. Furthermore, none 
of these studies observed real changes in HIV incidence, but surrogate markers of it like 
reported HIV cases and HIV prevalence, making it even more difficult to establish a temporal 
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correlation between variables. Also, in the cases of British Columbia and San Francisco 
where epidemics are strongly influenced by MSM and PWID respectively, this form of 
analysis largely oversees the impact of the repeated preventive interventions in these key 
populations. These findings have been largely discussed and criticized elsewhere [125, 126]. 
A different form of evaluation was performed by Tanser et al. in South Africa [127]. This 
group followed 17,000 HIV negative individuals for a period of eight years (2004 to 2011). 
They observed the infection events by tracking individual seroconversion and establish a 
relationship between this event and the level of ART coverage in the community surrounding 
each individual. Their findings show that in areas of high ART coverage (30 to 40% of all 
PLHA) the risk of acquiring HIV infection was reduced in a 38%, compared to individuals 
living in low coverage areas. This study even when uses an ecological exposure variable, 
measures the effect individually, making the attribution more valid, as stated by the authors.   
  
5.4 Mathematical modelling in HIV programme evaluation  
Models can be used in evaluation within the range of designs discussed above in different 
ways. In RCTs and C-RCTs modelling can be used in initial phases for sample size 
calculation and in more advance phases for exploration of causal relations and interim 
analysis. Mathematical models can also be used in the evaluation of health programs when no 
specific design was used, but interventions were rolled-out in the community. In 
observational studies they can help to estimate primary endpoints from intermediate 
outcomes. Finally, modelling can explore the causal relations between ecological 
observations. Some examples will be discussed and a proposed framework for understanding 
the role of modelling in health programme evaluations.  
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Models have been part of programme evaluation in the past and their role has been growing. 
As mentioned before models are an increasing feature in many trials during the planning 
phase as they provide a dynamic and flexible tool to inform about baseline assumptions about 
incidence and demographic characteristics. Some trials like PopART are also planning to 
incorporate mathematical modelling as a projection strategy during an interim analysis of 
their results [128].  
Garnett and others have proposed a framework for the role of modelling in the evaluation of 
health programmes [129]. According to this framework, modelling enters the evaluation 
process in three different ways:  a) Estimate the effect of an intervention on a specific 
outcome when other factors are simultaneously taking place; b) Use changes in intermediate 
outcomes to predict impact on a final simulated endpoint of interest. This might be useful 
when primary outcomes are difficult or costly to measure; and c) Exploring the relation of 
interventions with the measured outcomes [129].       
 A good example of modelling in programme evaluation of HIV prevention is the case of the 
Avahan study in India [130, 131]. In this programme, several districts in south India where 
different types of epidemics take place (PWID, FSW), were intervened with strategies to 
improve access to health services, promote behaviour change within key populations and a 
large distribution of free condoms[130].Mathematical models have been used here to explore 
the causal effect of the intervention,  as described in option a) of the framework proposed by 
Garnett et al. Modelling for Avahan was carried out in a specific district to explore to what 
extent an intervention in FSW could have explained the reductions observed in HIV 
prevalence in antenatal clinics (ANC). Their findings reported that even when a fraction of 
the effect is attributable to the interventions in FSW it was unlikely to explain completely by 
the programme, since very optimistic levels of intervention-uptake would be necessary to 
explain these changes [131].  
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Similarly, Hallett and others have addressed the subject of exploring causality, by exploring 
the relation between observed changes in behaviour change in Zimbabwe with drops in HIV 
prevalence, suggesting that earlier changes in risky behaviour over time was strongly related 
with declines in the epidemic trend in more recent years [132]. 
 
5.4.1 Models for estimating the impact of ART at the population level 
Assessing the potential impact of ART as a preventive tool as well as its retrospective impact 
in settings where it has been widely available for many years is an interesting and classic 
example of a “modelling” question.  Robust evidence at the individual level provided by 
HPTN 052 have opened a window of opportunity for modellers to explore all the possible 
barriers, co-factors and challenges of rolling-out TasP. Similarly, in the light of this evidence 
it has become a need to understand the past contributions of ART for prevention in many 
settings. 
Modelling the use of antiretrovirals to stop transmission at the community level has been 
taking place many years before HPTN 052 or even many of the observational cohorts backing 
its effect [73, 84]. The most significant and commented cases is that of Granich and 
colleagues, already discussed in this chapter. But more recently, studies have used the 
available evidence to exploit its possibilities.  
Eaton et al. [90] develop on the idea of ART as prevention within the framework of the 2013 
WHO guidelines for the delivery of ART to every HIV+ person whose CD4+ count falls 
below the threshold of 500 cell/mm
3
[133]. They used models to simulate the epidemic in four 
different scenarios that combined different existing conditions of ART coverage and 
epidemic type: South Africa with a generalised epidemic and moderate ART coverage, 
Zambia with a generalised epidemic and high coverage, India where epidemic is concentrated 
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and the coverage is moderate, and Vietnam with a concentrated epidemic and low ART 
coverage. The analysis consisted of a prospective projection in a period of 20 years to explore 
not only health benefits but costs and cost-effectiveness. Comparisons were made by varying 
the threshold in CD4+ count at which individuals could receive ART. Their findings suggest 
that in addition to the  substantial incidence reductions predicted, new recommendations for 
ART start (CD4+ <350cell/mm
3
) were very cost-effective compared to previous guidelines 
for ART initiation [90].  
 Models have also been used to explore past epidemic trends and assess the potential impact 
of ART and/or its relation with incidence patterns. Phillips and colleagues reproduced the 
epidemic of HIV among MSM in the UK where incidence in this group has remain 
unchanged or even increased despite high rates of testing and ART coverage[134]. Using 
stochastic individual base modelling, they explored the trends in incidence under assumptions 
of variability in the use of condoms and behaviour. Their main findings support the 
plausibility of an increase in incidence over time due to   slight reductions of condom use 
even in the presence of ART. However, when compared to a counterfactual scenario, model 
results suggested that ART have been useful to control further epidemic expansion [134].  
Many different forms of applying mathematical modelling to health programme evaluation 
have been described, and many advantages can be inferred from these examples. Models are 
capable of reproducing complex transmission dynamics while making use of robust evidence. 
The mechanistic nature of mathematical simulations provides powerful arguments to explain 
different phenomena where other evaluation methods fail (i.e. ecological studies). 
Furthermore, in the absence of RCTs and observational cohorts, mathematical models are the 
only form of assessment where counterfactual scenarios are reproducible, allowing the 
comparison of effect under the absence or presence of an intervention, and a wide range of 
possibilities for sensitivity analysis. 
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HIV research and prevention is a constantly expanding field of knowledge, producing large 
amounts of data, estimations and hypothesis each day. Processing and making appropriate use 
of this data is easier in the presence of mathematical modelling, for summarizing and 
translating this information into palpable outcomes.      
 
5.5 The importance of HIV incidence estimation for assessing the impact of interventions.   
As previously discussed, making the right choice of outcome for evaluation is an essential 
initial step of evaluation,  and HIV incidence is the most natural and direct observation of 
effect for any HIV prevention method. In this section, some important considerations about 
the role of HIV incidence estimations are discussed in an attempt to create a framework for 
further research that will be presented in chapter four.   
Estimates of HIV incidence are not always available and its estimation poses several 
challenges, related primarily to the scarcity of resources in most of contexts but also 
considerable methodological barriers. 
Observational cohorts and RCTs are the natural source of incidence estimations, but the 
quantity and presence of these study designs around the world is extremely low contrasted 
with the widespread and urgent need of HIV incidence measures. For this reason, for many 
years incidence estimates for the purpose of monitoring HIV epidemics has been derived 
from indirect estimation methods, like back calculation from AIDS mortality, from 
consecutive HIV prevalence estimates and from modelling. All of these indirect methods 
presuppose the existence of information upon which infection rate estimates are built.  
Back-calculation methods use surveillance data on AIDS mortality to infer past changes in 
the rate of infection by making assumptions about distribution of the incubation period [135].  
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Incidence have also been reconstructed from past HIV prevalence estimations structured by 
age, when there is a consistency in the sample population, and making a few assumption 
about survival, as Hallett et al. have demonstrated [136]. Finally, incidence has been 
recovered from mathematical simulations of transmission supported by detailed 
reconstruction of risk behaviours and individual contact patterns [137]. With its pros and cons 
all ultimately depend on the prior existence of a minimum level of information. 
In this thesis we discuss the case of settings for which none of these methods is the optimal 
solution for estimating HIV incidence at a national due to three main reasons: a) 
inconsistency between samples of key populations making it impossible to infer incidence 
trends; b) underreporting and biases in AIDS mortality data; and c) lack of behavioural data. 
These points will now be described in more detail.  
As described before in this chapter, HIV epidemics in in Latin America are mostly 
concentrated and prevalence estimations come from key populations. Also, prevalence from 
ANC is not always periodically collected. The fundament for making inferences on incidence 
out of prevalence does not hold for these cases since the population samples are mostly 
inconsistent. Regarding AIDS mortality data, even when surveillance systems are in place 
and data is collected routinely – as in most of countries in Latin America-, the assumption 
that AIDS mortality actually reflects past trends in infection rate is very risky one, given the 
large amount of underreporting in collected mortality data and particularly for the initial 
years of AIDS mortality report which are at the end the most informative for this method 
[135, 138, 139]. Finally, detailed transmission models show indeed a very useful solution but 
are still unfeasible for many settings where behavioural and programmatic data, are not at 
hand to accurately reproduce HIV infection. Moreover, the demands of time and data of 
transmission models make that option unfeasible as a surveillance tool to be used regularly.  
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In this sense, disparities can be identified in the type and amount of data available or 
regularly collected according to the type of epidemic:  broadly, we could say that the vast 
majority of states harbouring generalized epidemics have accumulated extensive information 
on risk behaviours. In many occasions this goes hand in hand with HIV seroprevalence 
studies, such is the case of Demographic Health Surveys (DHS) in most of Sub Saharan 
African states. DHS studies are also present in Latin America but HIV seroprevalence is not 
part of the surveys.    
In general, HIV incidence can be harder to estimate in many Latin American settings due to 
incomplete data about behaviours, necessary to inform current estimations like the UNAIDS 
Estimation and Projection Package [140] and other mathematical models. Also, inferring HIV 
incidence from past prevalence might not be feasible since ANC prevalence collection is not 
the norm, and inconsistencies in sampling from key populations makes it difficult to use the 
method for this groups.   For this reasons this thesis proposes a flexible modelling approach   
that does not make use of any behavioural data or prevalence estimation, and relies solely on 
case-report data to derive HIV incidence.   
 
6 RATIONALE AND THESIS LAYOUT 
This brief revision of many different aspects of HIV was intended to give an outlook of a 
specific region of the world in the context of the global efforts to contain the HIV epidemic. 
The current state of the epidemic in the contexts of Latin America and more specifically in 
Brazil and Colombia was described, noting that both countries have made important efforts to 
introduce ART and expand the coverage of ART as part as their response to the epidemic. 
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The impact of such efforts in in the light of recent evidence about the transmission prevention 
effect of ART is still unknown for these settings.  
Reviewing the importance of health programme evaluation and the role of modelling, it was 
made clear how essential it is for countries to have HIV incidence estimations at hand to 
evaluate the progress of their response to HIV. However, a gap between the type of 
information required for making use of the most popular methods for incidence estimation 
and the data actually collected, was identified for Latin American countries.  
This thesis aims to fill the gaps of knowledge mentioned above and for this purpose; this 
work has been organized and carried out in the following order.  
Chapters two and three study the cases of HIV transmission in Bogota, and Brazil, 
respectively. Transmission dynamics are reproduced through mathematical modelling in 
order to explain the main epidemiological trends among a heterogeneous population, to 
finally estimate the retrospective impact of ART and condoms for preventing new HIV 
infections.  
Chapter four proposes a method for estimating HIV incidence in settings where surveillance 
data is more readily available than other sources of data used in transmission models. Relying 
only on case-report data a mathematical model that estimates infection rates with an 
alternative flexible spline function is validated and applied to the case of Colombia. 
Chapter five discusses the main findings, limitations, challenges and the future prospects of 
this research.      
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1 INTRODUCTION 
The government of Colombia planned their response to HIV epidemic around four pillars: 
health promotion, prevention, counseling/testing and treatment. The first two pillars have  
been addressed through communication campaigns, educational workshops and distribution 
of condoms [1]. Bogota as the capital and most diverse city in the country has led the effort to 
direct the prevention campaigns to men who have sex with men (MSM) and female sex 
workers (FSW). NGOs like Ligasida have had a principal role in delivering HIV prevention 
in the city through activities such as mapping venues (baths, saunas, clubs and bars) and 
working closely with the vulnerable populations since its creation in 1983. Their activities 
included offering information and advice on sexually transmitted infections (STIs) and HIV, 
counseling and HIV testing, distribution of condoms and more importantly linking patients to 
HIV care [2].    Regarding the third pillar, HIV testing in Colombia is voluntary and with the 
very few exceptions where the health providers have tried to reach-out vulnerable 
populations, it has remained passive (i.e. available for those who seek the test) and only 
offered widely as part of the antenatal care package [3, 4]. Those who test positive flow 
through the system starting at the point of testing (i.e. Hospitals, primary-care centres and 
STI clinics) to be redirected to an HIV programme where confirmatory tests are performed 
(i.e. Western Blot). If a case is confirmed, a clinical assessment and laboratory appraisal – 
CD4 count and viral load among others - takes place in order to establish the stage of disease 
and the need of antiretroviral therapy (ART) [3]. Report of new HIV cases is mandatory and 
these are collected centrally by the Ministry of Health.          
Antiretroviral therapy and HIV/AIDS-related medical care is provided for free in Colombia 
since 1997, with the list of therapeutic options increasingly growing over the years. 
According to UNAIDS estimations, by 2013 29% of people living with HIV and AIDS 
(PLHA) where receiving ART in the country. [5]  
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It can be said that Colombia’s response has been strongly inclined towards the medical care 
and antiretroviral treatment delivery. This is supported by the national spending records, 
which showed that HIV prevention activities in Colombia are mainly funded by private and 
international sources (82% of the total spending) while the government is contributing with 
only 18% [6].  
However, Colombia´s Ministry of health (MoH) reported that 76% of HIV+ detected by the 
health system by 2007 were receiving ART [6], suggesting that detection is occurring during 
advance stages of the disease, when individuals are already in need of therapy. A brief 
analysis of data from MoH’s cuenta de alto costo3 supports the latter, showing the 
distribution of detected cases in Bogota over time by CD4+ cell count at the time of diagnosis 
(Figure 1).      
Bogota, as many other cities in Latin America, is the host of a highly concentrated epidemic 
among MSM but its response to it does not reflect this fact necessarily. Mainly focused on 
providing ART according to the changing international guidelines and lacking a solid policy 
that focuses on tackling the spread of the virus at its source, Colombia’s approach might not 
be capitalizing from the preventive effects of both ART and targeted prevention strategies to 
its full potential.  
The objective of this mathematical modelling analysis is to provide theoretical support to this 
argument, by estimating the retrospective impact of prevention interventions.  
 
                                                          
3
 Cuenta de alto costo (high-cost account) is a special branch of MoH in Colombia which deals with high-cost 
diseases like HIV, Cancer and renal disease. available in the internet from  http://www.cuentadealtocosto.org/ 
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Figure 1 Distribution of reported HIV/AIDS cases by CD4 cell count at time of detection, Bogota 1997-2011. 
Source: Cuenta de alto costo, MPS (Ministry of Health). 
 
 
2 METHODS 
 
2.1  Model structure  
A mathematical modelling approach was designed for the purposes stated above. A 
deterministic model that simulated the sexual transmission of HIV amongst sexually active 
population between 15 to 49 years old, while introducing the effects of preventive 
intervention over time (i.e. sex acts with condom and ART transmission effects) was 
developed.  
The initial stage of the model represents the HIV infection event where susceptible 
individuals get in contact with infectious individuals at different rates according to their 
sexual activity group “k”, as will be better described later in this section. Those acquiring the 
virus progress through the model structure in a series of stages that intends to represent the 
average decay in CD4+ cell count that characterise the natural history of HIV infection [7]. 
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Progression through stages of undetected infection competes with the rate of detection and 
recruitment into ART as seen in Figure 2. This rate of detection as will be explained later 
varies across disease stages and over the simulation time. Those who enter treatment start an 
alternative path that starts with a transient phase of un-suppressed viral load that was 
incorporated to capture the fact that the effect of ART on transmission depends on the extent 
of viral suppression. Afterwards, treated individuals move to a fully suppressed ART stage 
where progression to death is delayed according to the existent evidence on survival 
extension provided by ART. In these stages, individuals progress vertically (Figure 2) and 
not through CD4+ count stages. Failure on 1
st
 line of treatment is allowed and implies a step 
back to natural progression of disease in the absence of ART which competes again with 2
nd
 
line ART recruitment.  
All the stages of infection in the model represent the number of infectious individuals. This 
constantly changing “pool” of infectious individuals ultimately provides the risk of acquiring 
HIV infection for susceptible individuals at every point in time. However, infectiousness is 
not constant throughout the stages, and a transmission-modification factor was incorporated 
for the acute phase of infection and for the treatment stages. Despite the evidence provided by 
Hollingsworth et al. [8, 9] regarding increased transmissibility during the late phase of 
infection, here it was assumed that anyone with a CD4+ count < 50 cell/mm
3
 was too ill to 
engage in sexual activity.        
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Figure 2 Model structure for the sexual transmission of HIV: Susceptible individuals get infected at rate λk(t) 
(where k denotes the sexual activity group) progressing to Acute stage and leaving at a fixed rate ψ. Natural 
progression through CD4 count stages occurs at fixed rates ρ1 to ρ4 to finally progress to death at rate δ. Rates 
ρ1 to ρ4 are set to match an average CD4+ cell decay of 60cell/mm3 per year. Recruitment into ART occurs at 
rate τk
s(t), varying by CD4+ count “s” and risk group “k”. Individuals set on ART spend an average of 6 months 
(𝜑) in a non-supressed viral load phase. Vertical progression to death from ART suppressive stages occurs at 
rate δ * ϕs, where ϕs is the mortality hazard reduction according to the CD4 count stage “s” at the time of ART 
start. First line failure (𝜗) and second line failure (ξ) are allowed. Recruitment into second line ART occurs at 
fixed rate r, reflecting average retention rates for Colombia. First and second line failure stages progress to death 
at the same rate as the undetected stages.        
      
 
 
Heterogeneity in behaviour was introduced by stratifying the sexually active population of 
Bogota into eight different sexual-activity groups, using Demographic Health Survey data 
[10] (table 1) (Figure 3). The proportion in the sexually active population was estimated 
from data as one minus the proportion of people (men and woman) reporting no sexual 
activity in the last year, according to DHS data.  Following others [11], heterosexual activity 
for men and women was stratified into two different groups: high activity for those with 2 or 
more partners in the past year, and a low activity group, estimated as the remaining 
proportion of the population after estimating all other subpopulation sizes. The latter group is 
assumed to reflect stable heterosexual couples and consequently one partner per year was 
attributed to this group, and levels of condom use according to those reported for 
contraceptive purposes in the national health surveys.  
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FSWs population was previously estimated to be around 0.7% (CI 95% 0.61% to 0.87%) in 
Colombia in 2001 [12]. Since no local estimations for population size of clients of FSW were 
available, regional estimations were used. According to Carael et al. between 0.3% and 7% of 
men in Latin America and the Caribbean have paid for sex in the last year in 2002 [13]. MSM 
were subdivided into bisexual-MSM (MSMbi) and exclusive-MSM (MSMex) to incorporate 
risk heterogeneity within the group and also bridging transmissions between subpopulations. 
MSM population size was previously estimated to be 4.4% (95% CI 2% to 6.6%) of male 
population in Bogota. The relative size of sub-group MSMbi was estimated as ~ 26% of the 
complete MSM group according to reports on the fraction of MSM reporting female partners 
in the past year in a behavioural-survey carried out in Bogota in 2011 [14].  
 
 
Figure 3 Population stratification according to sexual behaviour and gender: Black solid line reflect preferential 
mixing which depends on the fraction of partners assigned to each subpopulation, abased on available evidence 
of mixing preferences or otherwise, based on assumptions. In the case of proportionate mixing, sex acts can 
occur with partners not necessarily preferred. These contacts depend on availability of partners, and are 
represented as “allowed partnerships” in the figure by red dotted lines.  
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2.2 Model Equations  
2.2.1  Ordinary Differential Equations  
 
Equations 1 to 32:  
The following equations are the mathematical representation of the model stages shown in 
Figure 2. For parameter and symbol description see Table 1 
    
1. 
𝑑𝑆𝑘 (𝑡)
𝑑𝑡
= [(𝜎 + 𝜇) (∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠
𝑎
+ 𝑆𝑘 (𝑡)) + (𝛿 ∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠=6
𝑎=0,3,6
) + 𝛿𝜙1𝐼𝑘
2,2(𝑡) + (𝛿𝜙2∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠=3
𝑎=2,5
) +
(𝛿𝜙3∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠=4
𝑎=2,5
) + (𝛿𝜙4 ∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠=5
𝑎=2,5
) + (𝛿𝜙5 ∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠=6
𝑎=2,5
) + 𝛾(𝑡) (∑ 𝐼𝑘
𝑎,𝑠(𝑡)𝑠
𝑎
+ 𝑆𝑘 (𝑡)) +𝑊𝑘(𝑡) +
𝐸𝑘(𝑡)] − 𝑆𝑘(𝑡)∑ (𝜆𝑘,𝑗(𝑡))𝑗  ;Susceptible 
 
2. 
𝑑𝐼𝑘
0,1(𝑡)
𝑑𝑡
= 𝑆𝑘(𝑡) ∑ (𝜆𝑘,𝑗(𝑡))𝑗 − 𝐼𝑘
1,0(𝑡)(𝜓 + 𝜇 + 𝜎); Acute HIV Infection undetected 
3. 
𝑑𝐼𝑘
0,2(𝑡)
𝑑𝑡
= 𝐼𝑘
0,1(𝑡)𝜓 − 𝐼𝑘
0,2(𝑡)(𝜌1 + 𝜏𝑘
1(𝑡) + 𝜇 + 𝜎) ; HIV Positive with CD4 > 500, undetected 
4. 
𝑑𝐼𝑘
0,3(𝑡)
𝑑𝑡
= 𝐼𝑘
0,2(𝑡)𝜌1 − 𝐼𝑘
0,3(𝑡)(𝜌2 + 𝜏𝑘
2(𝑡) + 𝜇 + 𝜎); HIV Positive with CD4 499-350, undetected 
5. 
𝑑𝐼𝑘
0,4(𝑡)
𝑑𝑡
= 𝐼𝑘
0,3(𝑡)𝜌2 − 𝐼𝑘
0,4(𝑡)(𝜌3 + 𝜏𝑘
3(𝑡) + 𝜇 + 𝜎); HIV Positive with CD4 349-200, undetected 
6. 
𝑑𝐼𝑘
0,5(𝑡)
𝑑𝑡
= 𝐼𝑘
0,4(𝑡)𝜌3 − 𝐼𝑘
0,5(𝑡)(𝜌4 + 𝜏𝑘
4(𝑡) + 𝜇 + 𝜎) ; HIV Positive with CD4 199-50, undetected 
7. 
𝑑𝐼𝑘
0,6(𝑡)
𝑑𝑡
= 𝐼𝑘
0,5(𝑡)𝜌4 − 𝐼𝑘
0,6(𝑡)(𝛿 + 𝜏𝑘
5(𝑡) + 𝜇 + 𝜎); AIDS, CD4 <50, undetected 
8. 
𝑑𝐼𝑘
1,2(𝑡)
𝑑𝑡
= 𝐼𝑘
0,2(𝑡)𝜏𝑘
1(𝑡) − 𝐼𝑘
1,2(𝑡)(𝜑 + 𝜇 + 𝜎); CD4 >500, on 1st Line ART, non-suppressed VL 
9. 
𝑑𝐼𝑘
1,3(𝑡)
𝑑𝑡
= 𝐼𝑘
0,3(𝑡)𝜏𝑘
2(𝑡) − 𝐼𝑘
1,3(𝑡)(𝜑 + 𝜇 + 𝜎) ; CD4 350-499, on 1st Line ART, non-suppressed VL 
10. 
𝑑𝐼𝑘
1,4(𝑡)
𝑑𝑡
= 𝐼𝑘
0,4(𝑡)𝜏𝑘
3(𝑡) − 𝐼𝑘
1,4(𝑡)(𝜑 + 𝜇 + 𝜎); CD4 200-349, on 1st Line ART, non-suppressed VL 
11. 
𝑑𝐼𝑘
1,5(𝑡)
𝑑𝑡
= 𝐼𝑘
0,5(𝑡)𝜏𝑘
4(𝑡) − 𝐼𝑘
1,5(𝑡)(𝜑 + 𝜇 + 𝜎); CD4 50 -199, on 1st Line ART, non-suppressed VL 
12. 
𝑑𝐼𝑘
1,6(𝑡)
𝑑𝑡
= 𝐼𝑘
0,6(𝑡)𝜏𝑘
5(𝑡) − 𝐼𝑘
1,6(𝑡)(𝜑 + 𝜇 + 𝜎); CD4 <50, on 1st Line ART, non-suppressed VL 
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13. 
𝑑𝐼𝑘
2,2(𝑡)
𝑑𝑡
= 𝐼𝑘
1,2(𝑡)𝜑 − 𝐼𝑘
2,2(𝑡)(𝛿𝜙1 + 𝜗 + 𝜇 + 𝜎) ; CD4 >500, on 1st Line ART, suppressed VL 
14. 
𝑑𝐼𝑘
2,3(𝑡)
𝑑𝑡
= 𝐼𝑘
1,3(𝑡)𝜑 − 𝐼𝑘
2,3(𝑡)(𝛿𝜙2 + 𝜗 + 𝜇 + 𝜎) ; CD4 350-499, on 1st Line ART, suppressed VL 
 
15. 
𝑑𝐼𝑘
2,4(𝑡)
𝑑𝑡
= 𝐼𝑘
1,4(𝑡)𝜑 − 𝐼𝑘
2,4(𝑡)(𝛿𝜙3 + 𝜗 + 𝜇 + 𝜎) ; CD4 200-349, on 1st Line ART, suppressed VL 
16. 
𝑑𝐼𝑘
2,5(𝑡)
𝑑𝑡
= 𝐼𝑘
1,5(𝑡)𝜑 − 𝐼𝑘
2,5(𝑡)(𝛿𝜙4 + 𝜗 + 𝜇 + 𝜎) ;CD4 50-199, on 1st Line ART, suppressed VL 
17. 
𝑑𝐼𝑘
2,6(𝑡)
𝑑𝑡
= 𝐼𝑘
1,6(𝑡)𝜑 − 𝐼𝑘
2,6(𝑡)(𝛿𝜙5 + 𝜗 + 𝜇 + 𝜎) ;CD4 50-199, on 1st Line ART, suppressed VL 
18. 
𝑑𝐼𝑘
3,3(𝑡)
𝑑𝑡
= 𝐼𝑘
2,2(𝑡)𝜗 − 𝐼𝑘
3,3(𝑡)(𝜌2 + 𝑟 + 𝜇 + 𝜎) ;CD4 350-499, on 1st Line ART failure 
19. 
𝑑𝐼𝑘
3,4(𝑡)
𝑑𝑡
= 𝐼𝑘
2,3(𝑡)𝜗 + 𝐼𝑘
3,3(𝑡)𝜌2 − 𝐼𝑘
3,4(𝑡)(𝜌3 + 𝑟 + 𝜇 + 𝜎) ;CD4 200-349, on 1st Line ART failure 
20. 
𝑑𝐼𝑘
3,5(𝑡)
𝑑𝑡
= 𝐼𝑘
2,4(𝑡)𝜗 + 𝐼𝑘
3,4(𝑡)𝜌3 − 𝐼𝑘
3,5(𝑡)(𝜌4 + 𝑟 + 𝜇 + 𝜎) ; CD4 50-199, on 1st Line ART failure 
21. 
𝑑𝐼𝑘
3,6(𝑡)
𝑑𝑡
= 𝐼𝑘
2,5(𝑡)𝜗 + 𝐼𝑘
2,6(𝑡)𝜗 + 𝐼𝑘
3,5(𝑡)𝜌4 − 𝐼𝑘
3,6(𝑡)(𝛿 + 𝑟 + 𝜇 + 𝜎) ;CD4 <50, on 1st Line ART failure 
22. 
𝑑𝐼𝑘
4,3(𝑡)
𝑑𝑡
= 𝐼𝑘
3,3(𝑡)𝑟 − 𝐼𝑘
4,3(𝑡)(𝜑 + 𝜇 + 𝜎) ;CD4 350-499, on 2nd Line ART, non-suppressed VL 
23. 
𝑑𝐼𝑘
4,4(𝑡)
𝑑𝑡
= 𝐼𝑘
3,4(𝑡)𝑟 − 𝐼𝑘
4,4(𝑡)(𝜑 + 𝜇 + 𝜎) ;CD4 200-349, on 2nd Line ART, non-suppressed VL 
24. 
𝑑𝐼𝑘
4,5(𝑡)
𝑑𝑡
= 𝐼𝑘
3,5(𝑡)𝑟 − 𝐼𝑘
4,5(𝑡)(𝜑 + 𝜇 + 𝜎) ;CD4 50-199, on 2nd Line ART, non-suppressed VL 
25. 
𝑑𝐼𝑘
4,6(𝑡)
𝑑𝑡
= 𝐼𝑘
3,6(𝑡)𝑟 − 𝐼𝑘
4,6(𝑡)(𝜑 + 𝜇 + 𝜎) ;CD4 <50, on 2nd Line ART, non-suppressed VL 
26. 
𝑑𝐼𝑘
5,3(𝑡)
𝑑𝑡
= 𝐼𝑘
4,3(𝑡)𝜑 − 𝐼𝑘
5,3(𝑡)(𝛿𝜙2 + 𝜉 + 𝜇 + 𝜎) ;CD4 350-499, on 2nd Line ART, suppressed VL 
27. 
𝑑𝐼𝑘
5,4(𝑡)
𝑑𝑡
= 𝐼𝑘
4,4(𝑡)𝜑 − 𝐼𝑘
5,4(𝑡)(𝛿𝜙3 + 𝜉 + 𝜇 + 𝜎) ;CD4 200-349, on 2nd Line ART, suppressed VL 
28. 
𝑑𝐼𝑘
5,5(𝑡)
𝑑𝑡
= 𝐼𝑘
4,5(𝑡)𝜑 − 𝐼𝑘
5,5(𝑡)(𝛿𝜙4 + 𝜉 + 𝜇 + 𝜎) ;CD4 50-199, on 2nd Line ART, suppressed VL 
29. 
𝑑𝐼𝑘
5,6(𝑡)
𝑑𝑡
= 𝐼𝑘
4,6(𝑡)𝜑 − 𝐼𝑘
5,6(𝑡)(𝛿𝜙5 + 𝜉 + 𝜇 + 𝜎) ;CD4 <50, on 2nd Line ART, suppressed VL 
30. 
𝑑𝐼𝑘
6,4(𝑡)
𝑑𝑡
= 𝐼𝑘
5,3(𝑡)𝜉 − 𝐼𝑘
6,4(𝑡)(𝜌3 + 𝜇 + 𝜎) ;CD4 200-340, on 2nd Line failure 
31. 
𝑑𝐼𝑘
6,5(𝑡)
𝑑𝑡
= 𝐼𝑘
5,4(𝑡)𝜉 + 𝐼𝑘
6,4(𝑡)𝜌3 − 𝐼𝑘
6,5(𝑡)(𝜌4 + 𝜇 + 𝜎)  ;CD4 50-199, on 2nd Line ART, suppressed VL 
32. 
𝑑𝐼𝑘
6,6(𝑡)
𝑑𝑡
= 𝐼𝑘
5,5(𝑡)𝜉 + 𝐼𝑘
5,6(𝑡)𝜉 + 𝐼𝑘
6,5(𝑡)𝜌4 − 𝐼𝑘
6,6(𝑡)(𝛿 + 𝜇 + 𝜎)  ;CD4 <50, on 2nd Line ART, suppressed VL 
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Sk are the susceptible in each risk category k (k=1 no risk women, k=2 low risk women, k=3 
high risk women, k=4 female sex workers, k=5 no risk men, k=6 low risk men, k=7 high risk 
men, k=8 bisexual MSM, k=9 exclusive MSM, k=10 clients of FSW.  𝐼𝑘
𝑎,𝑠
 is used for all 
HIV+ stages, where superscript a indicates the treatment status in the model, (a=0 is No ART, 
a=1 is 1
st
 line ART non-suppressed VL, a=2 is 1
st
 line ART suppressed VL, a=3 is 1
st
 line 
failure, a=4 is 2
nd
 line ART non-suppressed VL, a=5 is 2
nd
 line ART suppressed VL, a=6 is 
2
nd
 line failure). Superscript s, indicates the CD4+ count stage of disease: s=1 is Acute HIV 
Infection, s=2 is CD4+ count >500 cell/mm
3
, s=3 is CD4+ count 350 to 499 cell/mm
3
, s=4 is 
CD4+ count 200 to 349 cell/mm
3
, s=5 is CD4+ count 50 to 199 cell/mm
3
, s=6 is CD4+ count 
<50 cell/mm
3
.    
 
2.2.2 Force of Infection 
The expression for  force of infection ( 𝜆𝑘,𝑗(𝑡)) , contains the specific transmission rate for 
any given individual of risk category k who establishes effective contact with other individual 
from category j, where k is the choosing partner and j is the chosen one.[15]. Equations 33 to 
35 describe this process for three forms of sexual transmission allowed in the model, namely 
female to male, male to female, and male to male.  
   
 
Equation 33: Force of infection for the transmission of HIV-1 from females (j) to males (k),  
𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑((
𝐼𝑗
𝑎,𝑠
∑ 𝐼𝑗
𝑎,𝑠+𝑆𝑗
) ((1 − ((1 − 𝛽𝑓𝐿
𝑎,𝑠)
𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 − 𝛽𝑓𝐿
𝑎,𝑠𝜍)
𝛼𝑘,𝑗(𝜈𝑘(𝑡)))))], for j=2, 3, 4. 
And k= 6, 7, 8, 10. 
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Equation 34: Force of infection for the transmission of HIV-1 from males (j) to females (k),  
𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑((
𝐼𝑗
𝑎,𝑠
∑ 𝐼𝑗
𝑎,𝑠+𝑆𝑗
) ((1 − ((1 − 𝛽𝑚𝐿
𝑎,𝑠)𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 − 𝛽𝑚𝐿
𝑎,𝑠𝜍)𝛼𝑘,𝑗(𝜈𝑘(𝑡)))))], for j=6, 7, 8, 
10, and k= 2, 3, 4. 
 
Equation 35: Force of infection for the transmission of HIV-1 from females (j) to males (k),  
𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑((
𝐼𝑗
𝑎,𝑠
∑ 𝐼𝑗
𝑎,𝑠+𝑆𝑗
) ((1 − ((1 − 𝛽𝑚𝑠𝑚𝐿
𝑎,𝑠)𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 − 𝛽𝑚𝑠𝑚𝐿
𝑎,𝑠𝜍)𝛼𝑘,𝑗(𝜈𝑘(𝑡)))))], for j=8, 9, 
and k=8, 9.  
 
Irrespective of the type of exposure, the principle in these equations stays the same as the 
changing rate in susceptible and infectious individuals at each point in time determines the 
overall probability of transmission.  
Condom effectiveness is incorporated with the term(1 − 𝛽𝑓𝐿
𝑎,𝑠(1 − 𝜍))
𝛼𝑘,𝑗(𝜈𝑘(𝑡))
. The first 
part of this term reflects the reduction in the probability of infection in a single act with an 
infected partner and using a condom.  Here the symbol 𝜍 is the risk reduction in HIV 
transmission given the use of condom [16]. This term is raised to the numbers of acts 𝛼𝑘,𝑗 
occurring in the partnership between individual k and j, multiplied by the annual proportion 
of sex acts protected with condom for any person in group k,  𝜈𝑘(𝑡), according to local data 
(Table 1).    
On the other hand, risk ratios for transmission due to use of ART are incorporated with 
matrix 𝐿𝑎,𝑠. This term multiplies the transmission probability per act (𝛽𝑚, 𝛽𝑓𝑜𝑟 𝛽𝑚𝑠𝑚) 
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according to the disease stage and treatment status (s and a) of contact in category j. Specific 
transmission cofactor values can be consulted in Table 1. 
    
2.2.3 Mixing matrix and contact patterns in the model 
In equation 35 the term 𝑝𝑘,𝑗 indicates the matrix of mixing between different risk categories 
in the model.  
 
Equation 36: probability of interaction for a given individual of category k, with someone 
from risk group j.   
𝑃𝑘,𝑗 = (𝑒𝑀𝑘,𝑗) + [𝑖𝑘,𝑗(1 − 𝑒) (
𝑁𝑗𝑐𝑗
∑ 𝑁𝑗𝑐𝑗𝑗
)] 
 
Here, 𝑒 is the assortativeness parameter. When mixing is fully assortative (i.e. with like) 
𝑒 = 1, and 𝑒 = 0 when mixing is completely proportionate.  Equation 36, includes a slight 
modification of the system proposed by Garnett et al. (1999)[11], since it includes a mixing 
preference matrix 𝑀𝑘,𝑗  which means that during a fully assortative scenario (e=1) individuals 
from risk group k choose the partner exclusively according to their preference, as opposed to 
proportional mixing where coupling happens as a function of availability of partners in the 
sexually active pool of category j, when j is one of the “allowed” partnerships in the system. 
This restriction is reflected with the identity matrix 𝑖𝑘,𝑗. A graphical description of identity 
and preference matrix can be found in Figure 3. 𝑐𝑗 is the partner change rate in group j.  𝑁𝑗 is 
the sum of people in all stages included in sexual mixing, this means, available for coupling 
between k and j.  
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Equation 37: Matrix of available partners for each risk category j. 
𝑁𝑗 = ∑𝐼𝑘
𝑎,𝑠 + 𝑆𝑗
5
𝑎
𝑠=1
 
 
The mixing matrix described in equation 36 is calculated separately for each partnership 
formed between risk groups, leaving the possibility of imbalances given that risk group k 
might demand more or less partnerships than risk group j can provide. For this reason the 
mixing matrix is adjusted, following the methods described by Garnett et al.[11].   
Equation 38: mixing matrix balancing 
𝛥𝑘𝑗 =
 𝑐𝑗𝑝𝑗,𝑘𝑁𝑗
 𝑐𝑘𝑝𝑘,𝑗𝑁𝑘
 
𝑐𝑘 = 𝑐𝑘𝛥𝑘𝑗
𝜂
 
𝑐𝑗 = 𝑐𝑗𝛥𝑘𝑗
−(1−𝜂)
 
According to this system, the disparity between risk groups is first estimated (𝛥𝑘𝑗) and then 
use to redefine the partnership formation rates of groups j and k. Symbol 𝜂 is the balancing 
coefficient and determines the extent at which each partner commits to balance (i.e. adjust) 
the partnership formation rates.    
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2.2.4 Initial conditions and numerical solution 
Ordinary differential equations (ODE) were programmed and solved numerically using 
MATLAB® R2012b and the Runge-Kutta integration algorithm. The solution involves an 
algorithm coded to iterate in a loop according to a start point, time-step and stop time defined 
along with the epidemic initial conditions. The model considers a start point or times zero (t0) 
in 1975 with a time-step of 0.05 years. The simulation was run until 2014.  
The start of the epidemic is introduced as a seed or initial HIV prevalence in 1975. This 
initial prevalence was let to vary in the calibration process within the limits seen in Table 1. 
This seed was only applied for high risk groups, namely  MSMexclusive, MSMbisexual and FSW, 
considering the initial reports of the epidemic in the country [1].    
 
 
Equation 39: Seeding of HIV epidemic in the model in FSW, MSMexclusive and MSMbisexual 
𝐼𝑘
𝑎,𝑠(𝑡𝑠𝑡𝑎𝑟𝑡) = 𝑓𝛺𝑘(𝑠𝑒𝑒𝑑)𝑁0, for a=0, s=2 and k=4 
𝐼𝑘
𝑎,𝑠(𝑡𝑠𝑡𝑎𝑟𝑡) = (1 − 𝑓)𝛺𝑘(𝑠𝑒𝑒𝑑)𝑁0, for a=0, s=2 and k= 8,…, 9 
 
Here, f is the proportion of females in the total population of Bogota (table 1), and 𝛺𝑘 is a 
matrix containing the  proportion of each subpopulation k in population N0. tstart is the time of 
the start of the epidemic, and N0 is the total population in the model at time 0.    
 
 
 
Chapter 2: Estimating the impact of Antiretroviral Treatment in the HIV epidemic of Bogota 
 
77 
 
2.3 Data and parameterization  
A thorough search for demographic, biological, epidemiological, behavioral and 
programmatic data of HIV in Bogota was carried to parameterize the model. Table 1 
synthesizes the search results while stating which parameters were used for calibration. 
 
2.3.1 Behavior change: condom use in the model 
Behavior changes have been shown  to have modify the course of the HIV epidemic, such as 
for example, a reduction of sexual partners in Uganda and Zimbabwe [17, 18], and the drastic 
increases in condom use among sex workers in Thailand [19].  
In this model, behaviors are summarized by the partner change rates in each modelled sub-
population and the rates of condom use. The first component was set to be fixed over time in 
the simulation, mainly because of the lack of evidence to reproduce a varying time-trend of 
partner change rates. Condom use on the other hand was incorporated with risk-group and 
time variations, by interpolating point estimations of proportion of acts protected per year in 
each category, as reported by several surveys cited in Table 1.  
 
Table 1: Parameters and calibration information 
 
 
 
Calibration Range Prior 
Distribution  
 
Symbol Value Low High Source 
Demographic and Initial Model Conditions 
Total Population 15 to 49 years at time 0 (1970) N0 906000 - - - [20] 
Population growth rate Υ(t) See below - - - [20] 
Background mortality rate μ  1/65 years - - - [20] 
Rate of ceasing sexual activity σ  1/34 years - - - [20] 
Proportion of Female population f 0.52 - - - [20] 
Fraction of Sexually Active Women 1- Ω1 0.842 - - - [20] 
Fraction of FSW in female population Ω4 calibrated 0.005 0.02 Uniform [12] 
Fraction FSW out to Low Risk Group postSW 0.5 
   
Assumption 
FSW turnover rate γ Calibrated 1 20 Triangle [21] 
Fraction of female in High Activity category Ω3 0.0298 - - - [10] 
Fraction of female Low Activity category Ω2 1-( Ω1+ Ω3+ Ω4)  - - - Assumption 
Fraction male High Activity category Ω7 Calibrated 0.09 0.14 Uniform [10, 22] 
Fraction of male in MSM category Ω8 Calibrated 0.021 0.067 Uniform [14] 
Fraction of MSM in Bisexual activity category Ω9 Calibrated 0.11 0.43 Uniform [14] 
Fraction of male in CFSW in category Ω10 Calibrated 0.05 0.15 Uniform [23] 
Fraction of male in Low Activity category 
Ω6 1-( Ω5+ Ω7+ Ω8 Ω9+ 
Ω10) 
- - - Assumption 
Year of Start of the epidemic  1975 - - 
 
Assumption 
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Seed (HIV prevalence at time 0) seed - 0.0001 0.0025 Uniform Assumption 
Behaviour parameters 
Proportion testing for HIV per year (Hk(t)) 
𝐻𝑚𝑠𝑚(2006) Calibrated 0.122 0.177 Uniform [24] 
𝐻𝑚𝑠𝑚(2010) Calibrated 0.197 0.305 Uniform [14] 
𝐻𝑓𝑠𝑤(2007) Calibrated 0.421 0.506 Uniform [25] 
𝐻𝑓𝑠𝑤(2012) Calibrated 0.463 0.537 Uniform [21] 
𝐻𝑚𝑒𝑛(2007) Calibrated 0.049 0.065 Uniform [26] 
𝐻𝑤𝑜𝑚𝑒𝑛(2005) Calibrated 0.040 0.045 Uniform [27] 
𝐻𝑤𝑜𝑚𝑒𝑛(2005) Calibrated 0.086 0.098 Uniform [28] 
HIV testing cofactor according to CD4 count (Fs) 
 
F1 (CD4 >500) Calibrated 0.01 1 Uniform Assumption 
F2 (CD4 350-500 Calibrated 0.01 1 Uniform Assumption 
F3(CD4 200-349) Calibrated 0.01 1 Uniform Assumption 
F4(CD4 50-199) Calibrated 1 3 Uniform Assumption 
Proportion of sex acts protected with condom per year by risk 
group(νk(t)) 
 
νall(<1984) Calibrated 0.010 0.100 Uniform Assumption 
νmsm(2006) Calibrated 0.590 0.667 Uniform [24] 
νmsm(2010) Calibrated 0.530 0.650 Uniform [14] 
νfsw(2007) Calibrated 0.739 0.811 Uniform [25] 
νfsw(2012) Calibrated 0.956 0.982 Uniform [21] 
νhetero(1995) Calibrated 0.072 0.101 Uniform [29] 
νlow(2000) Calibrated 0.104 0.136 Uniform [30] 
νhigh(2000) Calibrated 0.020 0.24 Uniform [30] 
νlow(2005) Calibrated 0.121 0.148 Uniform [27] 
νhigh(2005) Calibrated 0.200 0.415 Uniform [27] 
νlow(2010) Calibrated 0.146 0.170 Uniform [28] 
νhigh(2010) Calibrated 0.260 0.444 Uniform [28] 
Year of Condom use  increase (Behaviour change) condyear80 Calibrated 1984 1994 Uniform Assumption 
Partner Change Rate by risk group per year (ck) 
 
clow_women 0.9522 - - - [10] 
chigh-women Calibrated 2 4 Uniform [10] 
clow_men 1 - - - [10] 
chigh_men Calibrated 2 4 Uniform [10] 
cfsw 638 159 1117 Triangle [21] 
cbi 10 2 45 Triangle [14] 
cmsm 10 2 45 Triangle [14] 
ccfsw - 2 30 Uniform Assumption 
Average number acts per partnership by risk grouper year (αk) 
 
 
αlow 53 - - - [31] 
αhigh 2 - - - Assumption 
αfsw 1 - - - Assumption 
αmsm 4 - - - [14] 
Assortativeness coefficient e - 0 1 Uniform Assumption 
Natural History of Disease 
Per-Act Female to Male HIV transmission probability βf Calibrated 0.00114 0.009 Uniform [9] 
Per-Act Male to female HIV transmission probability βm Calibrated 0.0008 0.002 Uniform [9] 
Per-Act MSM HIV transmission probability (combined)* βmsm Calibrated 0.002 0.025 Uniform [32] 
Average time in Early HIV infection stage (years) Ψ 0.25 - - - [8] 
Progression rates through CD4 stages (years) Ρ1, Ρ2, Ρ3, Ρ4 2.4 - - - [7] 
Progression rate to death  when CD4 <50 cell/mL (years) δ 0.75 - - - [8] 
Relative Infectiousness during Early HIV Infection L0,1 calibrated 4.47 18.18 Uniform [9] 
Interventions 
Recruitment rate into ART by stage of disease per year 
Cs(t) 
 
C5(2001) calibrated 0.56 5,98 Uniform (30) 
C4(2001) Calibrated 0.23 3,96 Uniform (30) 
C3(2001) Calibrated 0,23 2,53 Uniform (30) 
C2(2001) Calibrated 0,19 1 Uniform (30) 
C1(2001) Calibrated 0,16 1,02 Uniform (30) 
C5(2009) Calibrated 2.97 11,7 Uniform (30) 
C4(2009) Calibrated 1,99 11,7 Uniform (30) 
C3(2009) Calibrated 1 2,99 Uniform (30) 
C2(2009) Calibrated 0,52 2,96 Uniform (30) 
C1(2009) Calibrated 0,43 2,96 Uniform (30) 
Annual retention rate into ART r Calibrated 
0.4 0.9 
Uniform [33] 
Year of ART start - 1997 - - - [34] 
HIV transmission proportional reduction due to ART 
La,s 
For a=2,5 
Calibrated 0.73 0.99 Uniform [35] 
HIV transmission proportional reduction non-suppressed ART 
L
a,s
 
For a=1,4 
0.5 - - - Assumption 
Annual rate of failure on 1st line ART 𝜗 Calibrated 0.05 0.25 Uniform [36] 
Annual rate of failure on 2nd?1st line ART ξ 0.23 - - - [37] 
Average time spent in non-suppressed VL with ART (years) 𝜑 0.5 
   
[38] 
Relative disease progression reduction caused by ART by stage of 
disease 
 
Φ3 95% - - - [7] 
Φ4 91% - - - [7] 
Φ5 72% - - - [7] 
Condom efficacy on HIV transmission 𝜍 Calibrated 0.8 0.95 Uniform [39, 40] 
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Equation 40: Linear interpolation,  
𝑓(𝑥) = 𝑌𝑎 + (𝑌𝑏 − 𝑌𝑎)
𝑋 − 𝑋𝑎
𝑋𝑏 − 𝑋𝑎
 
Linear interpolation finds intermediate values from a function underlying the known data 
points. Thus, for two given data points (Xa, Ya) and (Xb,Yb), and a point in time X between Xa 
and Xb.   
However, the amount of information available to reconstruct this trend was not enough to 
confidently reproduce changes in condom use in the first years of the epidemic. It is likely, 
and has been observed elsewhere [41], that the recognition of HIV virus as the cause of AIDS 
could have prompted an increase in condom use. This increase in risk perception might have 
had an important role in shaping the early epidemic, and as such it was included in this model 
by calibrating the start of condom use increase, between 1983 and the time of the first point 
estimation of condom use per risk group.  
 
2.3.2 Modelling ART 
The event of enrolling HIV+ individuals into ART is a complex process that involves many 
steps and implies several barriers encountered between the moment of diagnosis and the final 
delivery of antiretroviral drugs. It was not the purpose of this research to investigate and 
reproduce the cascade of care (but rather to assess the impact of those known to be treated) 
therefore this process was simplified here. Making use of the relevant programmatic 
indicators and some assumptions based in previous observations, recruitment into ART was 
modelled based in three fundamental sources of variation/information: changes in the time 
trend of ART scale-up over time, differential rates by CD4+ count stage, and differential 
access by risk group.   
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The first and more important source of information was the dataset from Cuenta de alto 
costo
4
. This dataset collects periodical programmatic information of HIV patients around the 
country. For Bogota 7161 records were retrieved, and data regarding CD4+ count at the time 
of diagnosis and at the time  of ART initiation was analysed [33]. The first observation from 
this analysis was that the expansion in the number of HIV+ on ART in Bogota increased 
exponentially over time (Figure 4).  
Looking more closely into the characteristics of individuals receiving ART behind these 
numbers, we can find a changing pattern in the CD4+ count at which people had been 
recruited into treatment. The median time to ART (i.e. the time difference between date of 
HIV diagnosis and date of treatment initiation) was estimated and stratified by CD4+ cell 
count range at the time of ART initiation. This calculation was performed over 2351 records 
eligible after excluding those records without all the required information (Figure 5).   
 
Figure 4 Number of new patients receiving ART in Bogota, 1997-2011: Blue dots represent the annual number 
of people recruited into ART from 1997 to 2011, according to Ministry of health records for Bogota. Red line is 
the exponential function fitted to the observed data.     
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Figure 5 Median times between HIV diagnosis and ART initiation in Bogota, by time period: Estimated from a 
sample of 2351 records eligible for analysis in MoH datasets. Light green bars present the median time in years 
for individuals diagnosed between 1997 and 2005. Dark green bars for those diagnosed between 2006 and 2011. 
Error bars reflect the Inter-quartile Range (25 percentile and 75 percentile).  
 
The median time between HIV diagnosis and ART decreased overtime and across all CD4+ 
ranges shown in Figure 5. This observation suggested that time-varying rates of recruitment 
by clinical stage were an important variable to account for  when modelling ART scale-up in 
Bogota. It is worth noting that ART was allowed at every disease stage following this 
observation, contrary to what is stated in the national guidelines as the threshold for starting 
an HIV+ adult into ART in Colombia(i.e. symptomatic illness or CD4+ count less than 350 
cell/mm
3
 ) [42].  
The third component considered as a source of variation in ART delivery (i.e. variations in 
access to ART according to group of exposure) was approximated through estimations of 
HIV testing in different sub-populations. Using data from cross-sectional studies performed 
in Bogota among MSM, FSW and the general population (table 1), time-trends of HIV 
testing rates per year were reconstructed, by linearly interpolating point estimations as 
available. Testing trends for male and female were applied equally to both high and low 
activity classes.  
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These components were brought together in a single term 𝜏𝑘
𝑠(𝑡).  This is explained below in 
equation 41. Thus, recruitment rate works as a function of individual HIV-testing behaviours 
and programmatic efforts to link PLHA to care. Equation 41 describes and puts together the 
pieces of information mentioned before.  
 
Equation 41: Recruitment rate into ART over time in the model            
 𝜏𝑘
𝑠(𝑡) =  𝐻𝑘(𝑡)𝐹𝑠𝐺𝑠(𝑡) 
 
 
Where 𝐻𝑘(𝑡) is the function of HIV-testing rates/year,  𝐹𝑠 is a factor included to reflect the 
possible variations in testing rates by clinical stage, considering that symptomatic disease 
might lead to health-seeking behaviours (values can be found in Table 1). Finally, 𝐺𝑠(𝑡) 
incorporates the information about time-to-ART as shown before in Figure 5. As explained 
above, the scale-up of ART appear to have followed an exponential trend over time, thus 
𝐺𝑠(𝑡) was formulated as the exponential interpolation of times to ART (rates) (Figure 5) for 
periods 1997 to 2005, and 2006 to 2011. The median point of this time ranges was used for 
interpolation.  
 
 
 
 
 
HIV testing by 
risk group 
Testing co-factor 
by stage of 
disease 
Reflects waiting 
time between 
diagnosis and ART 
by CD4+ stage 
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Equation 42: Exponential interpolation   
𝐶𝑠(𝑡) = 𝑒𝑥𝑝 [𝑙𝑛(𝐶𝑠(2001) + [𝑙𝑛(𝐶𝑠2009) − 𝑙𝑛(𝑌𝑎)]
𝑡 − 2001
2009 − 2001
] 
 
This equation was solved for each disease stage s (for s = 2,…, 6), using data points for 2001 
and 2009 that were also calibrated, with prior ranges shown in Table 1. 
 
2.4 Model Calibration 
2.4.1 Parameter sampling 
Model calibration was carried out by fitting model outcomes to data on HIV prevalence 
among FSW, MSM and antenatal clinics, as well as numbers of deaths due to AIDS and 
patients receiving ART. Parameters were sampled from prior ranges obtained from the 
original sources of information or assumed in some cases. Complete details of prior ranges 
can be found in Table 1. A Latin Hypercube Sampling (LHS) technique was used, which 
provides a computationally efficient approach to  sampling multidimensional parameter space 
[43, 44]. Briefly, LHS starts with an iterative process of drawing parameter values to populate 
a table -LHS table-, sized p x i, where p is the number of parameters to be sampled and i is 
the number of desired runs. Sampling is made by stating a prior distribution of the parameter 
sample space, which is then sliced in equi-probable sections. These sections are sampled 
without replacement, and a value is chosen from within that range. A total of 61 parameters 
were chosen for calibration.        
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2.4.2 Fitting model outcomes to data 
Model outcomes were systematically compared against data from the city as follows.  
a. HIV prevalence in MSM: 
HIV prevalence estimations from available cross-sectional studies in Bogota were used as 
shown in table 2. The modelling outcome fitted here was overall HIV prevalence amongst all 
MSM (i.e. MSMex and MSMbi combined). 
 
Table 2: HIV prevalence studies among MSM in Bogota 
Year of observation Sample size Prevalence Source 
1999 643 20.4% [45] 
2002 660 19.7% [46] 
2006 630 11% [47] 
2010 485 15% [14] 
2012 1000 12% [48] 
 
 
b. HIV Prevalence among FSW: 
Similarly, information regarding HIV prevalence among female sex workers was available 
from studies carried out in Bogota, as can be seen in table 3. 
 
Table 3: HIV prevalence studies among FSW in Bogota 
Year of observation Sample Size Prevalence Source 
2002 514 0.78% [49] 
2007 529 0.76% [25] 
2012 706 0.20% [50] 
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c. HIV Prevalence in Antenatal Clinics (ANC): 
Data from antenatal clinics was fitted to overall HIV prevalence among women in the model, 
irrespective of their risk category. Data can be seen in table 4. 
 
Table 4: HIV prevalence studies among pregnant women in Bogota 
Year of observation Sample size Prevalence Source 
2003 139 0.72% [51] 
2009 2847 0.035% [52] 
 
 
 
 
 
 
d. Mortality due to HIV/AIDS: 
Time-series of reported annual numbers of deaths due to AIDS (total and among males) 
were available from Observatorio Nacional de la Gestión en VIH (National Observatory 
of HIV Management)
5
. Full dataset can be seen in table 5.  
Mortality reports by general causes and AIDS in Colombia have been shown to be 
susceptible to underreporting [53, 54]. For this reason, the matching modelling outcome 
to data on reported deaths was a modification of total AIDS mortality in the model, by 
including one parameter that incorporates variation in underreporting over time (Mreport). 
Therefore: 
 
 
                                                          
5 Observatorio Nacional de la Gestión en VIH routinely collects and publishes data on HIV report cases, mortality and care. Available in 
the internet at http://www.minsalud.gov.co/salud/Paginas/Observatorio_menu_monitoreo_evaluacion_vigilancia_salud_b.aspx 
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Equation 43.Model outcome for reported deaths due to AIDS 
𝑀𝑜𝑑𝑒𝑙𝐴𝐼𝐷𝑆𝑑𝑒𝑎𝑡ℎ𝑠(𝑡) = 𝑇𝑜𝑡𝑎𝑙𝐴𝐼𝐷𝑆𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦(𝑡) 𝑥 𝑈𝑛𝑑𝑒𝑟𝑟𝑒𝑝𝑜𝑟𝑡(𝑡) 
Underreporting over time was assumed to have followed a linear trend connecting the points 
Mreport ~U (0,0.9) in 1983 and 90% in 2010 according previous estimations [55] 
e. Number of people recruited into ART: 
Similarly, Observatorio Nacional de la Gestión en VIH provided time-series data on annual 
numbers of people recruited into ART from 1997 to 2011. (Table 5)  
 
Table 5:  Reported mortality due to AIDS and people receiving ART in Bogota 
Year 
Reported 
Deaths caused 
by AIDS 
Number recruited into 
ART 
1991 108 - 
1992 290 - 
1993 273 - 
1994 396 - 
1995 405 - 
1996 435 - 
1997 310 203 
1998 286 159 
1999 353 133 
2000 422 163 
2001 388 202 
2002 404 205 
2003 391 260 
2004 415 331 
2005 368 402 
2006 348 452 
2007 328 495 
2008 329 584 
2009 272 794 
2010 - 883 
2011 - 1011 
 
 
Chapter 2: Estimating the impact of Antiretroviral Treatment in the HIV epidemic of Bogota 
 
87 
 
2.4.3 Goodness of fit  
The selection of the set of model simulations that better reproduce the data described above, 
was carried out using Likelihood Estimation.  
Likelihoods were independently estimated for each data point and summed to obtain a global 
likelihood for each simulation. Prevalence data was compared against the matching model 
outcome using the Log-Likelihood binomial distribution function. 
 
 
Equation 44: Log-Likelihood function for binomial distribution 
- ln𝐿(𝑦, 𝜃) = ∑ 𝑁𝑖𝜃𝑖 𝑙𝑛(𝑦𝑖) + 𝑁𝑖(1 − 𝜃𝑖)𝑙𝑛 (1 − 𝑦𝑖)𝑖  
 
Here, 𝜃 the observed prevalence and y is the predicted model prevalence. N is the sample size 
for prevalence data 𝜃.     
For AIDS mortality and ART data, the Poisson distribution was assumed: 
Equation 45: Log-likelihood estimation for Poisson distributed data 
ln ℒ(𝑦|𝜃) =∑(𝜃𝑖𝑙𝑜𝑔𝑦𝑖 − 𝑦𝑖 − 𝑙𝑜𝑔𝜃𝑖!)
𝑛
𝑖=1
 
Here, the data-point (𝜃𝑖 ) (e.g. number of AIDS deaths) is being matched against the ith 
modelled outcome (𝑦𝑖).   
Log Likelihood estimations for each set of parameters were sorted in descending order to 
select the runs that summed-up up to 95% of the overall probability of the model reproducing 
the data. These runs are shown in the calibration section of Results in this document.  
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2.5 Plan of analysis 
2.5.1  Characterization of HIV epidemic in Bogota    
Using the series of fits coherent with data, we use model results to help characterize the 
epidemic in Bogota as follows. 
A) Determine the distribution of new HIV infection annually Per risk groups. 
B) Determine the source of infections, by determining the distribution of new HIV 
infections each year that originated from the different risk groups and stages of 
HIV infections. 
C) Estimated the Population attributable fraction for risk groups in the model. 
 
The first step of analysis was focused on trying to extract useful epidemiological insights out 
from the calibrated model of HIV transmission in Bogota. More than intending to provide 
definitive evidence about infection dynamics in this context, this analysis was made as means 
to explain the posterior results on HIV incidence reduction estimations, while “dissecting” 
the model mechanics of these simulations.     
The simulated epidemic in Bogota was characterized by assessing the distribution of 
cumulative new HIV infections by sub-population, and also by establishing the source of 
these infections over time by both risk group and clinical stage of the virus donor in the 
model.  This was carried out in order to provide two points of view on transmission: the 
relative size of the epidemic in each risk category and unveiling the more active “spreaders” 
of HIV.     
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 Drivers of the simulated HIV epidemic were identified by estimating Population Attributable 
Fraction (PAF).  In this analysis, a simulated scenario where transmission was removed from 
specific subpopulations was performed for observing the proportional reduction in 
cumulative HIV incidence when contrasted against the calibrated model,   for each pair of 
simulation with and without transmission from the relevant risk group 
 
2.5.2  Estimation of retrospective impact of interventions 
The impact of antiretroviral treatment was assessed by estimating total and proportional 
reductions in cumulative incidence of HIV over a period from 1997 to 2014. Three 
counterfactual scenarios were built to assess the retrospective impact of interventions:  
1) Baseline scenario - Combined intervention (calibrated model): This is the resulting set of 
simulations resulting from the model calibration process to all available data from Bogota. In 
this scenario the level of ART and condom use reflect those reported from the data over time. 
This scenario represents the best possible representation of the epidemic in Bogota according 
to this model.   
2) Condoms only (counterfactual 1): In this scenario, we use the same sets of parameters as in 
1) with the exception that we assume that ART was not introduced in the population at all for 
the whole period between 1997 (when it started) and 2014, therefore the resulting projection 
shows the epidemic as it would look like if only condoms had been made available. We used 
this counterfactual for estimating incidence reductions due to ART use. 
3)  ART only (counterfactual 2): In this scenario, condom use in all populations was removed 
from 1997, meaning that only ART use was represented (starting in 1997 as in 1). This 
counterfactual was used for estimating incidence reductions due to condom use. 
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4) No intervention (counterfactual 3): This scenario assumes that neither condom not ART 
were allowed in the simulation.  This counterfactual was used for estimating total HIV 
incidence reductions. 
To make all the scenarios comparable, and considering that condom use had historically been 
available as prevention for longer than ART, the above mentioned scenarios were compared 
from 1997 to date. This means that model projections are exactly the same as the calibrated 
model for the all scenarios until 1997 when interventions were either applied or removed.  
These scenarios were implemented initially in all the population in the model, and then were 
applied over specific risk groups. The first approach explores the overall contribution of each 
intervention scenario on the subsequent reduction in HIV incidence irrespective of who is 
intervened. The second approach intends to dissect these contributions by risk group and to 
establish which component had the largest impact at a population level.  
The outcome of choice was always the same for all comparisons, and it was cumulative HIV 
infections averted in the total population between 1997 and 2014. Absolute and proportional 
reductions are presented.  
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Equation 46: Absolute Cumulative HIV infections averted  
𝐶𝐻𝐼𝐴 =  ∫ ∑𝑆𝑘
0(𝑡) (𝜆𝑘,𝑗
0 (𝑡))
𝑗,𝑘
 𝑑𝑡
𝑏
𝑎
− ∫ 𝑆𝑘
𝑛(𝑡)∑(𝜆𝑘,𝑗
𝑛 (𝑡))
𝑗,𝑘
 𝑑𝑡
𝑏
𝑎
 
 
The term 𝑆𝑘(𝑡)∑ (𝜆𝑘,𝑗
0 (𝑡))𝑗  is the number of new HIV infections per unit time 𝑑𝑡 under the 
No-Intervention counterfactual scenario, symbolized by the superscript 0 over 𝜆.  Superscript 
n in the second term reflects any of the other three scenarios where interventions took place 
(i.e. Condoms only, ART only, and Combined). A proportional estimation of CHIA was also 
calculated by dividing the expression above by the first term, this is, the cumulative number 
of cases seen with the No-Intervention counterfactual scenario.       
This outcome was estimated for each of the n simulations obtained in the calibration process. 
Uncertainty around point estimations, in this case the median, is presented with interquartile 
range (IQR).   
To research further the source of HIV incidence reductions in the model, a final modification 
to the combined scenario was made by setting ART transmission effectiveness to zero. This 
was done to discriminate between the impact of ART’s transmission and survival effects on 
incidence reduction.  
      
3 RESULTS 
3.1 Calibration results 
After 500,000 model iterations (i.e. combination of parameters), the calibration procedure 
yielded 412 runs that were accepted under the criteria of the prior limits set on the model 
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outcomes. From these, 232 sets of parameters were selected as these represented the 95% 
weight of the cumulative likelihood. Figures 6 synthesize calibration results.  
The posterior distribution from the subset of sampled parameters sets can be seen in 
Appendix Figures S1 and S2. These figures show that transmission probabilities as well as 
partner change rates among FSW and MSM and the assortativeness parameter (e) were the 
distributions most influenced (informed) by the calibration procedure in contrast with their 
prior distribution. No major correlations between parameters were found as can be seen in the 
correlation matrix in Figure S3.     
 
 
Figure 6 Calibration results to reported mortality by AIDS data (top left), number of patients receiving ART 
(top right), HIV prevalence among MSM (middle-left), FSW (middle right) and pregnant women (bottom left), 
in in Bogota.. Grey lines reflect simulations for the 95% of the cumulative likelihood and black solid line is the 
median of this distribution. Red dots are data points available in each dimension.    
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3.2  HIV Epidemic Characterization  
From this model, it is estimated that a median of 26,200 cumulative HIV infections (IQR 
13120) have occurred in Bogota from the beginning of the epidemic to 2014.  
The model suggests that HIV incidence may have peaked in 1986 at an estimated median rate 
of 0.054% person-year (0.03 – 0.09) give uncertainty range with a smooth decline until date. 
A peak in HIV prevalence in Bogota shows a slight delay with respect with HIV incidence 
rate as can be seen from Figure 7.    
 
 
 
Figure 7 Modelled HIV incidence and prevalence in Bogota, 1975 2014: Left panel shows median HIV 
incidence estimation with 25/75 percentile around. Right panel shows median estimation of HIV prevalence 
with 25/75 percentile.   
 
 
 
3.2.1 3.2.1. HIV infections by risk group 
Distribution of cumulative HIV infections overtime by risk group in the model suggests that 
over 72% (IQR 17%) of cumulative incidence infections in Bogota have occurred among 
MSM. It also suggests that heterosexuals (non-sex work related) contributed with around 7% 
(IQR 6%) of infections until 1980, and reaching 22% by 2014, at the expense of a decrease in 
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cumulative contribution by the bisexual MSM sub-group. FSW and their clients show a stable 
contribution (6% to 10%) over time (Figure 8). 
 
 
 Figure 8: Distribution of cumulative HIV infections by risk group in Bogota, 1975-2015. Proportions showed 
reflect the median estimation.     
 
 
 
3.2.2 Sources of transmission  
Approximately 29% (IQR 27%) of new HIV infections in the model arose from infected 
individuals who were in the Acute stage of infection being this the major source of 
transmission cumulatively, followed by clinical stages with CD4+ > 500 cell/mm
3
 (25%, IQR 
24%), and the least coming from the stage with CD4+ 50-199 cell/mm
3
 (11%, IQR 
12%)(Figure 9).    
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From the start of the epidemic until 2014, 80% (IQR 16%) of all HIV infections had its 
source at MSM groups. The most noticeable change is the cumulative number of infections 
coming from heterosexual groups, with less than 5% in the first decade to increase to 13% 
(IQR 10%) in the last decade (Figure 9).       
 
 
Figure 9 Source of HIV transmission by clinical stage of infection: median cumulative fraction of new 
infections since the beginning of the epidemic, as distributed by the CD4+ count stage of the HIV donor.  
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Figure 10: Source of HIV transmission by risk category: median cumulative fraction of new infections since the 
start of the epidemic,  as distributed by the risk group of the HIV donor. 
   
 
3.2.3  Drivers of HIV epidemic 
Population Attributable Fraction from 1975 to 2014 was estimated for main risk-groups 
(MSMex, MSMbi, FSW and grouped low-risk and high-risk heterosexuals) as can be seen in 
Table 6.       
Table 6: Population Attributable Fraction of cumulative HIV incidence by risk group  
Exposure group PAF IQR  
Exclusive MSM 90.2%  34%  
Bisexual MSM 99%  12%  
Female Sex Workers 8.5%  15%  
Heterosexual 14%  10%  
Table 6 Population Attributable Fraction of cumulative HIV incidence by risk group: Proportional and absolute 
median reduction in cumulative HIV infections from the beginning of epidemic to 2014.     
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PAF estimations suggest that both MSMbi and MSMex are major drivers of HIV epidemic in 
the model, being particularly for the bisexual subgroup of MSM.      
3.2.4  Estimation of retrospective impact of interventions  
The scenario analysis shows that according to this model, the combination of condom use and 
ART (calibrated model) in Bogota may have averted a median of 54,200 (IQR 52000) new 
HIV infections from 1997 to 2014, when compared against a No-Intervention simulated 
scenario. If only ART would have been available for the same period, only 12800 (IQR 9300) 
cumulative infections could have been averted, compared to 52431 (IQR 46000) for a 
scenario with only condoms (Figure 11).    
 
 
Figure 11 Box Plot for the total number of cumulative HIV infections averted from 1997 to 2014: Cumulative 
HIV infections averted with three analysed scenarios of intervention in the total population (top-left), only 
targeted to MSM (top-right), only targeted to FSW (bottom-left) and targeted to heterosexuals (bottom right).     
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These results suggest that condom use was the main factor behind HIV incidence reduction in 
the model, and across all groups.   
When the analysis of simulated scenarios was performed by targeting specific risk groups, 
interesting conclusions were drawn from the visual comparison (Figures 12 & 13): removing 
ART from a single group would have had a noticeable impact in the overall epidemic only if 
done for MSM. Removing use of condoms in the same period showed a great impact when 
done for both FSW and MSM, but it is only when removed only from FSW that incidence 
levels reach the levels seen when condoms were removed in the total population. This 
suggests that condoms are the main factor preventing the emergence of a bigger epidemic 
amongst this group. On the other hand, is worth noting that targeted removal of interventions 
in the grouped-heterosexual category did not produce any noticeable change in HIV 
incidence in the general population (Figure 12).    
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Figure 12 Modelling results of effect of interventions over HIV epidemic in Bogota: Epidemic projections for 
four scenarios of intervention in Bogota, from 1997 to 2014. In orange, only condoms scenarios while the 
calibrated model and the ART scenarios are shown in solid grey and blue respectively. Panels for specific 
populations reflect incidence rates in the Total population when interventions where exclusively applied to that 
group.  
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4  DISCUSSION 
Transmission of HIV in Bogota was simulated using a mathematical model calibrated to local 
data. This model was able to reproduce epidemic trends and surveillance data, providing a 
plausible interpretation of what HIV transmission could have been in Bogota in the last four 
decades. According to these results, interventions had an important role in shaping the 
epidemic, with condoms being the main driver of epidemic control. ART in the model plays 
an additional role contributing with an important number of HIV infections averted, and its 
effect was more evident among MSM. A targeted analysis exploring the population effect of 
adding and removing interventions into specific groups raise interesting thoughts about how 
maximization of effectiveness could be achieved in epidemics with high transmissibility 
concentrated in small sub populations. In this model, removing all preventive interventions 
from the MSM groups (keeping other populations unchanged), resulted in an increment of 
70% in cumulative HIV incidence from the calibrated model results. This is consistent with 
the PAF analysis which suggests that MSM groups have an attributable fraction of the HIV 
incidence as big as 90% since the start of the epidemic. In conclusion, the epidemic 
representation of Bogota’s epidemic shows intense transmissibility within MSM, with a 
major role of bisexual activity males, and a high dependency on interventions to find the 
slowing in epidemic growth seen in the recent years.      
 
Incidence reduction due to treatment in this model is not insignificant (~ 20%) but was not 
very large, and a number of factors come to mind when trying to explain the constrained 
impact of antiretroviral drugs on transmission in this context: First, from the programmatic 
point of view and as exposed in the introduction of this chapter, the biggest portion of cases 
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detected and set on ART come from the more advanced phases of infection, while the 
modelled source of infection shows a distribution strongly skewed towards the early stages of 
infection. In summary, it is possible that ART is also not reaching the sub-populations 
generating the majority of infections, undermining the prevention potential of antiretroviral 
drugs. In this simulation the fraction of individuals receiving ART who belonged to the MSM 
group (Figure S4) matches the fraction of MSM affected by HIV (Figure 8). However, HIV 
testing rates are used here as a proxy of the possible variations in access to ART across risk 
groups in the city, which might underestimate the real barriers found by the most vulnerable 
groups.   
Another point to consider is related to the data used to calibrate the model in the ART 
delivery dimension: The city records for numbers of patients on ART only consider people 
receiving medical care from of the national health services. Even when coverage of such 
system is high among the population –around 75% in 2007- [6], there is still a small fraction 
of individuals getting their treatment out-of-pocket, and therefore not included in such 
records. In 2006 it was estimated that only 5.6% of all detected PLHA were not affiliated to 
the national health system. This figure came down to  0% by 2007 [6]. However, changes in 
more recent years could not be foreseen.       
 
The stage of infection could play an important role in the potential impact of ART as has 
been shown and debated elsewhere [56-59]. Here, the fraction of cases arising -cumulatively- 
from acutely infected individuals was around 25%. A very simple reasoning around this 
figure, suggests that any attempt to prevent HIV transmission by means of treating those 
infected in this context will not achieve effectiveness levels greater than 75%, and that is 
assuming optimal levels of detection and treatment delivery for those HIV+ with over 500 
CD4-cells/mm
3
.  
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Condom use displayed a significant impact in the simulated epidemic for Bogota, with 
reductions as high as 76% in cumulative HIV incidence for the period 1997 to 2014. This 
figure could be even higher if we consider that our analysis was restricted to the period 1997-
2014, for comparability reasons. This means that the previous impact of condom use during 
the early years of the epidemic was removed from this estimation. 
The first limitation about this approach is the restriction imposed in the model by not 
allowing other forms of behaviour change over the years, such as reduction of partners. This 
will tend to overestimate the impact of condoms as it will have to absorb and reproduce the 
impact of all other alternatives in HIV prevention. This restrictiveness in behaviour change is 
also found in the way that condom use was introduced. Even when it seems plausible to 
assume that a drastic decline in transmission might have appeared in several contexts given 
the start of the HIV testing era and increased risk awareness  [41, 60], this could have 
happened to different extents according to the form of exposure. This is not allowed in the 
model, in part because there is little evidence to support the contrary. As a result, this 
“forced” change in behaviour could be one of the factors why this model finds it difficult to 
produce epidemics that saturate and reach equilibrium with less help from external forces like 
ART and condoms. Besides, for an epidemic driven so strongly by MSM such as the one in 
Bogota, the risk heterogeneity within this group portrayed by the model is rather limited. It is 
indeed possible to conclude that a lack of risk heterogeneity within MSM groups in the model 
might be leading to an overestimation of the impact of condoms in this group, given that 
protection rates in this group are particularly high. Ideally, a more detailed specification of 
the MSM spectrum of behaviours would drive transmission to its equilibrium by means of 
natural dynamics of HIV transmission. Incorporating one or several more categories of risk 
within the MSM group would have a buffer effect in the model by diverting transmission 
from the very high risk pools to low or intermediate risk MSM sub-groups. Given a less 
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intense transmission within the lower risk groups, the epidemic would progress more 
smoothly from the early epidemic outburst to the endemic phase. Also, one would expect less 
protected acts within stable MSM couples than in the casual ones, thus decreasing the overall 
impact of condoms on incidence. Nevertheless, changing these features was bounded by the 
absence of information on the diversity and nuances of MSM population in Bogota, which is 
in itself an important finding of this research.          
 The characterisation of the simulated epidemic in Bogota showed it was highly concentrated 
among MSM and elucidated very high levels of dependency on HIV transmission coming 
from this population. This is evident from PAF calculation by risk group displayed in Table 
6, suggesting that HIV transmission would die out if MSM groups were removed from the 
infectious pool.   
Analysis of the source of infection by stage of disease reveals that in the early years of the 
simulated epidemic in Bogota more than 50% of new infections could be ascribed to 
transmission during the acute stage, whereas by 2014 ~25% were attributable to that stage of 
infection. This is consistent with previous findings, which highlighted the importance of the 
epidemic phase when estimating of the role of early HIV infection (EHI) in HIV transmission 
[57]. A greater contribution of the early phase to transmission in early epidemics is thought to 
be caused by an outburst of new cases, thus producing a higher proportion of infected 
individuals in acute and early stages. This proportion decays as epidemic approaches its 
endemic phase as does the role of the early HIV infection on transmission [61].  
Here, it is also important mentioning the role of number of sexual partners per year in the 
extent of incidence ascribed to the early HIV infection (EHI). Koopman, Kretzschmar and 
others [62-64] have already observed how the fraction of cases coming from primary HIV 
infection donors increases in the presence of concurrency and multiple partners. Xiridou et al.  
Chapter 2: Estimating the impact of Antiretroviral Treatment in the HIV epidemic of Bogota 
 
104 
 
[65] and Kim et al.[66] used modelling techniques to incorporate complexity around sexual 
partnership formation –durations, dissolution rates, concurrency- and found that this nuances 
were of central importance for accurately estimating the role of EHI in MSM driven 
epidemics. This model assumes a more simple approach, using an instant partnership 
formation at different rates according to the sexual partnership information available at the 
time this model was designed. Also, incorporation of further complexity around partnership 
formation was not only constrained by the paucity of data in Bogota but beyond the scope of 
our initial objectives.  
It is important to highlight that these results are the first and more in depth approach to 
estimate the role of ART and condom use in the sexual transmission of HIV in Bogota. 
Exploring the dynamics between sub-populations in this context can provide a theoretical 
base for better understanding the overall effect of programmatic efforts of the past. Therefore, 
these findings come to enrich the body of knowledge for understanding the epidemiological 
trends of HIV in Latin America and also other contexts where HIV remains hyper-endemic 
among MSM groups.  
Future efforts should be focused on applying methods with more flexible systems for 
reproducing behavioural nuances. Using future data on the more complex details about the 
structure of high transmissibility groups is a central part of research in concentrated 
epidemics.  
This model’s results led in some way to reflect about the urgent need of more evidence about 
targeted prevention interventions based on ART tailored to fit the needs of concentrated 
epidemics. Future work should explore different aspects of such interventions.  
The era of abundant international resources dedicated to HIV response world-wide might be 
coming to an end, especially in a number of states where health systems and infrastructure is 
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already in place to withstand the impact of the changing epidemic. The wisest move for these 
countries starts by understanding their own needs for designing those strategies that 
maximize their resources and exploits the potential of the available prevention technologies. 
Hopefully this work contributes in building the path in that direction.             
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1  INTRODUCTION 
In November 1996 the government of Brazil began one of the biggest ventures of public 
health in a middle income country by guaranteeing free and universal access to antiretroviral 
therapy (ART) to people living with AIDS. Brazil opted for the expansion of treatment 
amidst criticism from donors and international agencies which considered that developing 
countries should invest more in prevention interventions than treatment [1]. As 
a result, Brazil’s became the first and largest public AIDS programme in a middle income 
country.  
Brazil has a population of 202 million people [2], and its AIDS programme has reported over 
656,000 cases of AIDS since the first case in 1980 to 2012 [3]. According to the latest 
epidemiologic bulletin, by 2012 720,000 people were estimated to be living with HIV/AIDS 
in Brazil. Of these, 80% (574,000) had been diagnosed, 74% (531,000) linked to care, 61% 
(436,000) retained in the system, 44% (313,000) were receiving ART, and 33% (236,000) 
had an undetectable viral load (VL < 50 RNA-copies/mL) [4].  Reaching such numbers 
requires an infrastructure and a well-functioning system in place to not only deliver drugs but 
to detect new cases, link patients to care, perform clinical assessment and retain individuals in 
the programme.  
 Sistema Único de Saúde (Unified Health System) known in Brazil by its acronym, SUS, was 
created in 1990 after several years of political and social struggle in the country. After 21 
years of military regime (1964 to 1985), the start of the AIDS epidemic found Brazil in the 
middle of its transition to democracy, and the country’s definitive turn towards socially 
oriented governments [1]. With a new health system in place, the development of new drugs 
capable of keeping the virus in check, and the increasing need to respond to the growing 
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number of cases, one could say that Brazil’s AIDS universal treatment programme was a 
product of political will, social mobilization and “good timing”.  
Brazil’s ART programme is frequently portrayed as a “success story” of treatment scale-up, 
and rightly so: in a paper by Marins et al., [5] the authors report the striking increase in 
survival time from AIDS within individuals diagnosed in 1996 and starting combined ARV 
therapy (58 months) compared to those diagnosed between 1982-1985 (5 months) and 1995 
(18 months). Similar results have been observed at the regional level and in studies conducted 
in the major cities of Brazil [6]. Moreover drastic reductions in morbidity by opportunistic 
infections [7] and even tropical endemic diseases like malaria, Chagas disease and 
leishmaniasis were observed among HIV patients in Brazil [8].  
However, Brazil can hardly be taken as a single unit, and to understand the dynamics of HIV 
transmission as well as the impact of interventions as a whole, it is necessary to increase the 
level of detail at least to the regional dimension. Brazil is divided into five geographic 
regions, namely: North, Northeast, South, Southeast, and Central-west. The coasts of the 
country are densely populated in contrast to the centre and Amazonian regions, with the 
largest urban settlements (Sao Paulo, Rio de Janerio, Belo Horizonte) located in the Southeast 
(Figure 1). Consequently, the South and Southeast regions not only represent the vast 
majority of urban Brazil, but also concentrate the economic wealth of the country.  
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Figure 1 Population distribution of Brazil: proportional circles map showing population density in populated 
centres across the country in the year 2000.  
Source: Sampaio et al, 2008.[9]. Image reproduced with permission of the rights holder, Confins Revue ©. 
 
The populated urban centres in southeast Brazil offered the conditions for the spread of HIV 
across the country in the early years of the epidemic. Hosting the largest majority of men who 
have sex with men (MSM) as well as people who inject drugs (PWID) and a large rate of 
population mobility, the cities of São Paulo and Rio de Janeiro became the epicentre of the 
Brazilian HIV epidemic. The first AIDS case was reported in 1980 in São Paulo [10] and 
from there on the epidemic expanded with over 50% of cases detected occurring amongst 
MSM living in the southeast [1, 11]. An important number of cases emerged as well in PWID 
during the early 1990s, particularly in urban areas of the south, but different factors like a 
shift in drug use behaviours slowed transmission in this group [12, 13]. Despite an observable 
change in the male to female ratio of new infections and a greater role of rural Brazil in the 
distribution of new cases, the epidemic is still predominantly urban and concentrated among 
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MSM. Prevalence among the general population has been stable at 0.6% since 2004 [14, 15] 
while the estimate in different settings among MSM has ranged between 6% and 26% for the 
last 5 years (Table 1).  
There has been much debate about Brazil’s bold decision of choosing universal access to 
treatment instead of following international trends to invest in prevention [1]. However, 
evidence from HPTN 052 [16] on the effect of antiretrovirals for preventing HIV 
transmission bridged the gap between prevention and treatment, providing fresh arguments 
for this debate. In a country where the response to AIDS epidemic is synonym of AIDS-
treatment-expansion, establishing how much of that unprecedented approach actually ended 
up in preventing new HIV infections is a burning question for decision-makers and an 
interesting opportunity for HIV researchers.           
To answer the above question, this chapter aims to retrospectively estimate the HIV incidence 
reduction in Brazil in the context of a large scale intervention of free and universal access to 
ART for those in need. For this purpose, a mathematical model was designed and applied to 
the main five geographical regions in Brazil.   
 
2  METHODS 
The sexual transmission of HIV in Brazil since the beginning of the epidemic to date was 
reproduced through a compartmental deterministic mathematical model, calibrated separately 
for each major region in the country. This geographical approach was chosen based on two 
important considerations: first and more importantly, spread of infection patterns and HIV 
mortality have been shown to be closely related with the geographical macro-regions in the 
country [17]. The second argument is the systematic report of surveillance data in Brazil 
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which follows the regional distribution adopted in this chapter. The same approach of 
geographical division is widely used to inform and report research results in Brazil [18-21].    
Sexually active individuals over 15 years of age were simulated in a system that involves 
sexual mixing according to sexual behaviour. Interventions (i.e. condom and ART) were 
introduced in the model based on regional data. The mathematical expression of the models 
consists of a set of ordinary differential equations coded in MATLAB®, and solved 
numerically using the Runge-Kutta method.  
A comparison of model versus data was made in a Bayesian statistical framework, which 
incorporates the prior knowledge about the distribution of parameters to the overall 
probability of the model given the data.  
Equation 3.1: Posterior probability   
𝑝(𝜃, 𝑦) = 𝑝(𝜃)𝑝(𝑦|𝜃), 
 
Here, 𝜃 represents the model or parameter set and 𝑦 is the given data. Prior probability 
𝑝(𝜃) adds towards the posterior probability of the model explaining the data 𝑝(𝜃, 𝑦), together 
with our evidence provided by model comparison, summarized here as 𝑝(𝑦|𝜃), and translated 
as the likelihood.  
 
 
2.1 Model Structure  
As can be seen in Figure 2, some changes were made to the model structure described in 
Chapter 2 for the sexual transmission of HIV in Bogota:  CD4 count stages less than 50 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
115 
 
cell/mL were removed, with the CD4 count < 200 cell/mL compartments now representing 
the final stage of disease.  Infected individuals arriving at the acute infection compartment are 
allowed to move to any CD4 count stage, according to evidence on post-acute progression as 
reported by Lodi et al., [22]. Finally, the flow through treatment stages was simplified, now 
consisting of a single line of treatment stages and therefore a single set of “failure” stages.  
These changes obey to the need of simplifying the structure of the model considering the 
differences in data availability. 
 
2.2 Population Structure and risk heterogeneity  
Sexual mixing in the model follows the system developed by Garnett et al., [23], described in 
detail in Chapter two of this document. The modelled population was subdivided by main 
sexual activity group according to gender, sexual orientation and number of sexual partners in 
the last year (Figure 3). Sexually active population over 15 years was estimated for each 
region as the arithmetic complement of the No-Risk population (i.e. individuals with no 
sexual contacts in the last year) as reported in national surveys (Table 4).    
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Figure 2 Model structure: Susceptible individuals get infected at rate λk(t) progressing to acute 
infection and flowing through natural history of disease and ART. Full description of symbols and 
parameter values can be found in parameters table.  
 
 
Figure 3 Sexual mixing in the model: In solid lines are sexual contacts allowed between male and female sub-
populations. Same colour and loops reflect same sex contacts.    
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2.3 Model Equations 
 
2.3.1 Ordinary Differential Equations 
The dynamic system of compartments is mathematically expressed in equations 3.1 to 3.17, 
as follows: 
1. Susceptible 
𝑑𝑆𝑘 (𝑡)
𝑑𝑡
= 𝐸𝑘 + 𝑊𝑘
1 − 𝑆𝑘(𝑡)∑ (𝜆𝑘,𝑗(𝑡)) − 𝑆𝑘(𝑡)(𝜎 + 𝜇)𝑗 , 
 
2. Acute HIV Infection 
𝑑𝐼𝑘
0,1(𝑡)
𝑑𝑡
= 𝑆𝑘(𝑡)∑ (𝜆𝑘,𝑗(𝑡))𝑗 +𝑊𝑘
2 − 𝐼𝑘
0,1(𝑡)(𝛾1 + 𝜇 + 𝜎), 
 
3. HIV Positive with CD4 > 500 cell/μL, undetected 
𝑑𝐼𝑘
0,2(𝑡)
𝑑𝑡
= 𝐼𝑘
0,1(𝑡)(𝛾1𝜀1) +𝑊𝑘
3 − 𝐼𝑘
0,2(𝑡)(𝜌1(𝑡) + 𝛾2 + 𝜇 + 𝜎) , 
 
4. HIV Positive with CD4 350 to 499 cell/μL, Undetected 
𝑑𝐼𝑘
0,3(𝑡)
𝑑𝑡
= 𝐼𝑘
0,1(𝑡)(𝛾1𝜀2) + 𝐼𝑘
0,2(𝑡)𝛾2 +𝑊𝑘
4 − 𝐼𝑘
0,3(𝑡)(𝜌2(𝑡) + 𝛾3 + 𝜇 + 𝜎), 
 
5. HIV Positive with CD4 200 to 349 cell/μL, Undetected 
𝑑𝐼𝑘
0,4(𝑡)
𝑑𝑡
= 𝐼𝑘
0,1(𝑡)(𝛾1𝜀3) + 𝐼𝑘
0,3(𝑡)𝛾3 +𝑊𝑘
5 − 𝐼𝑘
0,4(𝑡)(𝜌3(𝑡) + 𝛾4 + 𝜇 + 𝜎), 
 
6. HIV Positive with CD4 <200 cell/μL, Undetected 
𝑑𝐼𝑘
0,5(𝑡)
𝑑𝑡
= 𝐼𝑘
0,1(𝑡)(𝛾1𝜀4) + 𝐼𝑘
0,4(𝑡)𝛾4 +𝑊𝑘
6 − 𝐼𝑘
0,5(𝑡)(𝜌4(𝑡) + 𝛾5 + 𝜇 + 𝜎), 
 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
118 
 
7. CD4 >500 cell/μL,  on 1st Line ART, Non-suppressed VL 
𝑑𝐼𝑘
1,2(𝑡)
𝑑𝑡
= 𝐼𝑘
0,2(𝑡)𝜌1(𝑡) +𝑊𝑘
7 − 𝐼𝑘
1,2(𝑡)(𝜑 + 𝜗 + 𝜇 + 𝜎), 
 
8. CD4 350-499 cell/μL,  on 1st Line ART, non-suppressed VL 
𝑑𝐼𝑘
1,3(𝑡)
𝑑𝑡
=  𝐼𝑘
0,3(𝑡)𝜌2(𝑡) +𝑊𝑘
8 + 𝐼𝑘
3,3(𝑡)𝜌2(𝑡) − 𝐼𝑘
1,3(𝑡)(𝜑 + 𝜗 + 𝜇 + 𝜎), 
 
9. CD4 200-349 cell/μL,  on 1st Line ART, non-suppressed VL 
𝑑𝐼𝑘
1,4(𝑡)
𝑑𝑡
=  𝐼𝑘
0,4(𝑡)𝜌3(𝑡) +𝑊𝑘
9 + 𝐼𝑘
3,4(𝑡)𝜌3(𝑡) − 𝐼𝑘
1,4(𝑡)(𝜑 + 𝜗 + 𝜇 + 𝜎), 
 
10. CD4 <200 cell/μL,  on 1st Line ART, Non-suppressed VL 
𝑑𝐼𝑘
1,5(𝑡)
𝑑𝑡
=  𝐼𝑘
0,5(𝑡)𝜌4(𝑡) +𝑊𝑘
10 + 𝐼𝑘
3,5(𝑡)𝜌4(𝑡) − 𝐼𝑘
1,5(𝑡)(𝜑 + 𝜗 + 𝜇 + 𝜎), 
 
11. CD4 >500 cell/μL,   on ART, Suppressed VL 
𝑑𝐼𝑘
2,2(𝑡)
𝑑𝑡
= 𝐼𝑘
1,2(𝑡)𝜑 +𝑊𝑘
11 − 𝐼𝑘
2,2(𝑡)(𝜃𝛾2 + 𝜗 + 𝜇 + 𝜎), 
 
12. CD4 350 to 499 cell/μL,   on ART, Suppressed VL 
𝑑𝐼𝑘
2,3(𝑡)
𝑑𝑡
= 𝐼𝑘
1,3(𝑡)𝜑 +𝑊𝑘
12 + 𝐼𝑘
2,2(𝑡)𝜃𝛾2 − 𝐼𝑘
2,3(𝑡)(𝜃𝛾3 + 𝜗 + 𝜇 + 𝜎), 
 
13. CD4 200 to 349 cell/μL,   on ART, Suppressed VL 
𝑑𝐼𝑘
2,4(𝑡)
𝑑𝑡
= 𝐼𝑘
1,4(𝑡)𝜑 +𝑊𝑘
13 + 𝐼𝑘
2,3(𝑡)𝜃𝛾3 − 𝐼𝑘
2,4(𝑡)(𝜃𝛾4 + 𝜗 + 𝜇 + 𝜎) , 
 
14. CD4 <200 cell/μL,   on ART, Suppressed VL 
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𝑑𝐼𝑘
2,5(𝑡)
𝑑𝑡
= 𝐼𝑘
1,5(𝑡)𝜑 +𝑊𝑘
14 + 𝐼𝑘
2,4(𝑡)𝜃𝛾4 − 𝐼𝑘
2,5(𝑡)(𝜃𝛾5 + 𝜗 + 𝜇 + 𝜎) , 
 
15. CD4 350 to 499 cell/μL, on ART failure 
𝑑𝐼𝑘
3,3(𝑡)
𝑑𝑡
= 𝐼𝑘
1,2(𝑡)𝜗 + 𝐼𝑘
2,2(𝑡)𝜗 +𝑊𝑘
15 − 𝐼𝑘
3,3(𝑡)(𝜌2(𝑡) + 𝛾3 + 𝜇 + 𝜎), 
 
16. CD4 200 to 349 cell/μL, on ART failure 
𝑑𝐼𝑘
3,4(𝑡)
𝑑𝑡
= 𝐼𝑘
1,3(𝑡)𝜗 + 𝐼𝑘
2,3(𝑡)𝜗 + 𝐼𝑘
3,3(𝑡)𝛾3 +𝑊𝑘
16 − 𝐼𝑘
3,4(𝑡)(𝜌3(𝑡) + 𝛾4 + 𝜇 + 𝜎), 
 
17. CD4 <200 cell/μL, on ART failure 
𝑑𝐼𝑘
3,5(𝑡)
𝑑𝑡
= 𝐼𝑘
1,4(𝑡)𝜗 + 𝐼𝑘
2,4(𝑡)𝜗 + 𝐼𝑘
1,5(𝑡)𝜗 + 𝐼𝑘
2,5(𝑡)𝜗 + 𝐼𝑘
3,4(𝑡)𝛾4 +𝑊𝑘
17 −
𝐼𝑘
3,5(𝑡)(𝜌4(𝑡) + 𝛾5 + 𝜇 + 𝜎), 
 
Where 𝑆𝑘 (𝑡) are all individuals in category k that are susceptible at time t. Stages named I 
represent all the HIV positive stages, with indexing code as follows:  
𝐼𝑘
𝑎,𝑠
 
:  Superscript “a” denotes the status of the HIV positive individual regarding ART with 
a=1 for those on treatment but unsuppressed viral load (VL); When a=2 for those on ART 
with supressed VL, and a=3 for those in treatment failure. Superscript “s” denotes the stage 
of disease, taking values from 1 to 5, namely: 1 = acute infection, 2 = CD4 >500 cell/μL, 3 = 
CD4 350 to 499 cell/μL, 4 = CD4 200 to 349 cell/μL, and 5 = CD4 <200 cell/μL.    
In equation 1, the term 𝐸𝑘(𝑡) is the expression to represent the input of new individuals 
entering the susceptible pool in each category k at time t. This number results from re-
introducing the same number of individuals “lost” from the system at time t-1(i.e. mortality 
due to AIDS, background mortality, and individuals leaving sexual activity). A population 
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growth rate is added 𝜖(𝑡), in accordance to population projections for each Brazilian region, as 
reported by IBGE
6
. The mathematical expression as follows: 
Equation 3.18:        
𝑑𝐸𝑘(𝑡)
𝑑𝑡
=  (𝜎 + 𝜇 + 𝜖(𝑡))
(
 ∑𝐼𝑘
𝑎,𝑠(𝑡)
𝑠
𝑎
+ 𝑆𝑘 (𝑡)
)
 + 𝛾5 (𝐼𝑘
0,5(𝑡) + 𝐼𝑘
1,5(𝑡) + 𝐼𝑘
3,5(𝑡)) + 𝛾5𝜃𝐼𝑘
2,5(𝑡) 
 
Another important consideration regarding the population structure and its balance in the 
system has to do with the rate at which women enter or leave the sex work category 
(turnover). Here, it is represented with the symbol 𝑊𝑘
𝑐, where k is risk category, and c takes 
the value of the corresponding compartment in the system (i.e. from 1 to 17). It is assumed 
that female sex workers spend a given time in sex work activity (Table 1) and leave this 
category in equal proportions to both the Low and High Activity categories, and irrespective 
of their HIV status or stage of disease. An equal number of women enter sex work, moving 
from the susceptible compartments of low and high activity women to become susceptible 
female sex workers. This guarantees the preservation of the relative population size in female 
subpopulations over the simulation time. Equally proportional recruitment into sex work 
according to activity group was considered given that no consistent evidence was available to 
support the contrary.      
2.3.2  Force of Infection 
As described in Chapter two, the force of infection ( 𝜆𝑘,𝑗(𝑡)) was defined as the probability of 
HIV transmission given an effective contact between two individuals of risk category k and j 
[24]. In this case, the force of infection must reflect three forms of sexual contact and 
transmission, namely, male to female, female to male and male to male.   
                                                          
6
 (IBGE) Brazilian Institute of Geography and Statistics. In the internet: http://www.ibge.gov.br 
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Equations 19 to 21 show the representation of these contacts, summarized in the 
matrix 𝜆𝑘,𝑗(𝑡), which contains the specific force of infection for each group k with contact j. 
This matrix is solved for every possible contact within activity groups using indices k, and j, 
where k is the choosing partner and j is the chosen one.   
Equation 3.19: Force of Infection for HIV transmission from females (j) to males (k)  
𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑ ((
𝐼𝑗
𝑎,𝑠(𝑡)
∑ 𝐼𝑗
𝑎,𝑠(𝑡)+𝑆𝑗(𝑡)𝑠
𝑎
)((1 − ((1 − 𝛽𝑓𝐿
𝑎,𝑠)
𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 −𝑠
𝑎
𝛽𝑓𝐿
𝑎,𝑠(1 − 𝜍))
𝛼𝑘,𝑗(𝜈𝑘(𝑡))
)))],   (𝑓𝑜𝑟 𝑗 = 2, 3, 4, 𝑎𝑛𝑑 𝑘 =  6, 7, 8, 10), 
 
Equation 3.20: Force of Infection for HIV transmission from males (j) to females (k)  
  𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑ ((
𝐼𝑗
𝑎,𝑠(𝑡)
∑ 𝐼𝑗
𝑎,𝑠(𝑡)+𝑆𝑗(𝑡)𝑠
𝑎
)((1 − ((1 − 𝛽𝑚𝐿
𝑎,𝑠)𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 −𝑠
𝑎
𝛽𝑚𝐿
𝑎,𝑠(1 − 𝜍))
𝛼𝑘,𝑗(𝜈𝑘(𝑡)))))] , (𝑓𝑜𝑟 𝑗 = 6, 7, 8, 10, 𝑎𝑛𝑑 𝑘 =  2, 3, 4), 
 
 
Equation 3.21: Force of Infection for HIV transmission from males (j) to males (k)   
𝜆𝑘,𝑗(𝑡) =  𝑐𝑘𝑝𝑘,𝑗 [∑ ((
𝐼𝑗
𝑎,𝑠(𝑡)
∑ 𝐼𝑗
𝑎,𝑠(𝑡)+𝑆𝑗(𝑡)𝑠
𝑎
) ((1 − ((1 − 𝛽𝑚𝑠𝑚𝐿
𝑎,𝑠)𝛼𝑘,𝑗(1−𝜈𝑘(𝑡))) (1 −𝑠
𝑎
𝛽𝑚𝑠𝑚𝐿
𝑎,𝑠(1 − 𝜍))
𝛼𝑘,𝑗(𝜈𝑘(𝑡)))))] , (𝑓𝑜𝑟 𝑗 = 8, 9, 𝑎𝑛𝑑 𝑘 = 8, 9) , 
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Condom effectiveness per act was incorporated with the term (1 − 𝛽𝑓𝐿
𝑎,𝑠(1 − 𝜍))
𝛼𝑘,𝑗(𝜈𝑘(𝑡))
, 
where 𝜍 is the relative risk reduction in HIV transmission with condom use [25], raised to the 
power of numbers of acts 𝛼𝑘,𝑗 between k and j, multiplied by the annual proportion of sex 
acts protected with condom in group k,  𝜈𝑘(𝑡).    
The matrix 𝐿𝑎,𝑠 incorporates coefficients that increase or reduce transmissibility within the 
couple according to the stage of infection (superscript “s”) (i.e. acute infection) and ART 
status of the contact (superscript “a”). Full description of symbols and its values can be found 
in parameters Table 4.  
For a description of the mixing matrix ( 𝑝𝑘,𝑗) please refer to the methods section in chapter 
two in this manuscript.  
 
2.4 Initial conditions  
The start of the epidemic was fixed in 1975. To reflect a delay in the start of transmission or 
different sizes of the early epidemic, the seed was calibrated as a proportion of individuals 
infected. The epidemic was only seeded in female sex workers, their clients, and both 
categories of MSM, considering that these were the groups with the highest risk. 
     
2.5 Condom use in the model 
Different sources of data were consulted to recreate plausible time trends of condom use 
among risk groups in each of the five regions of Brazil. The information retrieved were point 
estimates of proportion of sex acts protected with condom for a given period across regions 
and risk groups. However, condom use is thought to have changed over time, and for this 
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reason it was modelled in a way that allowed the exploration of different plausible scenarios 
of condom uptake and variation over time and across risk groups.  
Condom use before the AIDS era (i.e. before 1984 when HIV was recognized as causing 
AIDS) is thought to have been very low and fairly similar in all subpopulations. With the 
widespread knowledge of HIV being sexually transmitted and the HIV testing era after 1984 
it is plausible that the frequency of condom use increased radically, particularly among the 
groups with the highest sexual activity. Changes in behaviour affecting HIV epidemics have 
been observed and suggested in other contexts [26, 27]. 
Following this reasoning, rates of condom use were modelled as the linear interpolation 
between pre-AIDS rates and the point estimations found in the literature review. However, 
the lack of consistent data about condom use in these decisive years of the epidemic was 
overcame by calibrating a parameter (condstart) for the possible time spent between pre-AIDS 
era (before 1983) levels of use and the rates found in the first data point reported in the 
literature for each group.  
Point estimates of condom use carry uncertainty, and this uncertainty was controlled with a 
global parameter (condscenario) that determined which value within this range would be used 
during interpolation of data points. This parameter had a prior range between 0 and 1. It was 
applied to all data points and uncertainty ranges across groups. This means that values near to 
1 resulted in a “high condom use scenario” overall and those values near 0 resulted in the 
opposite.  
Equation 3.22: Condom use by sex group and according to uncertainty factor   
𝜈𝑘(𝑡) = 𝑙𝑜𝑤𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑘(𝑡) + (𝑐𝑜𝑛𝑑𝑠𝑐𝑒𝑛𝑎𝑟𝑖𝑜(𝑙𝑜𝑤𝑒𝑟𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑘(𝑡) − 𝑢𝑝𝑝𝑒𝑟𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑘(𝑡))) 
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Figure 4 exemplifies the range of possibilities in condom use trajectories allowed in the 
calibration process.    
 
Figure 4 Modelled proportions of acts protected by condom by risk group and region: results from 100 
simulations varying condstart and condscen parameters according to calibration ranges. 
 
 
2.6 Antiretroviral therapy in the model 
The access to antiretroviral drugs in Brazil has varied across regions and also by stage of 
disease as has been documented elsewhere [21, 28, 29]. However, the true shape of the 
function behind treatment expansion in each region and the possible fluctuations over time is 
unknown.  
Addressing ART scale-up is central for the aims of this research, and as such, a flexible and 
comprehensive approach was chosen for this task.   
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The rate at which HIV-infected are recruited into ART is expressed as 𝜌𝑗(𝑡), and is allowed 
to vary by CD4 cell count category j and calendar time t: 
 
Equation 3.22: ART recruitment rate 
𝜌𝑗(𝑡) = ((𝑚𝜔)𝑇𝑗 + 𝜌5(0)) 𝜎(𝑡)   
Where Tj is the average time (years) to reach CD4+ count category <200 cell/μL (j=5) for 
those in CD4 cell count category j=1,…,4 (T1=8.17; T2=7.93; T3=6.74; T4=3.74; T5=0).  
This parameterization sets the rate of detection to vary linearly as the time to reach CD4<200 
cell/μL decreases. The slope of this line is specified by parameter ω, which allows the linear 
relationship to be either positive or negative. With ω>0, individuals with low CD4 counts are 
more likely to be recruited into, which may be true if HIV testing is prompted by increasing 
experience of illness. However, with ω = 0, the rate at which individuals move into the 
treatment compartments is the same across CD4 categories.  The prior on ω reflects that both 
of these possibilities are equally likely: 𝜔~ 𝑈 (0,1). Parameter m is a constant scaling 
parameter which ensures that the ART rate is greater than zero for all CD4 categories, 
irrespective of the value of ω. 
Rate of recruitment into ART for those in CD4 cell count category <200 cell/μL (ρ5) has a 
prior distribution such that the average interval from infection to treatment is uniformly 
distributed between 0.5 and 10 years: ~𝑈 (
1
10
,
1
0.5
). 
σ(t) describes the change in the rates of treatment uptake over time. Here it is assumed that 
this change can be represented by the logistic function: 𝜎(𝑡) =
1
1+𝑒
−𝑟(𝑡−𝑡50)
 , where r is the rate 
of increase, and 𝑡50 is the time to reach half the upper limit rate. Parameter r is set at 0.003 
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and a prior was placed on t50 that allows a wide range in shapes in σ(t) from a stable trend 
over time (t50=1) to a sharp increase in this rate from close to zero at the start of ART scale up 
in 1997 (t50=0.1): 𝑡50~𝑈(0.1,1).  
ART eligibility criteria have changed over time in Brazil [6]. However, different reports have 
shown that despite a trend towards late entry into care, many individuals started on ART with 
greater CD4+ counts than those established in the guidelines over the years [21]. The way in 
which ART was modelled, as explained above, favours trends where the ART is provided at 
later stages in the first years and increasing the threshold of CD4+ over the years, but for the 
reasons mentioned before, it was not restricted to strict cut-off limits.     
 
2.7 Data and sources of information 
          
2.7.1  HIV prevalence among key populations 
The model was fitted to HIV prevalence estimates from different surveys and other cross-
sectional studies carried out in several locations of Brazil. HIV prevalence among female sex 
workers and MSM was collected and classified according to the main geographical region 
where the study was located. Table 1 describes in detail each study and the data point used 
during model comparison.  
 
2.7.2   Surveillance data 
HIV and AIDS information in Brazil is managed through a network of datasets that record 
information of different nature: SINAN dataset collects information on epidemiological 
variables; SICEL holds laboratory and clinical records; SICLOM contains data from the ART 
programme, and SIM gathers mortality reports. Two dimensions of data used in the 
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calibration process come from this network of information (i.e. reported deaths due to AIDS 
and numbers of people on ART).  
The first dimension corresponds to the annual number of reported deaths due to AIDS, and 
reflects the annual number of deaths caused by HIV and AIDS and reported for each region 
between 1995 and 2011.  
This data is periodically published in epidemiology bulletins by Brazil’s Ministry of Health 
[3] (Table 2). However, this data is thought to be susceptible to several forms of bias, 
particularly under-reporting, defined as absence of cases in the official records, and 
misclassification (the attribution of a different cause of death or omission of HIV/AIDS in the 
records). Fazito et al., have studied the percentage of misclassified and under-reported AIDS 
deaths in Brazil[20], and Pacheco et al., have done and exhaustive and equally extensive job 
for the major AIDS reference centre in Rio de Janeiro [30].  
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Table 1 HIV prevalence studies among FSW and MSM in Brazil 
    95% CI 
 
  
Year Region Study location HIV Prevalence (%) Lower Upper Sample 
Size 
Reference 
Female Sex Workers 
2006 North Amazonas 2.6 0.0 10.7 114 [31] 
2006 North Amazonas 2.6 0.1 5.1 154 [32] 
1988 Northeast Salvador 13.3 0.0 27.9 15 [33] 
1993 Northeast Fortaleza 1.6 14.8 23.0 496 [34] 
2000 Northeast Maranhão 3.0 0.4 5.6 164 [35] 
2000 Northeast Paraiba 3.0 0.4 5.7 169 [35] 
2000 Northeast Sergipe 1.2 0.0 2.8 165 [35] 
1987 Southeast Rio de Janeiro 6.0 1.3 10.7 100 [36] 
1987 Southeast Rio de Janeiro 3.0 0.0 6.3 101 [37] 
1987 Southeast Santos 3.0 1.5 4.5 470 [38] 
1988 Southeast Campinas 10.8 5.8 15.8 148 [39]  
1989 Southeast São Paulo State 2.8 1.1 4.5 347 [38] 
1990 Southeast São Paulo 11.0 8.5 13.5 600 [40] 
1991 Southeast Santos 35.0 26.6 43.4 125 [41] 
1994 Southeast Espírito Santo 8.6 4.0 13.2 140 [42] 
1996 Southeast São Paulo 8.3 6.3 10.4 697 [43] 
2000 Southeast Minas Gerais 5.9 2.2 9.6 153 [35] 
2000 Southeast São Paulo 2.4 0.6 4.7 164 [35] 
2006 Southeast Rio de Janeiro 12.9 6.1 19.7 93 [44] 
2006 Southeast São Paulo 5.7 2.3 9.1 175 [45] 
1992 South Paranaguá 4.6 1.0 8.1 132 [46] 
2000 South Paraná 3.9 1.0 6.8 168 [35] 
2000 South Santa Catarina 5.4 1.3 7.6 164 [35] 
2000 South Rio Grande do Sul 19.5 13.5 25.5 166 [35] 
2000 South Porto Alegre 4.8 3.5 6.1 980 [47] 
2003 South Santa Catarina 6.7 1.5 11.9 90 [48] 
2009 South Santa Catarina 5.2 1.4 9.0 134 [49] 
2010 Central-west Campo Grande 1.0 0.1 2.6 402 [50] 
Men who have sex with men 
2006 North Manaus 2.6 0.0 5.5 116 [31] 
2009 North Manaus 8.3 6.0 10.9 350 [19] 
1986 Northeast Salvador 19.0 11.6 26.4 109 [51] 
1988 Northeast Salvador 40.0 29.5 50.8 82 [33] 
1989 Northeast Bahia State 12.0 5.5 18.5 96 [51] 
1993 Northeast Salvador 10.0 7.5 12.5 550 [52] 
2009 Northeast Recife 5.2 2.7 8.2 350 [19] 
2009 Northeast Salvador 8.9 5.5 12.7 350 [19] 
1986 Southeast Belo Horizonte 9.6 5.5 13.8 197 [53] 
1987 Southeast Rio de Janeiro 25.0 17.5 32.5 128 [37] 
1994 Southeast Rio de Janeiro 24.0 21.6 26.4 1165 [54] 
1994 Southeast Belo Horizonte 8.8 6.6 11.0 642 [55] 
1994 Southeast São Paulo 12.5 6.1 18.9 104 [56] 
1994 Southeast Belo Horizonte 6.6 2.8 10.4 167 [57] 
1995 Southeast Rio de Janeiro 11.7 9.5 13.8 855 [58] 
1995 Southeast São Paulo 13.9 10.7 17.1 453 [59] 
2002 Southeast Belo Horizonte 9.5 7.4 11.6 746 [60] 
2005 Southeast Campinas 8.4 6.3 10.5 658 [61] 
2009 Southeast Belo Horizonte 10.6 4.2 16.1 350 [19] 
2009 Southeast Rio de Janeiro 18.3 10.9 24.9 350 [19] 
2009 Southeast Santos 9.0 5.2 13.5 350 [19] 
1996 South Porto Alegre 24.0 20.0 28.0 461 [62] 
2009 South Curitiba 18.9 12.6 25.9 350 [19] 
2009 South Itajaí 12.3 5.3 21.1 350 [19] 
1999 Central-west Goiânia 16.2 4.3 28.1 37 [63] 
2009 Central-west Brasilia 23.7 16.6 31.5 350 [19] 
2009 Central-west Campo Grande 6.7 3.5 10.7 350 [64] 
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Table 2: Number of reported AIDS deaths by region, Brazil 1995-2011 
Year North Northeast Southeast South Central-west 
1995 209 1159 11310 1787 691 
1996 270 1200 10914 1972 661 
1997 220 984 8488 1811 575 
1998 231 954 7167 1866 552 
1999 245 989 6796 1945 546 
2000 309 1147 6773 1961 540 
2001 390 1263 6634 2115 546 
2002 415 1341 6496 2246 557 
2003 495 1404 6409 2356 619 
2004 490 1393 6190 2354 593 
2005 579 1498 6009 2433 581 
2006 605 1603 5786 2417 635 
2007 691 1744 5752 2469 716 
2008 759 1887 5883 2585 725 
2009 799 2089 5872 2631 704 
2010 939 2061 5788 2589 774 
2011 922 2180 5682 2561 699 
Source: [2] 
 
In order to overcome the possible presence of biases, the annual numbers of deaths caused by 
AIDS, as estimated with the model, were adjusted to match the data reported by MoH. 
Firstly, with a parameter that incorporated the estimated proportion of deaths due to AIDS 
that were being reported in 1984 (Mort1984). This was the year when the official report of 
AIDS deaths started in Brazil. Mort1984 was calibrated with bounds between 0 and 1, with 1 
reflecting a 100% report of the total AIDS deaths occurred at time t. The increment over time 
of this reported proportion was modelled by linearly interpolating Mort1984 to a future 
expected report proportion Mort2016. The increment between these two points is introduced 
with a second parameter called Mortslope ~U(0,1). When Mortslope = 1, the future report 
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proportion in 2016 increases to 100%. If Mortslope =0, this proportion stays the same up to 
2016.    
Equation 3.23: proportion of AIDS deaths reported in 2016 
𝑀𝑜𝑟𝑡2016 = 𝑀𝑜𝑟𝑡1984 + (1 −𝑀𝑜𝑟𝑡1984)𝑀𝑜𝑟𝑡𝑠𝑙𝑜𝑝𝑒 
 
The other component of surveillance used in the model comparison was the annual number of 
people on ART (Table 3). As stated before, this information comes from SICLOM 
information system
7
. The modelling outcome matching this data is the total number of 
individuals on ART stages in the model per year.  
 
Table 3: Number of people receiving ART by region, Brazil 2008-2012 
Year North Northeast Southeast South 
Central-
west 
2008 5,291 21,797 102,555 43,903 10,454 
2009 6,492 26,820 118,749 48,594 11,932 
2010 7,573 32,549 133,225 53,574 14,028 
2011 8,894 37,496 144,906 60,077 16,213 
2012 11,173 42,249 158,392 66,622 18,211 
Source: Made available by A. Pascom at Departamento de DST, Aids e Hepatites Virais 
 
2.8  Parameter sampling  
An extensive literature review was carried out in order to inform the parameter selection. 
Regional data was used when available, and the absence of local estimates was resolved by 
using national estimates with wide prior ranges. Table 4 describes all the parameters in the 
                                                          
7
 Information on numbers on ART by region was retrieved and kindly made available by Ana Roberta Pascom at 
Departamento de DST, Aids e Hepatites Virais, and Francisco Inacio Bastos at Fundação Oswaldo Cruz.    
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model by region. Values are presented for fixed parameters and prior ranges for calibrated 
parameters.  
A total of 29 parameters were randomly sampled using a Latin Hypercube Sampling 
algorithm, as explained in Chapter 2, section 2.5.1 of this manuscript. All parameters were 
drawn from the uniform distribution, bounded according to values described in table 1.    
Table 4 Parameters table 
 Value/Prior Range  
Symbol Description North Northeast Southeast South Central-west Reference 
Demographic and Initial Model Conditions 
N0 
Total population 
>15 years at  
1970† 
1,915,943 15,410,702 24,453,223 9,448,452 2,784,704 [2] 
𝜖(𝑡) Population 
growth rate per 
annum 
0.04 0.022 0.022 0.02 0.031 
Manual 
calibration 
to IBGE 
data 
μ Background 
mortality rate 
1/65 years 
[2] 
σ Rate of ceasing 
sexual activity 
1/34 years 
Assumption 
F Proportion of 
female 
population 
0.5 
[2] 
NoRW Fraction of 
women out of 
sexually activity 
0.21 0.263 0.235 0.17 0.189 
[65] 
Ffsw Proportion of 
women in sex 
work 
~U (0.007,0.021) 
[65] 
Turnfsw FSW turnover 
rate 
~U (10,20) year-1 
[66] 
HRW Proportion of 
women in high 
activity group (> 
5 partners in the 
last year) 
0.055 0.041 0.043 0.026  
[67] 
LRW Proportion of 
women in low 
activity group. 
𝐿𝑅𝑊 = 1 − (𝑁𝑅𝑊 + 𝐹𝑓𝑠𝑤 + 𝐻𝑅𝑊) 
Assumption 
HRM Proportion of 
men in high 
activity group (> 
5 partners in the 
last year) 
0.132 
[65] 
Fmsm Proportion of 
men exclusive 
MSM 
~U (0.013,0.027) 
[65] 
Fbimsm Proportion of 
men  bisexual 
MSM 
~U (0.008,0.017) 
[65] 
Fcfsw Proportion of 
men clients of 
FSW 
~U (0.067,0.089) 
[65] 
NoRM Fraction of 
women out of 
sexually activity 
0.19 
 
LRM Proportion of 
women in low 
activity group. 
𝐿𝑅𝑀 = 1 − (𝑁𝑅𝑀 + 𝐹𝑚𝑠𝑚 + 𝐹𝑏𝑖𝑚𝑠𝑚 + 𝐹𝑐𝑓𝑠𝑤 + 𝐻𝑅𝑀) 
Assumption 
t0 Year of epidemic 1975 Assumption 
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start 
Seed Fraction HIV+ at 
t0. 
(1e-6 to 0.0025) 
Assumption 
Sexual Behavior 
Ck 
Partner change 
rate by activity 
group (pryr) 
Clowrisk =1 
Chighrisk ~U(2,5) 
Csexwork ~U(52,2000) 
Cclients ~U(2,50) 
Cmsm+bi ~U(2,50) 
Assumption 
[35, 65, 67] 
Assumption 
[68] 
 [69] 
Cond_fac 
Scaling 
condom 
parameter 
~U (0,1) Assumption 
𝛼𝑘,𝑗 
Number of sex 
acts per 
partnership 
Low Risk: 83 
High Risk: 8 
MSM~U (2,30) 
FSW & Clients~U (1,2) 
[70] 
Assumption 
𝑀𝑘,𝑗 
Preferential 
mixing matrix 
MSM to MSM ~U (0.1,0.9) 
MSMbi to MSMbi= 0.5 
Assumption 
𝜈𝑘(𝑡), 
𝑓𝑜𝑟 𝑘 =
2,…10 
Proportion of 
acts protected 
with condom in 
all groups 
before 1983 
(0 to 0.05) Assumption 
𝜈𝑘(𝑡), 
𝑓𝑜𝑟 𝑘
= 2,6 
Proportion of 
acts protected  
with condom in 
low activity   
1998:  (0.16 -0.23) 
2004:  (0.16 - 0.23) 
2008 : (0.18 - 0.26) 
(0.16 to 0.23) 
(0.18 to 0.21) 
(0.18 to 0.21) 
(0.16 to 0.22) 
(0.25 to 0.28) 
(0.18 to 0.21) 
(0.11 to 0.20) 
(0.25 to 0.30) 
(0.18 to 0.22) 
 
(0.16 to 0.22) 
(0.2 to 0.30) 
(0.13 to 0.19) 
 
[71] 
[67] 
𝜈𝑘(𝑡), 
𝑓𝑜𝑟 𝑘
= 3,7 
Proportion of 
acts protected 
with condom in 
high activity   
1998: (0.5-0.8) 
2004: (0.47-0.52) 
2008: (0.44- 0.55) 
(0.5-0.8) 
(0.50-0.55) 
(0.38- 0.42) 
(0.5-0.8) 
(0.46-0.50) 
(0.45- 0.48) 
(0.5-0.9) 
(0.58-0.64) 
(0.44- 0.5) 
(0.51-0.8) 
(0.5-0.59) 
(0.47- 0.55) 
[71] 
 
𝜈𝑘(𝑡), 
𝑓𝑜𝑟 𝑘
= 8,9 
Proportion of 
acts protected 
with condom in 
MSM 1999 
(0.44 to 0.55) (0.55 to 0.78) (0.44 to 0.87) (0.41 to 0.78) (0.7 to 0.87) [19] 
𝜈𝑘(𝑡), 
𝑓𝑜𝑟 𝑘 = 4 
Proportion of 
acts protected 
with condom in 
FSW 2000 
(0.45 to 0.54) (0.42 to 0.51) (0.68 to 0.67) (0.60 to 0.68) (0.82 to 0.92) [35, 50] 
e 
Assortativeness 
coefficient 
~U(0,1) Assumption 
Condstart 
Year of 
condom use 
rates increase 
~U(1985,2000) Assumption 
Natural History of Disease and transmission probabilities 
𝛽𝑓 
Per-act female 
to male HIV 
transmission 
coefficient 
~U (0.0014,0.009) [72] 
𝛽𝑚 
Per-act male to 
female HIV 
transmission 
coefficient 
~U (0.0008,0.002) [72] 
𝛽𝑚𝑠𝑚 
Per-act male to 
male HIV 
transmission 
coefficient†† 
~U (0.002, 0.025) [73] 
𝛾𝑠 
Average time 
spent in disease 
compartments 
(years) 
Acute Stage : 𝛾1 = 0.25 
CD4 >500     : 𝛾2 = 2.86 
CD4 350-499 : 𝛾3 = 2.86 
CD4 200-349 : 𝛾4 = 3.54 
CD4 <200      : 𝛾5 = 2.3 
 
[74]Adapted 
from[22] 
𝜀𝑠 
Post-acute 
progression 
rate (years) 
To CD4 >500     : 𝜀2 = 0.58 
   To CD4 350-499 : 𝜀3 = 0.23 
  To CD4 200-349 : 𝜀4 = 0.16 
To CD4 <200      : 𝜀5 = 0.03 
 
[22] 
L0,1 
Relative 
infectiousness 
coefficient 
during acute 
HIV infection 
~U(0.47,18.8) [72] 
ARV therapy and intervention effectiveness 
𝜌4 Recruitment  ~U(0.1,2) Assumption 
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rate into ART 
at CD4+ 
<200cell/μL 
 (year-1)   
m 
Slope scaling 
parameter. Is 
the slope for 
the line 
crossing (0, ρ4) 
and (0 , ρ1) 
𝑚 =
0 − 𝜌4(0)
9.25 − 0
 Assumption 
𝝎 Relative slope 
variation factor. 
~U(0,1) 
Assumption 
𝝈(𝒕) 
Function for 
the variation of 
ART 
recruitment rate 
over time 
𝜎(𝑡) =
1
1+𝑒
−𝑟(𝑡−𝑡50)
, for r=0.003 Assumption 
𝒕𝟓𝟎 
Shape 
parameter in 
function σ(t) 
~U(0.1,1) Assumption 
tart 
Year of ART 
introduction 
1997 [1] 
𝐿𝑎,𝑠 
For a=2 and 
s=2,...,5 
Relative HIV 
transmission 
reduction due 
to ART (with 
suppressed 
viral load) 
~U(0.73,0.99) [16] 
𝐿𝑎,𝑠 
For a=1 and 
s=2,...,5 
Relative HIV 
transmission 
reduction due 
to ART (with 
unsuppressed 
viral load) 
0.5 Assumption 
ς 
HIV 
transmission 
relative 
reduction due 
to condom use 
~U (0.35,0.94) [75] 
𝜗 
Average ART 
failure rate 
(pryr) 
0.17 [76] 
𝜑 
Average time 
spent in non-
suppressed VL 
compartments 
(years) 
0.5 [77] 
θ 
Relative 
progression 
rate reduction 
due to ART 
~U (0.1,0.5) [5] 
Mortslope 
Slope of 
underreporting 
function 
~U (0,1) Assumption 
Mort1984 
Mortality 
reporting 
capacity in 
1984 
~U (0,1) Assumption 
† Population at time zero (1975) was found by interpolation of decennial estimations.    
†† Combined unprotected receptive and insertive anal intercourse 
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2.9  Model calibration 
The model was run with 1,200,000 randomly drawn parameter sets for each region. 
According to the priors on inputs described above calibration was carried out as a three-step 
process which ended in the selection of the parameters sets eligible for further analysis.  
2.9.1 Prior Limits on output 
The first part of this process consisted in placing a priori constrains (or prior limits) upon 
simulated HIV prevalence in MSM and FSW. These prior limits were informed by the 95% 
confidence intervals around point estimates found in each region. Since the quality and 
quantity of point prevalence estimates for these groups varied greatly across regions, the final 
placement of limits was made case-by-case, as can be seen in Figures 5 to 9. Another 
constraint was set to reject those runs which incidence projections were not stabilizing by 
2016, when the simulation ends. This was incorporated simply by finding the maximum 
value in modelled incidence and comparing against the last value of incidence in the 
simulation. This last condition was intended to select plausible epidemic scenarios where 
incidence reached equilibrium via natural dynamics or with the help of interventions. 
 
2.9.2 Likelihood Estimation 
The second phase was applied to all runs that passed the initial step of the calibration 
procedure. HIV prevalence among MSM and FSW, annual number of people on ART and 
annual AIDS deaths reported, were produced from the selected parameter sets, and were 
systematically compared against regional data of the same nature.  
The likelihood function was applied for each dimension of the data and its matching model 
outcome (i.e. HIV prevalence in MSM and FSW, number receiving ART, and number of 
AIDS deaths reported). 
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For comparisons of binomially distributed data, such as HIV prevalence, the likelihood 
function for binomial distribution was applied. For ease of numerical computation the 
logarithmic form of these expressions was used.  
 
Equation 3.24: Log-Likelihood function for binomial distribution 
ln𝐿(𝑦, 𝜃) = ∑ 𝑁𝑖𝜃𝑖 𝑙𝑛(𝑦𝑖) + 𝑁𝑖(1 − 𝜃𝑖)𝑙𝑛 (1 − 𝑦𝑖)𝑖  
Here 𝜃 is the probability of success in a Bernoulli trial, in this case the given HIV prevalence 
data-point. N is the sample size of the study from where probability 𝜃 comes. N multiplies 𝜃 
and (1 − 𝜃) as an expression of the number of successes and failures, respectively. Symbol y 
is the modelled prevalence.  
Numbers of AIDS deaths reported and numbers of people on ART were assumed to follow a 
Poisson distribution. The deviance function for model comparison of Poisson outcomes, 
which contains itself the Poisson likelihood function, was used as described below: 
 
Equation 3.25: Log-Likelihood for Poisson distribution 
ln ℒ(𝑦|𝜃) =∑(𝜃𝑖𝑙𝑜𝑔𝑦𝑖 − 𝑦𝑖 − 𝑙𝑜𝑔𝜃𝑖!)
𝑛
𝑖=1
 
Here, the data-point (𝜃𝑖 ) (e.g. number of AIDS deaths) is being matched against the ith 
modelled outcome (𝑦𝑖).  This is assuming that both the number of deaths and numbers on 
ART are sampled observations of an underlying process.   
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2.9.3 Posterior weight and Model selection 
After assigning a specific posterior probability to each run in step 2, the marginal 
contribution of each of these parameter-sets to the overall probability estimated for each 
region was assessed by calculating a Posterior Weight.  
 
Equation 3.26: Weighted posterior  
𝑊𝑗 = 𝑒𝑥𝑝
𝐿𝑜𝑔𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑𝑗
max (𝐿𝑜𝑔𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑)
 
The posterior probability of each runj is re-scaled first by dividing over the maximum 
posterior across all runs, and then taking the antilog to work the weighted values in a positive 
scale.   
A vector of weights W was then sorted in descending order, having as first element of W the 
equivalent of the best fit simulation in a frequentist approach. Dividing each element of W by 
the cumulative sum of W allowed us to find the set of parameters that contributed with 95% 
of the total posterior weight, assembling a credible set of runs that would be posteriorly used 
for analysis. 
  
2.10 Analysis plan 
 
2.10.1 Post-calibration 
Calibration results are visualized for each region by plotting the resulting simulations against 
the available data for each location. Posterior and prior ranges of model parameters are 
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presented in Table 5 to understand which parameters where more susceptible to be shaped or 
informed during the calibration process.  
2.10.2  Estimating the impact of ART  
Reductions in incidence attributable to ART were estimated by subtracting the cumulative 
number of HIV infections obtained with the calibrated model(s) for the period 1997 to 2014, 
from the cumulative number of cases in a counterfactual scenario where no ART was 
available during the same period.  
 
Equation 3.28: Absolute reduction of HIV infections due to ART during 1997 to 2014 
𝐶𝑑𝑖𝑓𝑓 = ∫ 𝜆0(𝑡)𝑆(𝑡)
2014
1994
−∫ 𝜆1(𝑡)𝑆(𝑡)
2014
1994
 
 
Equation 3.29: Relative reduction of HIV infections with ART during 1997 to 2014 
𝐶𝑅𝑑𝑖𝑓𝑓 =
∫𝜆0(𝑡)𝑆(𝑡) − ∫𝜆1(𝑡)𝑆(𝑡)
∫ 𝜆0(𝑡)𝑆(𝑡)
 
 
The first term, 𝜆0(𝑡)𝑆(𝑡), expresses the number of HIV infections occurring at time t in a an 
alternative scenario of No-ART. The second term of the equation reflects the same outcome 
but in the current known scenario (i.e. the calibrated model). 
Similarly, estimations of absolute and relative reductions in incidence stratified by risk group 
are presented. 
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To explore the association between the posterior distribution of model parameters and the 
main outcome of analysis (i.e. Cumulative HIV incidence reduction) partial rank correlation 
coefficients (PRCC) were calculated, as described elsewhere [78]. PRCC values range 
between 1 and -1, with coefficients of around 1 meaning a very strong positive correlation 
between the parameter and the outcome, and values near -1 standing for a strong negative 
correlation. Values around zero show weak correlations.     
 
3  RESULTS 
 
3.1  Calibration results 
The calibration procedure -after 1,200,000 initial runs for each region- yielded 785 (North), 
107 (Northeast), 219 (Southeast), 184 (South) and 773 (Central-west) eligible parameter sets 
for further analysis.  
The propagation of uncertainty throughout the simulations is a reliable diagnostic of the 
calibration procedure, and in this case it shows how the availability of data influenced the 
resulting trends in each region (Figures 5 to 9). The Northern region is the one with less 
information available and that is translated into wide uncertainty bounds.  
Across all regions, modelled numbers of people receiving ART showed the greatest 
uncertainty, especially in the early years of ART scale-up for which no data is available. The 
initial shape of treatment expansion was highly uncertain in all cases, with various scenarios 
for ART scale-up -from steep increase to slowly growing shapes- leading to plausible and 
acceptable model fits. Not having one single trajectory to explain the ART scale-up but a 
collection of possible trends might reflect a mismatch between the data and the modelled 
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outcome. The reported number of people on ART each year is not an outcome that emerges 
naturally from the epidemic dynamics, but a product of the HIV treatment cascade and 
therefore susceptible to biases. Leaks across the cascade of treatment could have been in 
place in Brazil’s systems which were not adequately captured by this model. Double 
counting, under-reporting and reporting delays may also be present in the data used for 
calibration.    
Incidence rate projections from the posterior calibrated models suggest that MSM are the 
driving force behind HIV transmission across regions, with Central-western region displaying 
the largest incidence rate in this group, which is in line with the fact that the highest HIV 
prevalence estimates in MSM in later years were found in this location (Table 4) (Figure 
10). However, the lack of prevalence data in the early years in Central West Brazil might be 
allowing oversized early epidemics to take-off and find an early sharp decline, in contrast to 
other regions where the presence of early information is constraining an initial epidemic 
explosion. HIV in FSW has a relevant role in South and Southeast epidemics, and extends to 
their clients. In general, a consistent decline across groups and regions can be seen in all 
estimations. Some trajectories find its peak in the late 1980s and early 1990s, plausibly by the 
effect of natural dynamics (saturation of risk groups) or high levels of condom use in the 
years after the HIV testing era.             
Calibration had a different impact on informing the posterior parameter distribution in 
relation to the main outcome of the model (i.e. cumulative HIV incidence reduction due to 
ART) as can be seen in Table 5. Parameters with the greatest variation in their posterior 
distribution from its prior were: the shape parameter for ART scale up (t50), the partner 
change rate in FSW (c_fsw), mortality reporting rate in 1984 (Mort1984), the mixing balance 
coefficient, number of acts per partnership in MSM (αmsm) and the factor of mortality 
reporting (Mortslope).    
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Table 5: Prior and posterior parameter ranges and PRCC analysis for cumulative HIV incidence reduction (1997-2014) due to ART 
      Posterior Range 
  Prior Range North Northeast Southeast South Central-West 
  
Lower Upper PRCC Lower Upper PRCC Lower Upper PRCC Lower Upper PRCC Lower Upper PRCC Lower Upper 
  
Seed 1.00E-06 0.0025 -0.2* 1.81E-05 0.0025 -0.2 4.26E-05 0.0025 -0.3* 3.49E-05 0.0025 -0.2 5.06E-05 0.0025 -0.2* 1.64E-05 0.0025 
Condfac 0 1 -0.1 0.00 1.00 0.0 0.00 0.98 -0.2* 0.01 0.99 0.0 0.01 0.98 -0.1 0.00 1.00 
𝜌4 0.333 10 0.7* 0.362 9.988 0.7* 0.350 9.998 0.7* 0.530 9.940 0.6* 0.342 9.993 0.7* 0.336 9.977 
m 0 1 -0.4* 0.0016 0.9970 -0.2 0.0015 0.9954 -0.5* 0.0022 0.9989 -0.2* 0.0043 0.9951 -0.3* 0.0034 0.9974 
t50 0.01 1 -0.9* 0.0109 0.9459 -0.9* 0.0382 0.8582 -0.9* 0.0104 0.8569 -0.9* 0.0162 0.8104 -0.9* 0.0101 0.8939 
c_hrw 2 5 -0.1 2.0 5.0 -0.2 2.0 5.0 0.0 2.0 5.0 0.1 2.04 4.97 0.0 2.00 5.00 
c_fsw 52 2000 0.1 129 1998 -0.2 271 1989 0.1 310 1995 0.1 248 1996 0.0 78 1994 
c_bi 2 50 -0.1 2.0 49.9 -0.1 2.3 49.8 -0.1 2.2 49.9 0.0 2.1 48.9 0.1 2.2 49.8 
C_cfsw 2 50 0.0 2.0 50.0 0.1 2.2 49.7 0.0 2.4 49.8 0.1 2.2 49.8 0.0 2.0 50.0 
e 0 1 0.0 0.00 1.00 0.3* 0.03 1.00 -0.2 0.00 1.00 0.0 0.01 1.00 0.0 0.00 1.00 
𝛽𝑓 0.0003 0.001 0.0 0.0003 0.0010 -0.1 0.0003 0.0010 0.0 0.0003 0.0010 0.2 0.0003 0.0010 0.0 0.0003 0.0010 
𝛽𝑚 0.0002 0.0008 0.1* 0.0002 0.0008 0.0 0.0002 0.0008 0.1 0.0002 0.0008 0.1 0.0002 0.0008 0.0 0.0002 0.0008 
𝛽𝑚𝑠𝑚 2 20 0.1 2.0 20.0 0.1 2.1 19.6 0.0 2.1 20.0 0.1 2.0 19.5 0.0 2.0 19.9 
L0,1 4 18 -0.3* 4.0 18.0 -0.4* 4.1 17.9 -0.4* 4.1 17.8 -0.2 4.1 17.9 -0.3* 4.0 18.0 
L2,i 0.04 0.7 -0.7* 0.04 0.70 -0.7* 0.04 0.70 -0.8* 0.04 0.70 -0.7* 0.05 0.70 -0.7* 0.04 0.70 
ς 0.35 0.94 -0.4* 0.35 0.94 -0.3* 0.35 0.93 -0.5* 0.35 0.93 -0.4* 0.35 0.93 -0.3* 0.35 0.94 
Ffsw 0.007 0.021 0.0 0.007 0.021 -0.2 0.007 0.021 0.0 0.007 0.021 0.1 0.007 0.021 -0.1 0.007 0.021 
Fmsm 0.013 0.027 0.0 0.013 0.027 -0.2 0.013 0.027 0.1 0.013 0.027 0.2* 0.013 0.027 0.0 0.013 0.027 
Fcfsw 0.067 0.089 -0.1 0.067 0.089 0.0 0.067 0.089 0.0 0.067 0.089 0.2 0.067 0.089 0.1* 0.067 0.089 
c_msm 2 50 0.1 2.1 49.9 0.0 2.2 48.9 0.0 2.0 49.8 0.0 2.2 49.7 0.0 2.0 50.0 
θ 0.2 0.9 0.2* 0.20 0.90 0.2 0.21 0.90 0.2* 0.20 0.89 0.2 0.20 0.90 0.2* 0.20 0.90 
Cond_start 1985 2000 -0.2* 1985 2000 -0.3 1985 2000 -0.2* 1985 2000 0.0 1985 2000 -0.2* 1985 2000 
Mort1984 0.1 1 0.0 0.1 1.0 0.1 0.1 0.9 0.0 0.1 1.0 0.2 0.1 0.9 0.0 0.1 1.0 
balance 0 1 -0.1 0.0 1.0 0.0 0.0 1.0 0.0 0.0 1.0 -0.1 0.0 0.9 0.0 0.0 1.0 
Mmsm 0.1 0.9 0.0 0.1 0.9 0.0 0.1 0.9 0.0 0.1 0.9 0.0 0.1 0.9 0.0 0.1 0.9 
αmsm 2 30 0.1 2 30 0.0 2 30 0.1 2 28 0.0 2 29 0.1 2 30 
αcfsw 1 2 0.1 1 2 -0.1 1 2 -0.1 1 2 0.1 1 2 0.1 1 2 
Turnfsw 10 20 0.0 10 20 -0.1 10 20 -0.1 10 20 0.2* 10 20 0.0 10 20 
Mortslope 0 1 0.0 0.00 1.00 0.1 0.01 0.96 -0.1 0.00 0.99 0.1 0.00 0.93 0.0 0.00 0.99 
*p value <0.01
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Figure 5 Model comparison to data in Northern region: Top panels show model simulations (green) for reported 
number of deaths due to AIDS (top-left) and number of people receiving ART (top-right). Blue dots are data 
points as reported by Brazil DTS and AIDS department. Panels in the bottom show prevalence of HIV in both 
MSM (left) and FSW (right). Dots and error bars represent point estimations and its 95% confidence intervals. 
Median values in black solid lines. 95% percentile range is shown within dashed black lines. Black starts are 
prior limits.  
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Figure 6 Model comparison to data in North-eastern region: Top panels show model simulations (Orange) for 
reported number of deaths due to AIDS (top-left) and number of people receiving ART (top-right). Blue dots are 
data points as reported by Brazil DTS and AIDS department. Panels in the bottom show prevalence of HIV in 
both MSM (left) and FSW (right). Dots and error bars represent point estimations and its 95% confidence 
intervals. Median values in black solid lines. 95% percentile range is shown within dashed black lines. Black 
starts are prior limits. 
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Figure 7 Model comparison to data in South-eastern region: Top panels show model simulations (blue) 
for reported number of deaths due to AIDS (top-left) and number of people receiving ART (top-right). 
Red dots are data points as reported by Brazil DTS and AIDS department. Panels in the bottom show 
prevalence of HIV in both MSM (left) and FSW (right). Dots and error bars represent point estimations 
and its 95% confidence intervals. Median values in black solid lines. 95% percentile range is shown 
within dashed black lines. Black starts are prior limits. 
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Figure 8 Model comparison to data in Southern region: Top panels show model simulations (pink) for 
reported number of deaths due to AIDS (top-left) and number of people receiving ART (top-right). 
Blue dots are data points as reported by Brazil DTS and AIDS department. Panels in the bottom show 
prevalence of HIV in both MSM (left) and FSW (right). Dots and error bars represent point estimations 
and its 95% confidence intervals. Median values in black solid lines. 95% percentile range is shown 
within dashed black lines. Black starts are prior limits. 
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Figure 9 Model comparison to data in Central-western region: Top panels show model simulations 
(yellow) for reported number of deaths due to AIDS (top-left) and number of people receiving ART 
(top-right). Blue dots are data points as reported by Brazil DTS and AIDS department. Panels in the 
bottom show prevalence of HIV in both MSM (left) and FSW (right). Dots and error bars represent 
point estimations and its 95% confidence intervals. Median values in black solid lines. 95% percentile 
range is shown within dashed black lines. Black starts are prior limits. 
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Figure 10 Model projections of HIV incidence rate among MSM, FSW, CFSW and Low and High activity 
heterosexuals in Brazil: projections reflect the median of the posterior distribution of the calibrated regional 
models.    
 
 
 
3.2  Estimated impact of ART for reducing HIV incidence in Brazil 
This model found that the introduction of ART in 1997 could have had a substantial impact in 
reducing HIV transmission in Brazil. The majority of infections averted come from the 
southeast region (median ~ 150,000), the more populated area and host of the biggest HIV 
epidemic in Brazil (Figure 10). Overall, the aggregated regional estimations tell us that a 
median 272,000 new HIV infections could have been averted in Brazil between 1997 and 
2014 given the introduction of ART. This is in relative terms an average of 30% of HIV 
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infections averted in that period. Looking closely at the regional level it is evident that the 
lowest point in relative reduction was found in the Northeast, with a median reduction of 23% 
(IQR 17%). However, uncertainty bounds are wide around point estimates, showing 
overlapping ranges, making it difficult to draw conclusions on the regional differences on this 
regard.  
 
  
Figure 10 Cumulative absolute and relative HIV incidence reductions from modelling results: Coloured bars for 
the absolute estimated number of HIV infections averted. Dots and lines are the median relative reduction in 
each region. Error bars showing interquartile ranges (percentile, 27/75).   
 
Projecting modelling results of HIV incidence and prevalence by region reveals the possible 
impact that ART has had in shaping the current regional epidemics of Brazil (Figures 11 and 
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areas incidence projections would have found equilibrium by force of natural dynamics and 
condom use alone.  
 
  
Figure 11 Modelled HIV incidence rate in five regions of Brazil under two scenarios of ART availability: Solid 
coloured lines are the median of the posterior incidence rate estimated with calibrated model. Dotted line shows 
the median posterior for a scenario of No ART. Error bars along curves are the interquartile ranges of the 
posterior model projections.  
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Figure12 Modelled HIV prevalence in five regions of Brazil under two scenarios of ART availability: Solid 
coloured lines are the median of the posterior prevalence estimated with calibrated model. Dotted line shows the 
median posterior for a scenario of No-ART. Error bars along curves are the interquartile ranges of the posterior 
model projections. 
 
ART resulted in a great number of HIV infections averted within MSM over the other risk 
groups in this model (Figure 13).     
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Figure 13 Cumulative absolute and relative HIV incidence reductions from modelling results by risk group and 
region in Brazil: each panel shows the absolute (bars) vs proportional (dots) incidence reduction by risk group, 
in descending order. Error bars are interquartile range around the posterior median of model projections.  
 
Correlations between the posterior distribution of parameter values and the decrease in 
cumulative new HIV infections provides further insights about the model behaviour and the 
factors determining the estimated impact of ART (Table 5). The strongest correlations were 
observed in those parameters related to ART expansion and effectiveness. This finding was 
common to all regions. The rate at which individuals with CD4+ count <200 cell/mL move 
into ART (𝜌4) was positively correlated with the cumulative incidence reduction (PRCC 
~0.7). This shows that higher recruitment rates during a late stage of disease would actually 
boost the overall impact of ART for preventing HIV transmission. Similarly, the ART 
expansion shape-parameter t50 was very strongly negatively correlated with the outcome 
(PRCC~ -0.9). This parameter sets the turning point of the sigmoidal-like function used here 
to describe ART scale-up. Small values of t50 result in a very steep function, meaning a rapid 
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increase in the rate of recruitment into ART. On the contrary, large values lead to a smoothly 
growing shape that result in a lesser number of people being set on ART. Finally, the 
coefficient for relative reduction of HIV transmission due to ART (L
2, i
) showed a strong 
negative correlation with cumulative infections averted in all regions. This was expected, 
since small values of L
2, i
 result in large relative reductions as the parameter is introduced in 
the model as (1-L
2, i
).  
Posterior distributions of this parameter show slightly right-skewed distributions, suggesting 
a systematic selection of low values of ART effectiveness on transmission during calibration 
(Figure 14). 
      
 
Figure 14 Posterior distribution of ART effectiveness on transmission parameter: frequency histogram by 
region. Black solid line shows prior distribution density. 
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4  DISCUSSION 
This mathematical modelling analysis of the retrospective impact of ART in Brazil, found 
that an average 30% (IQR 22%) relative reduction in cumulative new HIV-1 infections was 
achieved with the introduction of ART across the five major regions of Brazil from 1997 to 
2014. HIV incidence in Brazil in 2014 is 63% (IQR 22%) lower than it would be if ART had 
not been introduced.    
For all of the regions, the model was able to reproduce epidemic trends among FSW and 
MSM while preserving the fit to surveillance data in the general population level. This model 
behaviour suggests an adequate choice of assumptions and an accurate simulation of the 
infection dynamics within the risk groups. 
Nevertheless, the lack of detail and quantity of information available in some regions 
increased the uncertainty around estimations, particularly for the cases of North and Central-
West regions.   
Large absolute reductions of cumulative new HIV infections were estimated for both South 
and Southeast regions. Relative reduction estimations on the other hand, were similar for all 
five models, with the North-eastern region displaying the shortest reduction of all (23%, IQR 
17% to 34%).  This point is of particular interest and adds to a conclusion that can be drawn 
by simple observation of basic demographic and surveillance data in Brazil: the Northeast is 
the second most populated region in the country after the Southeast, and is still only third in 
number of patients receiving HIV treatment (Tables 2, 3 and 4). From the surveillance 
perspective the Northeast holds the smallest epidemic in Brazil [79], that is, based on the rate 
of cases diagnosed per year. This contrasts not only with our findings, but with other analyses 
where the size of the epidemic in Brazil has been assessed [80]. We can conclude from a 
modelling perspective that the Northeast might hold a larger epidemic than it has been 
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reported, possibly by low levels of detection leading to a relatively low amount of patients 
receiving treatment. Grangeiro et al, have analysed Brazil’s HIV programme data from 2003 
to 2006 to establish the rates of late entry into AIDS care (diagnosed at death, AIDS illness or 
CD4 count < 200cell/mL)  for different regions [21]. Their findings support our observations: 
the Northeast and the North present the biggest proportion of late entry into care among all 
regions (53.4% and 48.1% respectively) in Brazil.   
It is evident from these results that MSM are the driving force behind HIV-1 transmission in 
Brazil, and as such seem to have benefited the most from the ART preventive effect. The 
estimated numbers of HIV infections averted are the consequence of simulating very 
concentrated epidemics in the context of equal access to treatment, that is, proportional 
effects of ART on incidence according to the contribution of each group to the overall 
epidemic. Looking closely at the relative reductions of cumulative infections by risk group it 
is clear that no major differences can be reported across risk groups. The differences 
observed then correspond to the nature of local epidemics and not to a differential effect by 
sub-population, since access to ART was modelled as a homogenous rate across risk groups, 
and was only set to vary over time and CD4 count stages. It can be said though, that those 
groups whose risk of infection is higher (MSM, FSW, CFSW) obtained the greater benefit of 
the preventive effects of antiretrovirals, when measured as the absolute number of new HIV-1 
infections averted between 1997 and 2014, and under the assumptions of this model. This 
might oversimplify a more complex reality where vulnerable groups have unequal access to 
health services or different levels of adherence to treatment. It is possible that allowing all 
sub-populations to access treatment homogeneously in this model is overestimating the 
preventive effect of ART. However the lack of consistent data on this point makes it a 
difficult task to include differential access.        
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ART has proven its effectiveness for reducing infectiousness in individuals [16] and the 
evidence supports its population effects [81-83]. Cohen et al, found that the relative hazard 
reduction was 96%, while cohort studies have found a 92% reduction in the risk of 
transmission among serodiscordant couples [81]. The 30% reduction estimated with this 
modelling analysis is by no means contrary to “outside of trial” observations of the impact of 
preventive effect of antiretrovirals. Tanser et al. analysed a prospective cohort in KuaZulu-
Natal finding a reduction of 38% in the risk of HIV acquisition for indviduals in communities 
with high ART coverage (30% to 40% of all PLHA) [84]. Jia et al, have found a 26% 
reduction of HIV incidence by reconstructing the largest serodiscordant cohort to date, with 
38 862 couples followed in China [85]. Other studies have found reduction effects as small as 
9% in Uganda [86]. In Brazil, a cohort of 93 serodiscordant couples in Porto Alegre was 
reconstructed by Melo et al [87]. During the follow-up time, 6 seroconversion events were 
observed, all in the No-treatment arm. No cases were observed in the ART arm. However, the 
effect was non-significant, but suggested a large impact of ART in that context. In general, 
the estimated reductions with this analysis are in line with the argument that it is plausible 
that bringing ART scale-up programmes outside the trial context might reduce the 
experimental effect of treatment for stopping transmission. In any case, this model was 
designed to reproduce retrospectively the impact of ART in Brazil, in a period were halting 
HIV transmission by the means of antiretrovirals was not in the agenda. It is therefore an 
unfair comparison for Brazil’s programme. Moreover, the change in epidemiological context 
is a central factor of the impact of treatment for prevention, as has been described by Dodd et 
al [88]. 
One limitation in the population structure of this model is the absence of PWID. This group 
has played a role in the HIV epidemic of Brazil, particularly in the urban areas of the country 
(South and Southeast), contributing with a large amount of cases during the 1990s [13]. In 
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order to maintain comparability across regions and to limit the model complexity, PWID 
were not included. It is therefore possible that the contribution of the other groups present in 
the model is over estimated by the absence of PWID, particularly in the first years of the 
simulation.  
As reported by different authors, the use of drugs has changed drastically in Brazil as a 
function of prices and the availability of new options reducing the frequency of injecting 
behaviour during the 2000s[12]. This sustained reduction in the number of PWID overlaps in 
time with ART scale-up increases, which might mean that this population was not widely 
exposed to ART, thus its absence is not affecting these estimations to a large extent. On the 
other hand, irrespective of the population size of PWID during ART introduction, these 
modelling results might be overestimating the marginal impact of ART by risk group due to 
the assumption of no-PWID.     
Another limitation found here, might be one related to oversimplification of the flow inside 
the treatment programme for a given patient in Brazil: this model allows for one single line of 
treatment, whose effectiveness is the same from the introduction of ART to the current date, 
and despite the presence of failure stages, patients return to the same line of treatment if they 
are re-linked to treatment. It is not possible to predict the effect of this assumption in these 
results, but a more detailed approach should observe the increasing potency of antiretroviral 
schemes over time as well as a second and third line treatments. As described before, this 
analysis is also limited by the level of detail of the programmatic data used for fitting the 
model outcomes. This is reflected in large amounts of uncertainty around these projections 
that could be addressed in the future with a better understanding of the collection and 
construction of these indicators.   
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Brazil has committed from the beginning of the HAART era to universal access to treatment, 
and as a programme has been reviewing its own standards to make the most out of its 
infrastructure and its health system capacity. These estimations shed light over the effect of 
treatment during the implementation of one of the biggest programmatic efforts in public 
health history, and might offer new perspectives for planning ahead the future use of 
antiretrovirals in the era of treatment as prevention.     
      
5  REFERENCES 
 
1. Nunn, A., The politics and history of AIDS treatment in Brazil. 2009, New York ; London: 
Springer. 
2. Instituto-Brasileiro-de-Geografia-e-Estatística.  [cited 2013 01-10]; Available from: 
http://www.ibge.gov.br. 
3. Departamento-de-DST-Aids-e-Hepatites-Virais, Boletim Epidemiológico, M.d. Saúde, Editor. 
2012, Ministério da Saúde: Brasília DF. 
4. Departamento de DST, A.e.H.V., Aids e DST, in Boletim Epidemiológico, M.d. Saúde, Editor. 
2013, Ministério da Saúde: Brasília. p. 1:64. 
5. Marins, J.R., et al., Dramatic improvement in survival among adult Brazilian AIDS patients. 
AIDS, 2003. 17(11): p. 1675-82. 
6. Hacker, M.A., et al., The first ten years: achievements and challenges of the Brazilian 
program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. 
Cad Saude Publica, 2007. 23 Suppl 3: p. S345-59. 
7. Guimarães, M.D., [Temporal study in AIDS-associated disease in Brazil, 1980-1999]. Cad 
Saude Publica, 2000. 16(## Suppl 1): p. 21-36. 
8. Morgado, M.G., et al., Human immunodeficiency virus/acquired immunodeficiency syndrome 
and tropical diseases: a Brazilian perspective. Mem Inst Oswaldo Cruz, 2000. 95 Suppl 1: p. 
145-51. 
9. Sampaio, R. and H. Théry, Orientação metodológica para construção e leitura de mapas 
temáticos Confins, 2008(3): p. 1:21. 
10. Saúde, M.d., Boletim Epidemiológico'AIDS. 1999. 
11. Szwarcwald, C.L., et al., [The spread of the AIDS epidemic in Brazil from 1987 to 1996: a 
spatial analysis]. Cad Saude Publica, 2000. 16(## Suppl 1): p. 7-19. 
12. Bastos, F.I., Structural violence in the context of drug policy and initiatives aiming to reduce 
drug-related harm in contemporary Brazil: a review. Subst Use Misuse, 2012. 47(13-14): p. 
1603-10. 
13. Mesquita, F., et al., Trends of HIV infection among injection drug users in Brazil in the 1990s: 
the impact of changes in patterns of drug use. J Acquir Immune Defic Syndr, 2001. 28(3): p. 
298-302. 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
157 
 
14. Barbosa Junior, A., et al., [Proposed UNGASS indicators and the monitoring of the AIDS 
epidemic in Brazil]. Rev Saude Publica, 2006. 40 Suppl: p. 94-100. 
15. Dourado, I., et al., Risk factors for human T cell lymphotropic virus type I among injecting 
drug users in northeast Brazil: possibly greater efficiency of male to female transmission. 
Mem Inst Oswaldo Cruz, 1999. 94(1): p. 13-8. 
16. Cohen, M.S., et al., Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J 
Med, 2011. 365(6): p. 493-505. 
17. Teixeira, T.R., et al., Social geography of AIDS in Brazil: identifying patterns of regional 
inequalities. Cad Saude Publica, 2014. 30(2): p. 259-71. 
18. Szwarcwald, C.L. and E.A. Castilho, [Estimated number of HIV-infected individuals aged 15-49 
years in Brazil, 1998]. Cad Saude Publica, 2000. 16(## Suppl 1): p. 135-41. 
19. Kerr, L.R., et al., HIV among MSM in a large middle-income country. AIDS, 2013. 27(3): p. 
427-35. 
20. Fazito, E., et al., Identifying and quantifying misclassified and under-reported AIDS deaths in 
Brazil: a retrospective analysis from 1985 to 2009. Sex Transm Infect, 2012. 88 Suppl 2: p. 
i86-94. 
21. Grangeiro, A., M.M. Escuder, and J.C. Pereira, Late entry into HIV care: lessons from Brazil, 
2003 to 2006. BMC Infect Dis, 2012. 12: p. 99. 
22. Lodi, S., et al., Time from human immunodeficiency virus seroconversion to reaching CD4+ 
cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes 
in treatment guidelines. Clin Infect Dis, 2011. 53(8): p. 817-25. 
23. Garnett, G.P., et al., The transmission dynamics of gonorrhoea: modelling the reported 
behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci, 
1999. 354(1384): p. 787-97. 
24. Anderson, R.M. and R.M. May, Infectious diseases of humans : dynamics and control. Oxford 
science publications. 1991, Oxford ; New York: Oxford University Press. viii, 757 p. 
25. Pinkerton, S.D. and P.R. Abramson, Occasional Condom Use and HIV Risk Reduction. Journal 
of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1996. 13: p. 13-16. 
26. Bezemer, D., et al., 27 years of the HIV epidemic amongst men having sex with men in the 
Netherlands: An in depth mathematical model-based analysis. Epidemics, 2010. 2(2): p. 66-
79. 
27. Hallett, T.B., et al., Assessing evidence for behaviour change affecting the course of HIV 
epidemics: a new mathematical modelling approach and application to data from Zimbabwe. 
Epidemics, 2009. 1(2): p. 108-17. 
28. Fernandes, J.R., et al., [Initiation of antiretroviral therapy in HIV-infected patients with severe 
immunodeficiency in Belo Horizonte, Minas Gerais State, Brazil]. Cad Saude Publica, 2009. 
25(6): p. 1369-80. 
29. Souza-Jr, P.R., C.L. Szwarcwald, and E.A. Castilho, Delay in introducing antiretroviral therapy 
in patients infected by HIV in Brazil, 2003-2006. Clinics (Sao Paulo), 2007. 62(5): p. 579-84. 
30. Pacheco, A.G., et al., Estimating the extent of underreporting of mortality among HIV-
infected individuals in Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses, 2011. 27(1): p. 25-8. 
31. Benzaken, A.S., et al., Field evaluation of the performance and testing costs of a rapid point-
of-care test for syphilis in a red-light district of Manaus, Brazil. Sex Transm Infect, 2008. 
84(4): p. 297-302. 
32. Dutra JC and V. F, Syphilis and HIV prevalence among female sex workers from Manaus, 
Amazon port zone, using respondent driven sampling - RDS., in Research report. 2006, 
Brazilian National STD/AIDS Program.: Brasília. 
33. Ivo-dos-Santos, J., et al., Prevalence of HIV-1 antibodies in selected groups of a Brazilian city 
with African sociodemographic characteristics. J Acquir Immune Defic Syndr, 1991. 4(4): p. 
448-9. 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
158 
 
34. Broutet, N., et al., Prevalence of HIV-1, HIV-2 and HTLV antibody, in Fortaleza, Ceara, Brazil, 
1993-1994. Int J STD AIDS, 1996. 7(5): p. 365-9. 
35. Departamento-de-DST-Aids-e-Hepatites-Virais, Avaliação da Efetividade das Ações de 
Prevenção Dirigidas às Profissionais do Sexo, em Três Regiões Brasileiras, M.-d.-S. 2004, 
Editor. 2004, Ministério-da-Saúde, 2004: Brasília DF. 
36. Rodrigues, L.G. and P. Chequer, AIDS in Brazil, 1982-1988. Bull Pan Am Health Organ, 1989. 
23(1-2): p. 30-4. 
37. Cortes, E., et al., HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med, 
1989. 320(15): p. 953-8. 
38. Granato, C., W. Johnson, and C. Brites, Retrovirus Infection in Prostitutes in Brazil, in VI 
International Conference on AIDS. 1990: San Francisco. 
39. Aoki, F.H., L.J. N., and W.B. Abreu, HIV Infection among Prostitues and Transvestites in Brazil, 
in V International Conference on AIDS 1989: Montreal. 
40. Lurie, P., et al., Socioeconomic status and risk of HIV-1, syphilis and hepatitis B infection 
among sex workers in Sao Paulo State, Brazil. Instituto Adolfo Lutz Study Group. Aids, 1995. 9 
Suppl 1: p. S31-7. 
41. Bueno, R.C., G. L. Paes, and F. C. Mesquita, A Comparison of IVDU and Heterosexual 
Transmission in Sex Workers of Low Social-Economics Situation in Santos, Brasil, in VIII 
International Conference on AIDS. 1992: Amsterdam  
42. Pires, I.C.P. and A.E.B. Miranda, Prevalência e fatores correlatos de infecção pelo hiv e sífilis 
em prostitutas atendidas em centro de referência DST/AIDS. Revista Brasileira de Ginecologia 
e Obstetrícia, 1998. 20: p. 151-154. 
43. Szwarcwald, C.L., et al., The relationship of illicit drug use to HIV-infection among commercial 
sex workers in the city of Santos, São Paulo, Brazil. The International journal on drug policy, 
1998. 9(6): p. 427-436. 
44. Barroso, P.F., et al., Barriers to recruit female commercial sex workers for HIV vaccine trials: 
the Rio de Janeiro experience. J Acquir Immune Defic Syndr, 2009. 50(1): p. 116-7. 
45. Lacerda, R., et al., Respondent Driving Sampling (RDS): An effective methodology to estimate 
HIV transmission vulnerability among sex workers from Santos.   , in Research report. 2006, 
Brazilian National STD/AIDS Program.: Brasília. 
46. Andrade-Neto, J.L., Female Sex Work in Brazil: Risk and Prevalence, in Tenth International 
Conference on AIDS. 1994: Yokohama, Japan. 
47. Froes, A., Prevencao de DST/AIDS Associada ao Reconhecimento e Exercicio da Cidadania de 
Mulheres Profissionais do Sexo em Porto Alegre/RS, in I Forum e II Conferencia de 
Cooperacao Tecnica Horizontal da America Latina e do Caribe em HIV/AIDS e DST. 2000: Rio 
de Janerio, Brasil. 
48. Trevisol, F.S. and M.V. Silva, HIV frequency among female sex workers in Imbituba, Santa 
Catarina, Brazil. Braz J Infect Dis, 2005. 9(6): p. 500-5. 
49. Schuelter-Trevisol, F., et al., HIV genotyping among female sex workers in the State of Santa 
Catarina. Rev Soc Bras Med Trop, 2007. 40(3): p. 259-63. 
50. Fernandes, F.R., et al., HIV seroprevalence and high-risk sexual behavior among female sex 
workers in Central Brazil. AIDS Care, 2014. 26(9): p. 1095-9. 
51. Mott, L., et al., Impact of condom use to prevent HIV transmission among male homosexuals 
in Bahia, Brazil[abstract] in Sixth International Conference on AIDS. 1989&#x9;&#x9;  : San 
Francisco, California, USA. 
52. Ribeiro, T.T., et al., Serologic validation of HIV infection in a tropical area. J Acquir Immune 
Defic Syndr, 1993. 6(3): p. 319-22. 
53. de Lima e Costa, M.F., et al., Factors associated with AIDS and AIDS-like syndrome among 
homosexual and bisexual men in Minas Gerais, Brazil. Int J Epidemiol, 1990. 19(2): p. 429-34. 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
159 
 
54. Sutmoller, F., et al., Human immunodeficiency virus incidence and risk behavior in the 
'Projeto Rio': results of the first 5 years of the Rio de Janeiro open cohort of homosexual and 
bisexual men, 1994-98. Int J Infect Dis, 2002. 6(4): p. 259-65. 
55. Saúde., M.d., Bela Vista e Horizonte: estudos comportamentais e sorológicos entre homens 
que fazem sexo com homens. 2000, Ministério da Saúde.: Brasília. 
56. Greco, D.B., J.R. Carvalheiro, and F. Sutmoller, Feasibility of Clinical Trials with Candidate 
HIV/AIDS Vaccines in Brazil, in 12th World AIDS Conference. 1998: Geneva, Switzerland. 
57. Viana, L.G., A.C. Toledo, and C.M. Antunes, Laboratory Status of Homo/Bisexual Men from a 
Cohort Study in Belo Horizonte, Brazil., in XI International Conference on AIDS. 1996: 
Vancouver, Canada. 
58. Friedman, R.K., J. Rodrigues, and L.F. Fraga, Prevalence of Markers for Sexually Transmitted 
Diseases in a Male Population at High Risk for HIV Infection, in 12th World AIDS Conference. 
1998: Geneva, Switzerland. 
59. Luna, E.J.A., G.M. Figueiredo, and L.Y.L. Mirim&#x9;, Sexually Transmitted Diseases (STD) 
and HIV Infection Incidence among Men Who Have Sex with Men (MSM).  , in XI International 
Conference on AIDS. 1996: Vancouver, Canada. 
60. Utsch, M.J.D., M.A.P. Greco, and Silva, Acompanhamento de Homo/Bissexuais Masculinos 
em Belo Horizonte Para Avaliacao da Incidencia da Infeccao Pelo HIV e Futuros, in 2nd Forum 
on HIV/AIDS/STD in Latin American and the Caribbean. 2003: La Havana, Cuba. 
61. Tun, W., et al., Sexual risk behaviours and HIV seroprevalence among male sex workers who 
have sex with men and non-sex workers in Campinas, Brazil. Sex Transm Infect, 2008. 84(6): 
p. 455-7. 
62. Barcellos, N.T., S.C. Fuchs, and F.D. Fuchs, Prevalence of and risk factors for HIV infection in 
individuals testing for HIV at counseling centers in Brazil. Sex Transm Dis, 2003. 30(2): p. 166-
73. 
63. Pereira, G.A., et al., Human immunodeficiency virus type 1 and hepatitis C virus co-infection 
and viral subtypes at an HIV testing center in Brazil. J Med Virol, 2006. 78(6): p. 719-23. 
64. Wood, E., et al., Vienna Declaration: a call for evidence-based drug policies. Lancet, 2010. 
376(9738): p. 310-2. 
65. Departamento-de-DST-Aids-e-Hepatites-Virais, Pesquisa de Conhecimentos, Atitudes e 
Práticas na População Brasileira de 15 a 64 anos 2008 (PCAP 2008), M.d. Saúde, Editor. 
2011, Ministério da Saúde: Brasilia DF. 
66. Fazito, E., et al., Analysis of duration of risk behaviour for key populations: a literature 
review. Sex Transm Infect, 2012. 88 Suppl 2: p. i24-32. 
67. Departamento-de-DST-Aids-e-Hepatites-Virais, Pesquisa de Conhecimento Atitudes e 
Práticas na População Brasileira de 15 a 54 anos, 2004. Ministério da Saúde, 2005.: Brasília 
DF. 
68. Kerr-Pontes, L.R., et al., Self-reported sexual behaviour and HIV risk taking among men who 
have sex with men in Fortaleza, Brazil. Aids, 1999. 13(6): p. 709-17. 
69. de Mello, M., et al., Assessment of risk factors for HIV infection among men who have sex 
with men in the metropolitan area of Campinas city, Brazil, using respondent-driven 
sampling. Horizons Final Report. 2008, Washington DC.: Population Council. 
70. Stover, J., J.T. Bertrand, and J.D. Shelton, Empirically Based Conversion Factors for 
Calculating Couple-Years of Protection. Evaluation Review, 2000. 24(1): p. 3-46. 
71. Berquo, E., R.M. Barbosa, and L.P. Lima, Trends in condom use: Brazil 1998 and 2005. Rev 
Saude Publica, 2008. 42 Suppl 1: p. 34-44. 
72. Boily, M.C., et al., Heterosexual risk of HIV-1 infection per sexual act: systematic review and 
meta-analysis of observational studies. Lancet Infect Dis, 2009. 9(2): p. 118-29. 
73. Baggaley, R.F., R.G. White, and M.C. Boily, HIV transmission risk through anal intercourse: 
systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol, 2010. 
39(4): p. 1048-63. 
Chapter 3: Estimating the retrospective impact of Antiretroviral Treatment scale-up in Brazil 
160 
 
74. Hollingsworth, T.D., R.M. Anderson, and C. Fraser, HIV-1 transmission, by stage of infection. J 
Infect Dis, 2008. 198(5): p. 687-93. 
75. Weller, S. and K. Davis, Condom effectiveness in reducing heterosexual HIV transmission. 
Cochrane Database Syst Rev, 2002(1): p. Cd003255. 
76. Cesar, C., et al., Rates and reasons for early change of first HAART in HIV-1-infected patients 
in 7 sites throughout the Caribbean and Latin America. PLoS One, 2010. 5(6): p. e10490. 
77. Vo, T.T., et al., Durability and outcome of initial antiretroviral treatments received during 
2000--2005 by patients in the Swiss HIV Cohort Study. J Infect Dis, 2008. 197(12): p. 1685-94. 
78. Blower, S.M. and H. Dowlatabadi, Sensitivity and Uncertainty Analysis of Complex Models of 
Disease Transmission: an HIV Model, as an Example. International Statistical Review, 1994. 
62(2): p. 13. 
79. Saúde, M.d., Brazilian Policy on addressing AIDS: results, progress and perspectives, A.a.V.H. 
Department of STD, Editor. 2012: Brasilia. 
80. Grangeiro, A., M.M. Escuder, and E.A. Castilho, Magnitude and trend of the AIDS epidemic in 
Brazilian cities, from 2002 to 2006. Rev Saude Publica, 2010. 44(3): p. 430-40. 
81. Donnell, D., et al., Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a 
prospective cohort analysis. Lancet, 2010. 375(9731): p. 2092-8. 
82. Das, M., et al., Decreases in community viral load are accompanied by reductions in new HIV 
infections in San Francisco. PLoS One, 2010. 5(6): p. e11068. 
83. Montaner, J.S., et al., Association of highly active antiretroviral therapy coverage, population 
viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based 
study. Lancet, 2010. 376(9740): p. 532-9. 
84. Tanser, F., et al., High coverage of ART associated with decline in risk of HIV acquisition in 
rural KwaZulu-Natal, South Africa. Science, 2013. 339(6122): p. 966-71. 
85. Jia, Z., et al., Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in 
China (2003-11): a national observational cohort study. Lancet, 2012. 
86. Anglemyer, A., et al., Antiretroviral therapy for prevention of HIV transmission in HIV-
discordant couples. Cochrane Database Syst Rev, 2013. 4: p. Cd009153. 
87. Melo, M.G., et al., Sexual transmission of HIV-1 among serodiscordant couples in Porto 
Alegre, southern Brazil. Sex Transm Dis, 2008. 35(11): p. 912-5. 
88. Dodd, P.J., G.P. Garnett, and T.B. Hallett, Examining the promise of HIV elimination by 'test 
and treat' in hyperendemic settings. AIDS, 2010. 24(5): p. 729-35. 
 
 
 
 
 
 
 
Chapter 4: Estimating HIV incidence from case-report data 
161 
 
 
 
 
 
 
Chapter 4: Estimating HIV Incidence from Case-report 
Data: Method and an Application in Colombia 
 
 
 
 
 
 
 
 
 
Chapter 4: Estimating HIV incidence from case-report data 
162 
 
1 INTRODUCTION 
In any setting, one of the most important pieces of information in responding to an HIV 
epidemic, evaluating past efforts, and planning for the future, is the time-course of the HIV 
incidence rate.  
Direct observation of new infections, whether through cohort studies or via the use of 
incidence assays and algorithms (1), is not feasible in most national settings. Mathematical 
modelling provides an alternative mean to infer incidence using other more readily available 
data. Currently, UNAIDS estimates of HIV incidence trends in generalised epidemics are 
derived through fitting a simple model to HIV prevalence measurement among pregnant 
women and prevalence measurements in national household surveys (2, 3). This approach has 
been less effective in settings with concentrated epidemics, due to a combination of factors: 
inconsistencies in the measurements of prevalence over time, scarce prevalence 
measurements among hard-to-reach groups, and lack of robust estimates on the size of these 
groups. For this reason, it is important to explore other means of estimating HIV incidence in 
these settings, which would not exclusively rely on estimates of HIV prevalence and size 
estimates of key populations. 
Other sources of available data, which could potentially be combined with models to draw 
inference on incidence in concentrated epidemics, include time-series data on AIDS deaths 
and reported cases. Here, the focus is on the use of reported cases.  
In many settings, especially in Latin America and Europe, systems are in place to centrally 
record the number of persons newly diagnosed with HIV. In many settings, it is believed that 
the coverage of this system (the proportion of newly diagnosed cases that are counted) could 
be as high as 80% (4, 5). However, the interval between an infection and a diagnosis is not 
known and may change over time and this would confound all estimates of incidence unless 
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further information could be included on the interval between testing and diagnosis. Possible 
candidates to inform the interval between infection and diagnosis are the clinical stage and 
CD4 cell count (6). Further, in the future, measurement of a well characterized biomarker of 
recent infection may also be available (7). 
This method builds on prior work (8, 9) to develop a modelling framework that can be used 
to estimate HIV incidence drawing primarily on HIV case report data. Synthetic data is used 
to test the performance in recovering a wide range of possible incidence trajectories. Finally, 
the model is applied to Colombia to derive HIV incidence estimates, which are then 
compared to other estimates available for Colombia. 
2 METHODS 
2.1 Mathematical Model 
The proposed model consists of a deterministic mathematical model to simulate the process 
of HIV infection and disease progression, death and diagnosis (Figure 1).  
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Figure 1 Model of HIV infection and progression: Parameter values and prior distributions for calibration can 
be found in table 1.  
  
This structure is expressed through a set of six ordinary differential equations as follows: 
𝑑𝑈(𝑡)
𝑑𝑡
= 𝛼(𝑡) − 𝑈(𝑡)(𝑠(𝑡) + 𝛿) ;  Eq.1: Susceptible 
𝐼1(𝑡)
𝑑𝑡
= 𝑠(𝑡)𝑈(𝑡) − 𝐼1(𝛿 + 𝛾1 + 𝜌1(𝑡)); Eq.2: Acute infection 
𝐼2(𝑡)
𝑑𝑡
= 𝐼1𝛾1𝜀2 − 𝐼2(𝛿 + 𝛾2 + 𝜌2(𝑡)); Eq.3: CD4+ count >500 cell/μL 
𝐼3(𝑡)
𝑑𝑡
= 𝐼1𝛾1𝜀3 + 𝐼2𝛾2 − 𝐼3(𝛿 + 𝛾3 + 𝜌3(𝑡))); Eq.4: CD4+ count 350-500 cell/μL 
𝐼4(𝑡)
𝑑𝑡
= 𝐼1𝛾1𝜀4 + 𝐼3𝛾3 − 𝐼4(𝛿 + 𝛾4 + 𝜌4(𝑡)); Eq.5: CD4+ count 200-350 cell/μL 
𝐼5(𝑡)
𝑑𝑡
= 𝐼1𝛾1𝜀5 + 𝐼4𝛾4 − 𝐼5(𝛿 + 𝛾5 + 𝜌5(𝑡));  Eq.6: CD4+ count <200 cell/μL 
 
Where 𝑈(𝑡) is the number of persons HIV susceptible at time t; 𝐼1(𝑡) is the number of 
infected individuals in acute infection at time t; 𝐼𝑗(𝑡) (j=2,…,5) is the number of infected 
individuals in CD4+ count category j at time t; and 𝑠(𝑡) is the time-varying rate at which the 
population of infected individuals transmits HIV to susceptible persons. The rate at which 
Chapter 4: Estimating HIV incidence from case-report data 
165 
 
new infections occur in this population is given by 𝑠(𝑡)𝑈(𝑡). All symbols and parameters are 
described in Table 1.  
At infection, individuals pass through a stage of acute infection following which individuals 
enter one of four CD4 cell count categories (<200, 200-350, 350-500, 500+ cell/μL). 
Thereafter, individuals progress to lower CD4 cell counts at rates which have previously been 
estimated from European data (10). Individuals with CD4 cell count below 200 cell/μL die of 
AIDS. The overall median survival time is 10.4 years, consistent with estimates from low and 
middle-income countries (11). In the model framework, these parameters describing the 
progression of HIV infections are considered to be known perfectly.  
At all times after infection, individuals can be diagnosed with HIV. At that point they 
transition into a ‘diagnosed’ category. The number of HIV-infected persons that transition to 
the diagnosed category in a given year in the model is compared with the data on the number 
of reported cases. 
 
2.2 Model parameterization  
2.2.1 HIV infection rate 
Following Hogan et al. (2), the instantaneous hazard of infection for susceptible individuals 
s(t) is specified as a B-spline function of time. The B-spline is parameterised by a vector of 
coefficients (𝛽1,…,𝑛), where n-3 is the number of knots of the spline which were evenly 
spaced on the time interval 1975 to 2015. This flexible functional form allows many credible 
incidence trajectories whilst constraining the trajectory to evolve smoothly with respect to 
time. This does not attempt to provide a mechanistic description of HIV transmission. Note 
that in other formulations, the spline describes a force of infection (which gives incidence 
when multiplied with the product of U(t) and all infected individuals) rather than a hazard of 
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infection but this is not possible here as, for parsimony, the entire infected population is not 
modelled. 
It was set β1 = β2= β3 =0, to anchor the incidence trajectory at zero before 1975, while β4 to 
β6 were independently specified with uniform priors: β4  ~ 𝑈 (0,5), β5~ 𝑈 (−5,5) , and 
β6 ~ 𝑈 (−5,5) . Penalties were imposed (12) on the spline, in order to limit over-fitting to 
potentially noisy data and to represent our prior assumption that rapid large oscillations in the 
HIV incidence rate are unlikely.  The second degree difference penalties (12) used are 
expressed as: 
𝛽𝑖 = 2𝛽𝑖−1 − 𝛽𝑖−2 + 𝜇𝑖 ,…, for 𝑖 > 6  
where the error 𝜇𝑖 is the amount of deviance from the trajectory defined by the two previous 
coefficients.  
The prior for 𝜇𝑖 is normally distributed with parameters  𝑁 (0, 𝜏
2), where 𝜏2 is a hyper-
parameter controlling the overall smoothness of the function; small values of 𝜏2 result in little 
deviance from the previous trajectory and large values in contrast produce more flexible 
curves. 
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2.2.2. HIV detection rates 
The rate at which HIV-infected individuals are diagnosed is 𝜌𝑗(𝑡), and is allowed to vary by 
CD4 cell count category j and calendar time t: 
𝜌𝑗(𝑡) = ((𝑚𝜔)𝑇𝑗 + 𝜌5(0)) 𝜎(𝑡)   
where Tj is the average time (years) to reach CD4+ count category <200 cell/μL (j=5) for 
those in CD4 cell count category j=1,…,4 (T1=8.17; T2=7.93; T3=6.74; T4=3.74; T5=0).  
This parameterization sets the rate of detection to vary linearly as the time to reach CD4<200 
cell/μL decreases. The slope of this line is specified by parameter ω, which allows the linear 
relationship to be either positive or negative. With ω>0,  individuals with high CD4 counts 
are more likely to be detected, which is plausible scenario if exposure to HIV is suspected or 
symptoms of acute infection drive testing; with ω<0, individuals with low CD4 counts are 
more likely to be detected, which may be true if HIV testing is prompted by increasing 
experience of illness. The prior on ω reflects that both of these possibilities are equally 
likely: 𝜔~ 𝑈 (−1,1). Parameter m is a constant scaling parameter which ensures that the 
diagnosis rate is greater than zero for all CD4 categories, irrespective of the value of ω. 
Rate of testing for those in CD4 cell count category <200 cell/μL (ρ5) has a prior distribution 
such that the average interval from infection to diagnosis is uniformly distributed between 0.5 
and 10 years: ~𝑈 (
1
10
,
1
0.5
). 
σ(t) describes the change in the rates of diagnosis over time. Here it is assumed that this 
change can be represented by the logistic function: 𝜎(𝑡) =
1
1+𝑒
−𝑟(𝑡−𝑡50)
 , where r is the rate of 
increase, and 𝑡50 is the time to reach half the upper limit rate. Parameter r is set at 0.003 and a 
prior was placed on t50 that allows a wide range in shapes in σ(t) from a stable trend over time 
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(t50=1) to a sharp increase in the rate of diagnosis from close to zero at the start of the 
epidemic (t50=0.1): 𝑡50~𝑈(0.1,1).  
 
2.3 Model validation and calibration procedures 
The inference on the HIV incidence rate is done in a Bayesian framework. The likelihood is 
given by the probability of observing the number of HIV cases without AIDS reported in a 
year, the number of HIV cases with AIDS reported in a year (i.e. symptomatic illness or 
CD4+ count <200 cell/μL), and the number of persons diagnosed with HIV after death in a 
given year, each modelled as Poisson process. The Metropolis Hastings algorithm was used 
with component-wise updating to sample from the posterior distribution of the model. Also, 
an adaptive proposal density variance was used in order to achieve an acceptance rate of 
approximately 30%. Three chains were run in parallel for 500,000 iterations after which 
chains were visually inspected for convergence and 50% of the initial runs were discarded.  
Models are estimated that use B-spline functions with number of knots n=7, 8, 10, and with 
hyper-prior for 𝜏2 variously given as ~U(0.001,0.1), ~U(0.1,0.5), ~U(0.5,1.0), ~U(1.0,1.5) or 
~U(1.5, 2.5),  giving a total of 15 models runs for each estimation problem. Among these, a 
model is chosen that has the greatest agreement to data, given its number of effective 
parameters, as measured by the model with smallest Deviance Information Criterion (DIC) 
(13). For that chosen model, a sample from the joint posterior distribution is formed by 
randomly sampling 1000 iterations across all its chains. Medians and 95% credible intervals 
are reported for the posterior samples. 
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Table 1: Model parameters 
Symbol Description Value/Prior Distribution Reference 
α(t) Birth Rate 
𝑁(𝑡)𝐸 + (𝛿) (∑𝐼𝑗(𝑡)
𝑖
+ 𝑈(𝑡))
+ 𝐼5(𝑡)𝛾5 
 
N(t) Total population at any time t 𝑈(𝑡) +∑𝐼𝑗
𝑗
,   𝑓𝑜𝑟 𝑗 = 1,… ,4 - 
E Average population growth per year 2.7% (14) 
δ Background mortality rate 1/72 years (14) 
θ 
Fraction of AIDS related deaths detected 
post mortem  
~𝑈(0,1) Assumption 
 
𝜸𝒋 
 
Progression rates (1/years) from CD4+ 
count stage k to the subsequent inferior 
CD4+ count category 
(1/yrs) 
𝛾1 =
1
0.24
 
𝛾2 =
1
2
 
𝛾3 =
1
3
 
𝛾4 =
1
3
 
𝛾5 =
1
2.4
 
(10, 15) 
𝜺𝒋 
Proportion moving to each CD4+ stage 
after acute infection 
𝜀2 = 0.58 
𝜀3 = 0.23 
𝜀4 = 0.16 
𝜀5 = 0.03 
(10, 16) 
𝝆𝟓 Diagnostic rate at CD4+ <200cell/μL 𝜌5~𝑈 (
1
10
,
1
0.5
) Assumption 
𝒎 
Slope scaling parameter. Is the slope for 
the line crossing (0 , ρ5) and (0 , ρ1) 
𝑚 =
0 − 𝜌5(0)
8.17 − 0
 Assumption 
𝝎 Relative slope variation factor. 𝜔~𝑈(−1,1) Assumption 
𝝈(𝒕) 
Function for the variation of HIV 
detection over time 
𝜎(𝑡) =
1
1+𝑒
−𝑟(𝑡−𝑡50)
, for r=0.003 Assumption 
𝒕𝟓𝟎 Shape parameter in function 𝜎(𝑡) 𝑡50~𝑈(0.1,1) Assumption 
𝜷𝒊 Basis coefficients for spline function s(t) 
𝛽𝑖 = 0,  for i=1,..,3 
𝛽𝑖  ~𝑈(0,5), i=4 
𝛽𝑖  ~𝑈(−5,5), i=5,6 
𝛽𝑖 = 2𝛽𝑖−1 − 𝛽𝑖−2 + 𝜇𝑖 ,  
For i= 7,…,n 
 
𝝁𝒊 
Deviance of the ith β from the former two 
coefficients 𝛽𝑖−1 and 𝛽𝑖−2 , for i=7,…,10. 
𝜇𝑖~𝑁(0, 𝜏
2) 
𝜏2~𝑈(0,2) 
Assumption 
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2.4 Assessment of Model Performance Using Synthetic Data 
The performance of model in recovering the ‘correct’ incidence trajectory from sets of 
synthetic data was assessed. One major concern was that the specification of this estimation 
method would render it unable to correctly discern all possible trajectories with different 
amounts of variation over time or timing of inflections. For this reason, three “challenge 
datasets” were created using the same assumptions as the estimation model about natural 
history but varying the number in the spline function that generates that incidence rate (n=7, 
8, 10). Synthetic data were generated under the assumption of constant rates of diagnosis over 
time and CD4 cell count. 
2.5 Application of the Model to Colombia 
Between 1983 and 2010 Colombia reported 78,999 cases of HIV and AIDS, the vast majority 
coming from urban areas and major cities (17). Overall prevalence was estimated at 0.22% in 
2009 in the adult population overall (18), but HIV prevalence appears to be substantially 
concentrated among men-who-have-sex-with-men (MSM), among whom prevalence has 
been estimated to be between 5.6% and 24.1% in different cross-sectional studies in 2010 
(19). In this method it is assumed equivalence between an AIDS diagnosis in the data and a 
diagnosis for a patient with a CD4 cell count below 200 in the model.  
There have been official records of the number of deaths that were classified as AIDS deaths 
among persons who had not previously been recorded as HIV-infected (i.e. post mortem HIV 
diagnosis) since 1985 (20). No reporting bias or misclassification in this is assumed. 
Data was used on the total number of HIV tests reported to have been performed in Colombia 
to centre the prior on the trend in the rate of diagnosis over time (21). This trend can be 
broadly described as a sigmoid increase with a turning point in 1996 and a plateau in the 
more recent years.  
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These data were used in the method outlined above to estimate incidence over time. The 
results were compared with reported estimates of incidence from UNAIDS (22), which are 
based on fitting a model to prevalence data and population size estimates for key populations 
(3).  
 
3 RESULTS 
 
3.1 Assessment of Model Performance Using Synthetic Data 
Three challenge datasets with different epidemic trajectories were proposed and the current 
method was able to successfully recover each of them (Figure 2). A part of the method is to 
estimate multiple models and then select that model with the lowest DIC; as expected, the 
model that was favoured in each these tests was the model which has the same number of 
knots as that used to generate the synthetic data. Also as expected, uncertainty becomes 
greater in more recent years as the data on case reports are less informative on current 
incidence rates. Uncertainty for estimates in the recent years is especially great when the data 
indicate that trend in incidence has changed.  
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Figure 2Incidence estimation with three configurations of the spline function: In each panel, the black solid line 
is the true simulated incidence trend; the dashed red is the incidence estimation using the proposed method 
(median of the posterior distribution); the shaded blue region gives a 95% credible interval for incidence using 
the proposed method. The synthetic data was created using a model with 7 knots (a), 8 knots (b) or 10 knots (c). 
 
 
3.2 Estimating HIV Incidence in Colombia   
The model was applied to Colombian data using the proposed method. Model estimates and 
data on HIV cases, AIDS cases and post mortem detection are presented in Figure 3(a-c) and 
resultant estimates of HIV incidence are presented in Figure 3(d). For Colombia, the model 
formulation with the lowest DIC was one with 8 knots and hyper-prior  𝜏2 ~U(1, 1.5). 
The model has a good fit with the observed data (Figure 3(a-c)) in the early years, while 
uncertainty is widely propagated in the recent years as noted in the experiments with 
synthetic data. The data for post mortem detected cases and AIDS cases exhibit complex 
patterns which the model is forced to reconcile with the clear monotonic increase in reported 
HIV cases and with the a priori belief that the incidence trajectory should vary smoothly over 
time.  
The resulting estimate of HIV incidence (Figure 3(d)), describes an early peak in new 
infections in 1990 and resurgence in the epidemic since 2000. The period with the highest 
incidence rate is estimated to be 2008-2009. 
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These incidence estimates can be compared with those previously presented by UNAIDS and 
which are based on an entirely different methodology whereby models are fitted to observed 
prevalence data and estimated sizes of key population (Figure 4). In recent years, the 
estimates derived through the proposed method and the UNAIDS methods are in very close 
agreement. However, the UNAIDS estimated historical trajectory of incidence suggests very 
high peak incidence during 1995, of 0.3 per 100 person-years at risk (pyar) whereas the 
proposed method suggests an incidence rate much lower, at 0.03 per 100 pyar. 
 
 
 
Figure 3 Model fit to data in Colombia: Panels with data points (blue dots) as reported on a yearly basis by 
Colombian surveillance system, in three categories: cases previously undiagnosed and only detected after death 
(a); cases detected during AIDS stage (b); and cases detected and classified as non-AIDS at the time of 
diagnosis (c). In a-c, the coloured lines are the posterior estimation from the model chosen for Colombia. (d) 
The resulting HIV incidence trajectory in Colombia from the proposed method (red dashed line) with 95% 
credible interval (shaded area). 
Chapter 4: Estimating HIV incidence from case-report data 
174 
 
 
Figure 4 Estimated number of new HIV infections in Colombia: from the proposed method (black dashed lines) 
and current UNAIDS methods (blue dots). The orange shaded area shows the 95% credible interval of the 
estimates of the proposed method. Note that UNAIDS does compute uncertainty intervals for most of its 
statistics but intervals were not retrievable from online data sources for this statistic (22). 
 
 
4 DISCUSSION 
Here a method for estimating HIV incidence from case-report data was examined. It has been 
shown that it is capable of correctly recovering a wide range of possible incidence trajectories 
and has been applied to data from Colombia to give complementary estimates of incidence to 
that derived from other methods.  
Whilst it is promising that this method can broadly identify a wide range of incidence 
trajectories, some small inconsistencies remained. It is possible these will be due to the 
setting of the fixed placement of the knots and the rigid ordering of unconstrained and 
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constrained knots. It will be possible to determine whether the evaluation of a wider range of 
models that incorporate these differences and model selection based on DIC is sufficient to 
overcome these challenges. This would inevitably increase the computational demands of the 
estimation procedure and so alternative methods for estimating the model will also be 
explored. 
It will also be useful to examine how this method works under different conditions of data 
availability. In the challenges with synthetic data, it was assumed that all required data were 
present and unbiased. Whilst this may be a reasonable assumption for some settings, it will 
not be universally the case and small errors in early estimates of number of cases may 
propagate to large errors in the inferred incidence trajectory. The same assumption for the 
natural history of HIV was used (survival rates and CD4 progression) in the method that 
generated the synthetic data as in the estimation model, which will inevitably flatter the 
performance of the model. A further step would be to examine the impact of the survival 
rates used to generate the synthetic data departing from those assumed in the estimation 
model, as well as propagating uncertainty in the assumptions about natural history in the 
estimation procedure. Finally, here the impact of the use of inappropriate assumptions on the 
trend in diagnosis rates over time was not assessed.  
This method give uncertain results especially in recent years and this is because there remains 
confounding by potential changes in the interval between infection and death and because 
numbers of cases and deaths are informative of incidence rates sometime in the past rather 
than current incidence. Therefore, in the current form this method cannot be expected to 
reliably detect recent changes in incidence, which would be very important in monitoring a 
national epidemic. We can expect, however, that it would be highly advantageous for this 
method to draw on further data. It will be possible to extend this method to incorporate data 
and/or estimates on deaths and numbers on ART, which should contribute to discriminating 
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the earlier part of incidence trajectory in particular. Although it is not commonly used at 
present, the addition of measurement of biomarkers that relate to recency of infection at 
diagnosis could also help discriminate current incidence levels, although this would depend 
on the characteristics of the biomarker and how well they are known (Bao et al. unpublished). 
Estimates of HIV incidence for Colombia must be interpreted with a high degree of caution 
and in light of this method’s assumptions and present limitations. Of particular note, the 
estimates from the proposed model suggest that incidence was historically much lower than 
the levels the previous UNAIDS estimate indicate. This could stem from the assumption of 
complete case reporting and no misclassification of AIDS deaths: if, in fact, some diagnoses 
go unreported and some true AIDS deaths are misclassified, then these estimates will be too 
low. Nevertheless, it seems unlikely that these biases would fully explain the discrepancy and 
it is also noteworthy that, as reported elsewhere (Sabin et al., unpublished), the total all-cause 
deaths implied in the UNAIDS estimates are substantially greater than estimated all-cause 
death rate by IHME (23). For that reason, future incidence estimates by UNAIDS will be 
scaled such that this discrepancy is minimised, and that may bring a closer agreement 
between UNAIDS estimates and those derived using the method proposed here. 
In conclusion, this method is promising technique for estimating HIV incidence trends that 
does not rely on using prevalence data and size estimates of key populations, and which 
leverages high quality routinely collected data. Future work should focus on updating the 
model structure to allow other forms of surveillance data, such as AIDS deaths and people on 
ART and further scrutiny of model performance under circumstances of missing or biased 
availability of data. 
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HIV spread in Latin America is largely constrained by transmission within vulnerable sub-
groups of the population. This is different to the generalized epidemics seen in other parts of 
the world like sub-Saharan Africa. The pattern of concentrated transmission has been 
extensively documented in most Latin American countries through surveillance and 
population surveys. These have shown the disproportionate burden that HIV has had on 
vulnerable groups, especially among MSMs, when compared to the general population [1-4]. 
This has led transmission to occur within restricted networks and means that the epidemic has 
not found the appropriate conditions to sustain its spread on a larger scale in the general 
population. How much of that containment is due to natural transmission dynamics and to 
what extent it is the reflection of interventions, is a question that this research has sought to 
answer for the cases of Brazil and Bogota. Interventions for HIV prevention have taken place 
in both countries, with ART delivery and medical care being prioritized over other forms of 
prevention. Extended delivery of condoms, and, to a lesser extent, behaviour change 
strategies, have also been applied in these settings [5-9]. In both Brazil and Colombia, ART 
introduction and the subsequent periodical update of guidelines for an earlier delivery of 
ART has allowed these countries to reach the same level of treatment coverage as in most 
industrialized countries. Brazil has gone even further and is now attempting to be the first and 
largest case-study of TasP - fully funded by the government and implemented at a national 
level [10]. Determined policy-making and a strong infrastructure for further ART expansion 
have meant that ART interventions have been rolled-out as real life programmes as opposed 
to carefully tailored trials. In contexts like these, where no intervention is available for 
comparison, mathematical modelling provides a central part of programme evaluation. Two 
chapters of this thesis have carried out a retrospective evaluation of HIV interventions and 
have revealed the distinction between the differential effects attributable to ART, and to 
behaviour change and that which has been observed by epidemic dynamics.  
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In Brazil and Colombia, programmatic and surveillance data prevail over behavioural data 
and other estimations obtained through cross-sectional studies. This is partly due to 
surveillance systems and health programmes in place and also to the concentrated nature of 
the epidemic. Disproportions in risk of acquiring HIV in these settings are mirroring 
disproportions in vulnerability and social marginalization, making key populations hard to 
reach through behaviour and seroprevalence surveys [11-13].  These data are essential pieces 
of information for most of the current methods for estimating HIV incidence. At the same 
time, incidence is crucial for evaluating the effect of interventions. With this in mind, a 
method for estimating incidence, that relies exclusively in case reporting data, has been 
proposed, validated, and applied to the case of Colombia in chapter four.   
This Discussion chapter discusses the main findings of the thesis, its limitations and reflects 
about its implications and future development.  
8 SUMMARY OF MAIN FINDINGS  
Deterministic mathematical models were designed, calibrated and analysed for the contexts 
of Bogota, Colombia, and five macro-regions of Brazil. HIV transmission was simulated 
considering the risk heterogeneity of each population and interventions were introduced for 
further estimations of their effect on HIV incidence. To the latest knowledge of the author, 
these are the first analysis of this kind to be conducted in any of the settings studied in this 
thesis.  
ART had a role in containing further HIV incidence in Brazil and Bogota when compared 
against counterfactual scenarios where ART had been removed. A summary of modelling 
results can be seen in Table 1. The effect of interventions (ART and condoms) in at least two 
regions of Brazil (North and South) was necessary for bringing HIV incidence to declining or 
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equilibrium patterns. In Bogota, ART had a lesser role while condoms were crucial for 
bringing the epidemic to stable levels. Absolute reductions in HIV infections were larger 
among MSM in Bogota studies and, across all regions modelled in Brazil. Relative reductions 
of incidence were similar when seen by risk group (MSM and FSW) in Brazil. In Bogota, a 
substantial difference was observed between these two groups.  
A novel approach to HIV incidence estimation from case-report time series was able to 
retrieve different incidence trajectories generated for validation. Application of the method to 
real data from Colombia showed that some inconsistencies remain producing wide ranges of 
uncertainty particularly for the most recent years.  
 
Table 1 Summary table of modelling results of the impact of ART on HIV Incidence 
   Brazil 
Outcome Population  
Bogota  North 
North 
East 
South 
East 
South 
Central 
West 
Median Cumulative 
HIV Infections 
Averted 1997 -2014 
Due to ART 
 
Total population 53,178 10,822 30,153 151,230 62,893 16,693 
Relative HIV 
infections averted 
1997 -2014 due to 
ART , % (IQR)* 
Total population 17% (12) 30.2%(24) 23.7%(17) 31.4%(24) 29.2%(22) 30.7%(23) 
MSM 16%(6.7) 30.2%(23) 22.4%(16) 31.5%(23) 29%(20) 31%(23) 
FSW 2%(3.5) 29%(25) 24%(17) 30%(27) 31%(25) 26%(24) 
*Relative to a counterfactual scenario of no interventions for the same period. 
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9 THE ROLE OF MODEL ASSUMPTIONS IN THE IMPACT OF INTERVENTIONS  
9.1 The impact of ART in the presence of behaviour changes  
ART needs to be understood in a framework of combination interventions if prevention 
outcomes want to be maximized [14-17]. Even in the context of a large ART-scale up 
programme like Brazil, condoms alone had a bigger impact in averting HIV infections in the 
modelling results of this thesis (Table 1). This needs to be interpreted as a result of factors 
stemming from the transmission mechanics of the model and the assumptions regarding 
behaviour change. Evidence has been put forward about the re-emergence of MSM epidemics 
in contexts of high coverage of ART and prevention interventions like The Netherlands [18] 
and the UK[19]. These increases seem to be related to further increases in risk behaviours 
after the introduction of ART as a form of risk compensation. These behaviours are expressed 
by Bezemer et al. [18] in terms of increment in the reproduction number R(t) , and explained 
by Phillips and others [19] as a result of changes in the reported condom-less anal sex in 
more recent years. This evidence shows a pattern that might be taking place in other MSM 
epidemics like those in Latin America. The models in the present thesis incorporated condom 
use as the only form of behaviour change. A single window for wide variations in condom-
use was allowed from 1984 to ~1999 in the simulation and survey data informed the trends 
for the rest of years. This approach could be restrictive and over-relying in self-report data 
about condom use, which ultimately results in an overestimation of the preventive benefit of 
condoms. It is well documented that self-report data is susceptible to recall and several forms 
of motivational biases that could lead to an over-report of protective behaviours in risk 
populations [20, 21]. Furthermore, a simplistic approach was taken regarding the rate of 
change in partners by fixing the values for the duration of the simulation. Partner change rates 
were calibrated but not allowed to change over time. This necessarily imposes a heavy 
burden on condom-use to represent preventive effects on incidence, which could result at the 
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end in overestimation of its overall effect. However, if partner change rates declined in MSM 
or FSW over time is not certain for these settings.  
9.2 Different approaches to modelling ART in key populations 
Modelling results in this thesis have shown that interventions had a role in controlling HIV 
transmission. ART had a greater effect in preventing new infections in Brazil than in Bogota. 
This seems feasible, and the higher levels of ART coverage in Brazil are possibly reflected in 
greater preventive benefit. More precisely, UNAIDS have estimated that 46% of people 
living with HIV/AIDS (PLHA) in Brazil were receiving ART in 2013, while in Colombia the 
same indicator was 29% [22]. Nevertheless, the two models incorporated ART in different 
manners and these assumptions need to be stated clearly for a proper interpretation of the 
results. In Bogota, ART uptake was interpreted as a function of differential rates of HIV 
testing in risk groups, and variations in detection rates by CD4+ stage. This information was 
assembled and interpolated over an exponential function. This explains the differentiated 
effect of treatment on HIV incidence in MSM contrasted with a very small (2%) effect 
among FSW. HIV testing rates are playing their part here by generating differential rates of 
access to ART by risk group. In Brazil, a more flexible approach was adopted, allowing 
variation in ART-enrolling rates by stage of disease and generating a wide range of ART 
expansion trends by calibrating the shape parameter of a sigmoidal function (i.e. allowing 
from vertical increase and saturation to slow growth and exponential rise). This approach (i.e. 
the one in Brazil) did not consider any variability over risk group, which means that access to 
ART was equally likely for any individual regardless of their risk category. The first 
approach, used in the model for Bogota, might be a more realistic assumption when model 
parameters are calibrated (like in this case) against data on reported numbers of people on 
ART, and there are no further details about the risk condition of those receiving the 
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treatment. On the other hand, the presence of detailed data about the risk status of reported 
people on ART could favour a more flexible calibration procedure like the one used in the 
model for Brazil.  
9.3 HIV Prevention effect in concentrated epidemics  
Important insights about the characteristics of the epidemics and its relation to the effect of 
interventions can be drawn from this modelling analysis. PAF estimations as the one 
performed for the case of Bogota, reveals the potential impact of targeting interventions in 
gay and bisexual men in this context. The attributable fraction of cumulative incidence, as 
estimated by mathematical models, offers a good indicator of the direct and indirect effect of 
a single transmission group within its community. As such, its estimation is a proxy of the 
prevention potential if a complete halt of HIV transmission is achieved. PAF and intervention 
effects as reported in chapter two revealed that the gross effect of any of the interventions in 
the model was achieved by reducing transmission among MSM. The analysis by source of 
infection confirms this. This is to say that through these two simple calculations it was 
possible to infer what was subsequently observed in the impact evaluation. These measures 
are important tools for epidemic appraisal and provide a better understanding of the drivers 
behind than other more commonly used measures like short-term distribution of new HIV 
infections [23, 24].    
The complexity and nuances in sexual behaviour makes risk categorization a difficult task. 
The risk heterogeneity proposed in this work is arguably far from describing in detail MSM 
and sex-work behaviours in Brazil or Colombia. This configuration of sub-populations 
proved to be sufficient to sustain a concentrated epidemic among MSM and replicate real 
trends of HIV prevalence among this group. However, the added value of more heterogeneity 
within MSM and FSW could have been reflected in better incidence projections. Some of the 
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natural dynamics missing in some projections of this work can be related to the lack of the 
effects of core-groups saturation which is naturally achievable by increasing with-in group 
heterogeneity:  subdividing MSM in smaller fractions of risk (e.g. Trans, male sex workers, 
stable MSM couples) let smaller groups of susceptible to be rapidly infected (saturated) 
which leads to incidence trends finding its peak naturally and decay slowly as the lower risk 
groups start absorbing that number of infections “spilling-over” from the high-risk sub-
groups. From the health policy perspective, a detailed depiction of group heterogeneity 
allows for a better identification of nuances in behaviour that in practice can be targeted in 
the field. A good example of detailed representation of MSM behaviour in a similar setting 
was done by Gomez and colleagues [25]. This approach demands larger amounts of 
information and for the purpose of this thesis was hardly reproducible, particularly for 
broader geographical locations like the macro-regions of Brazil.           
9.4 HIV prevention effect and the stage of infection 
Acutely infected individuals are more likely to pass the virus to their partners as has been 
demonstrated [26], but  the contribution of acutely infected individuals to the epidemic is 
debated. The fraction of the total transmission that can be attributed to individuals in the early 
stage of infection has been estimated from data and also through modelling and the results are 
still inconclusive ranging from 5% to 50% [27-29]. This piece of information has become 
more important recently as it has been suggested that a greater proportion of cases arising 
from early transmitters would hamper the overall effect of TasP [29]. The argument behind 
this, basically, says that individuals in the early stage of infection are less likely to be 
detected and therefore treated, thus the greater the proportion of infections arising from them, 
the lesser the impact of ART for reducing HIV incidence. However, new modelling evidence 
from Eaton and Hallett [30] suggests that it might not be that straight forward. Their 
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modelling analysis of the generalized epidemic of South Africa shows that other complexities 
play an important role when assessing early infection and its impact on ART interventions, 
such as behaviour changes, assortativeness in mixing and the rate at which individuals move 
from high to low risk groups. More importantly, they concluded that while early infection 
might be important in the short term evaluation of ART programmes, in the long term might 
be counterbalanced by other factors that can be reducing R0 in the long run.       
The model for Bogota found that cumulatively, by 2014, ~30% of all HIV infections in the 
overall epidemic had its source in individuals at the acute-stage. Similar values where found 
in the epidemic of Lilongwe, where 38% of cases came from this stage of infection [31]. The 
implications of this finding might have an important effect in the models described in this 
work. Both models recreate stages of increased infectiousness during the first 3-5 months of 
infection, and both models assume that no testing or recruitment into care is happening at this 
stage. As stated before in chapter two, this means that the maximum preventive potential that 
could be achieved is 70% by any intervention. This assumption could be relaxed in the future 
to explore the programmatic impact of strategies reaching this group.  
10 MORE AND BETTER DATA FOR BETTER ESTIMATIONS 
A barrier found in the design of detailed transmission models in Chapters two and three, was 
the scarcity of data and in particular that related to sexual behaviours. The absence of 
appropriate sources to inform all the required parameters of sexual mixing and transmission 
resulted in great uncertainty around the estimations. The computational cost of the 
simulations was also increased since large parameter spaces needed to be explored during the 
calibration algorithms.  
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But scarcity of information about behavioural parameters is not the only source of uncertainty 
in these of models. The quality and frequency of the data used for model fitting is in close 
relation with the accuracy of model projections, and here a notorious gap divides the 
modelling of HIV in Latin America and contexts like sub-Saharan Africa. In many African 
settings behavioural data and HIV prevalence estimations are routinely collected even at 
national level through the demographic health surveys guaranteeing consistency or at least 
representativeness of the statistical sample across the surveys. This, of course, is possible 
given the widespread epidemic found in such settings, where HIV+ individuals are not 
necessarily hard to reach. This consistency in the data makes simulations robust when fitted 
accurately. On the contrary, HIV prevalence data from risk groups such as FSW, MSM or 
PWID are not routinely collected and almost never comes from the same population sample. 
This observation is shared by others and has been previously discussed elsewhere [32]. A hint 
of this was previously exposed in Table 1 of Chapter 3, where prevalence studies among 
MSM and FSW in Brazil are listed.  There, striking differences in size, quality and 
estimations can be seen. Survey data in many locations of South America is robust and 
sufficient enough to designed detailed transmission models. However, the task of producing 
national-level estimations can be a limited by the absence of consistent behavioural and 
serological data. In response, the proposed method as described in Chapter four moved in a 
complementary direction towards the rest of the work carried out in this thesis, with a 
common motivation of elucidating accurately how HIV transmission has occurred in these 
concentrated epidemics settings. It proposed a flexible system to simulate transmission 
without making any behavioural assumptions and it relied exclusively on case report data. 
When put through different challenges, the system was successful in revealing different 
incidence shapes from “challenging” datasets. The method was applied to Colombia, 
producing estimations with a great amount of uncertainty in more recent years and somehow 
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missing that flexibility in the early years of the epidemic to reproduce more natural epidemic 
forms. An interesting insight comes from the greatest limitation of this method: case-report 
data is not informative enough in the context of a highly uncertain method as the one used 
here. Methodological inconsistences are still to be clarified regarding the appropriate 
configuration of the spline function, but from a broader perspective it was made clear that 
more or more detailed information was required. Having precise information about the 
clinical stage at the time of report could bring more precise estimations. Expanding the model 
structure to allow ART could as well improve the estimations. Another possibility to be 
explored in the future is the use of mortality data. Since the uncertainty resides in the amount 
of information that is fed to the model to interpret the time between an incident infection and 
the observed event (case-report, death), mortality could add to inform this gap.  
Conclusions can be drawn as well as recommendations from this research regarding the data 
needs in the region. First, the strengthening of surveillance information is central since it is a 
rich source of information in Latin America. Greater effort must be made to introduce a 
greater level of detail to data recorded routinely, especially regarding modes of transmission 
and sexual orientation, as a handle to understand the distribution of new cases in the 
population. This data currently is not reliable and does not reflect the trends of transmission. 
Also, systematic biases and sources of underreporting need to be assessed in these contexts. 
Equally important is the systematic recording of the clinical stage and CD4+ count at the time 
of reporting. This information is usually collected in clinical settings but a systematic linkage 
of official reports and clinical data does not exist or is not completely implemented. In this 
line of thinking, the possibility of introducing algorithms for estimation the recency of 
infection (RITA) needs to be explored.  
Strengthening surveillance systems however will not suffice to gather the necessary 
information for understanding the factors behind transmission in concentrated epidemics. 
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More behavioural surveys are urgently needed in Latin America particularly addressing the 
more vulnerable populations. Vulnerable populations, their behaviours and seroprevalence 
must be placed higher in the national health agendas of Latin American countries for an 
effective response to HIV. The current vehicles for data consecution (i.e. national health 
surveys) should attempt to explore further in sexual behaviour and sexual trends, involve men 
more strongly in their samples and make an effort to take advantage of MSM and FSW 
subsamples. Moreover, independent surveys in MSM, clients of FSW, FSW, male sex 
workers and PWID should be carried out more frequently. Sampling hard-to-reach population 
is not an easy task, but the constant developments in this research field are producing more 
robust and consistent estimations and should be applied in the region [33].               
11 INSIGHTS FROM THE METHODOLOGICAL APPROACH 
The methodological exploration in this thesis offers the possibility of contrasting different 
methods often used in mathematical epidemiology, but rarely found together in a single piece 
of research. This thesis explored sampling and calibration procedures across a spectrum from 
frequentist to a fully Bayesian approach. However, this should not be seen as a statement 
about the quality or appropriateness of any of the methods, but a as an opportunity to draw 
useful conclusions for future work.  
Latin Hypercube Sampling (LHS) and Maximum Likelihood Estimation were used in the 
case of Bogota, while a mixed methodological approach and pure Bayesian methods were 
used subsequently for Brazil and the incidence estimation model respectively. LHS proved to 
be a very efficient method for parameter sampling. Its algorithm is moderately easy to code 
and its application was easy.  LHS also exploits the computational power of parallel 
computing, since it works with completely independent parameter sets, after an initial 
randomization. LHS appears as an ideal method for very large parameter spaces when 
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computational power and time are limited. However, this complete independence of model 
runs exposes its weakness at assimilating parameter correlations and an over- reliance on the 
assumptions made about the prior parameter distributions.  
On the other hand, the Markov Chain Monte-Carlo (MCMC) method offers a heuristic 
process capable of exploring “wisely” the parameter space as it constantly improves the 
probability of the parameter values for explaining the data. The Metropolis-Hastings was the 
algorithm of choice in Chapter 4, and although its application is not extremely difficult, it 
poses many more challenges for understanding the mechanics of the process. It also demands 
a careful exploration of the sampling settings, and tuning-up procedures are strongly 
recommended. Moreover, when dealing with asymmetrical parameter distributions, the 
corrections required during the process can be cumbersome.     
MCMC is a very thorough and informative method which goes way beyond merely sampling 
parameter values. If done properly, it not only produces very robust results but also enriches 
the knowledge about the model behaviour and the connection between parameters and the 
outcome. It is however very demanding in terms of time and computation and its intertwined 
nature of events makes it difficult to parallelize (i.e. a single MCMC chain). For these reasons 
MCMC should be the method of choice when the time and resources are available, and if a 
thorough exploration of parameters is required. For large parameter spaces and when a good 
prior knowledge about the nature of the parameters is at hand, LHS offers a very efficient and 
reliable option.    
A different sort of challenge was found in the incidence estimation model presented in 
Chapter 4. Establishing the right amount of flexibility allowed in the spline-function 
parameterisation was a challenging task. It was clear from these results that tuning the 
location and number of knots in the function seem to be one of the keys to produce more 
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accurate estimates with this method. Sampling and calibration of the components of the 
spline function is something that requires further exploration. The global parameter (hyper-
parameter) controlling the overall flexibility of the function requires fine-tuning and this 
appeared very difficult to control during the calibration process, resulting in the uncertainty 
propagation seen in the model projections. Alternative approaches should be explored to 
make the most of this flexible and promising method.  
12 THE SCOPE OF RESEARCH AND A HEALTH POLICY PERPSPECTIVE 
Two specific areas of South America were studied throughout this thesis. Generalizability of 
this work varies across the region and depends on the scope of analysis. In the case of 
Bogota, an urban setting with high HIV prevalence in MSM and moderate coverage of ART, 
the results might be informative for other urban areas even outside the country which hold the 
same type of epidemic. Health infrastructures and overall capacity for prevention delivery is 
similar across the region, which makes the results generalizable. The case of Brazil is more 
particular given the unprecedented approach to ART expansion that took place in the country. 
However, the lessons learned in terms of possible impact of such programmes could be 
highly valued by other settings that intend to follow a similar path in prevention.  
Prevention programmes implemented at a large scale are a valuable source of evidence. Its 
results are a faithful reflection of “real-life” effectiveness and if evaluated properly they 
could bring not only solid estimations of an intervention’s effect but also a rich source of 
experience for future policy implementation. Limitations of this approach include the lack of 
generalizability, less systematic recording of outcomes and limited dimensions for analysis. 
Generalizability of results in health programmes of this kind can be limited by the fact that all 
the estimations obtained are hard to disentangle from confounding factors and the competing 
effect of parallel interventions. Also, a poor or inconsistent recording of primary and 
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secondary outcomes can reduce the level and dimensions in which the intervention can be 
analysed.   On the other hand, more scientific approaches to evaluation (e.g. RCTs, C-RCTs, 
observational cohorts) reduce those limitations at the expense of the “real life” effectiveness 
factor that health programmes can provide. Health programmes should be planned with the 
aim of being evaluated. Better engagement of the scientific community during the planning 
and implementation could reduce future costs by preventing the loss of valuable resources.     
The specific case of current TasP expansion in Brazil leaves room for a reflection about what 
was mentioned before: irrespective of the assumption we make about the real world 
effectiveness of treatment as prevention, the positive externalities provided by ART at the 
population level are undeniable. Having the chance to exploit this effectiveness in a setting 
where transmission is mainly circumscribed to one group of people is a one-off opportunity 
that should be grasped before is too late. It is also true that the challenges of targeting 
prevention could overwhelm any sensible policy maker, but the infrastructure and the know-
how are already in place. Reaching out for vulnerable populations requires an effort and a 
strong bond between policy makers, researchers and activists, this is, the will, the method and 
the way. Political will, not only as a mere whim, but as the capacity of understanding the 
benefits of such approach and being able to translate it into action. The method is what 
research provides by establishing the priorities and the evidence. Finally the way is the 
experience that brings scientific theory to life.  
13 FUTURE WORK 
With its strengths and limitations, this work opens the doors for many possible directions for 
future exploration. This thesis may contribute to different areas: from the epidemic appraisal 
point of view it has provided fresh and distinct estimations of the past and present of HIV 
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epidemics in South America, and it has also contributed to the development of new modelling 
methods for estimating HIV incidence from surveillance data. 
A more thorough exploration of the assumptions regarding behaviour change in the impact 
evaluation case-studies of Bogota and Brazil is a priority in the development of these 
chapters. A sensitivity analysis to see the impact of other forms of behaviour change over 
time (i.e. apart from condoms) and how these variations might impact the estimated impact of 
condoms and ART on HIV incidence is necessary to understand better the reach of the 
results.    
Assessing the role of people who inject drugs (PWID) in the overall epidemic of Brazil was a 
limitation of this work and should be addressed in future research. Similarly, the implications 
of modelling such vast areas in Brazil should be investigated. Narrowing the scope of the 
modelling analysis might open the possibility to use more detailed clinical and programmatic 
data for more accurate results.   
The model for HIV incidence estimation was a first and important effort on which future 
research can be built. As mentioned before, many technical details may be addressed in future 
versions of this model. Using other dimensions of surveillance data like people receiving 
ART and AIDS mortality might be the missing link to informing the time variations in 
incidence.   
Modelling results unveiled in some way the urgent need to explore the potential of targeted 
interventions in these settings. HIV incidence reductions among MSM represented the largest 
fraction of infections averted in the two study cases, suggesting that a re-assessment of how 
the resources are being deployed is a top priority in the HIV response. In the same line of 
thinking, a thorough assessment of the added value of having surveillance data by group of 
exposure is urgently needed in the region. Given that surveillance is one of the strengths of 
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Latin America, more efforts must be made to improve the level of detail and start making 
these data work for the benefit of the countries.  
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Figure A1.1 Prior (red line) and posterior (black bars) distribution histogram of model parameters 1 to 30. 
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Figure A1.22 Prior (red line) and posterior (black bars) distribution histogram of model parameters 30 to 61. 
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Figure A1.3 Correlation matrix of posterior parameter values.   
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Figure A1.4 Distribution of people receiving ART in the model for Bogota by group of exposure, 1997-2014 
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